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1. Introduction 1 
1. Introduction 
 
1.1. Purinergic receptor and its subtypes 
 
Purinergic receptors were first defined in 1976.
1 
Later on they were divided into two families, 
P1 and P2 (for adenosine and nucleotides, respectively).
2 
The P1 (adenosine (1)) receptors 
were divided into four receptor subtypes (A1, A2A, A2B, A3) and the P2 receptors were 
subdivided in two big families (P2X and P2Y receptors).
3,4
 The P2Y receptors comprise eight 
subtypes (P2Y1,2,4,6,11–14) which are G protein-coupled receptors (GPCR) activated by ADP 
(2), ATP (3), UDP (4), UTP (5) or UDP-glucose respectively.
5-7
 The P2X receptors are seven 
ligand-gated ion channel subunits (P2X1–7) and activated by ATP (3)
8,9
 (Figure 1 and 2; Table 
1). Both, P2XR and P2YR subtypes, can form homomers and heteromers.
10
 The combinations 
of different receptor subtypes can result in different receptor characteristics regarding agonist 
and antagonist potencies and selectivities, signaling and desensitization properties. Beside P1 
and P2, P0 receptors were recently suggested as a third family of purinergic receptors which 
are GPCRs activated by the nucleobase adenine (6) (Figure 1 and 2).
5
 
 
1.1.1. P2 Receptors 
 
1.1.1.1. P2X receptors 
 
P2X receptors define a third major family of ionotropic receptors (besides Cys-loop channels 
and glutamate-gated channels) and consist of 379–595 amino acids, possessing tertiary 
structures with two transmembrane domains, intracellular N- and C-terminus, and post-
translational modifications including glycosylation and phosphorylation. Most of the 
conserved regions are in the extracellular loop, with the transmembrane domains being less 
conserved. The extracellular loop of cloned P2X1–7 receptors has 10 conserved cysteine 
residues, 14 conserved glycine residues and 2–6 potential N-linked glycosylation sites. It is 
believed that disulfide bridges in the extracellular loop may form the structural constraints 
needed to couple the ATP-binding site to the ion pore. Alignment of the sequences of the 
cytoplasmic C-terminal regions of P2X subunits shows that a motif (a tyrosine and a lysine 
separated by three amino acids) present in 39 of the 41 full-length receptor sequences in the 
database is conserved, and that this motif is responsible for appropriate cell surface expression 
and polarization of P2X2–6 receptors.
11
 
The first crystal structure of an ATP-gated P2X4 ion channel in a closed, resting state, 
provided atomic-resolution evidence that these receptors are trimeric in subunit stoichiometry, 
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with each subunit being composed of two continuous, transmembrane α-helices, intracellular 
termini and a large disulphide-bond-rich extracellular domain.
12
 
 
 
 
Figure 1. The purinergic receptor family. 
 
The location of the ATP-binding site remains unknown. However it was proposed that ATP 
binds to a non-canonical site, 45 Ǻ from the ion channel domain, in a deep cleft, inducing 
conformational changes within and between subunits. These changes are spread to the ion 
channel by conserved residues located at the interface between the transmembrane domain 
and the extracellular domain, opening the ion channel pore.
12 
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Figure 2. Physiological agonists for selected purinergic receptor subtypes. 
 
Desensitization takes place for all P2XRs. Some of the P2XR subtypes are desensitized very 
fast (P2X1 and P2X3 receptors), whereas in others it occurs 100–1000 times more slowly 
(slow desensitization: P2X2, 4–7 receptors) (Table 1).
11
 
 
A common property to all P2X subtypes is a direct influx of extracellular Ca
2+
 (as well as 
Na
+
), promoted by purines through the receptor channel itself. This entry is the first event in 
the purinergic machinery, and represents a significant source of the overall intracellular Ca
2+
 
pool. This transduction mechanism does not depend on production and diffusion of second 
messengers within cytosol or membrane and, therefore, the cellular response-time is generally 
within 10 ms.
11
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Table 1. A summary of the molecular, biophysical, functional and cellular properties of recombinant homomeric P2X receptors 
 P2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7 
Molecular properties 
Amino acids
13-20
 399 472 393 389 455 379 595 
Membrane 
expression
13-20
 
Good Good Good Good Poor No expression 
in most cases 
Good 
Desensitization 
(complete in)
13-20
 
Fast (<1 s) Slow (>20 s) Fast (<1 s) Slow (>20 s) Slow (>20 s) - Slow (>20s) 
Pharmacological agonist EC50 values (µM)
20-26 
(Figure 3) 
 
ATP (3) 0.07 1.2 0.5 10 10 12 100 
2-MeSATP (7) 0.07 1.2 0.3 10 10 9 100 
α,β-MeATP (8) 0.3 > 300 0.8 > 300 > 300 > 100 > 300 
BzATP (9) 0.003 0.75 0.08 7 > 500 - 20 
Antagonist IC50 values (µM)
20-26 
(Figure 4) 
 
Suramin (11) 1 10 3 > 500 4 > 100 500 
NF279 (12) 9 30 50 > 100 - - 20 
PPADS (13) 1 1 1 > 500 3 > 100 50 
TNP-ATP (16) 0.006 1 0.001 15 - - > 30 
A-317491 (15) > 10 > 100 0.10 > 100 - > 100 > 100 
RO-3  (17) > 100 > 100 0.10 > 100 >100  > 100 
IP5I  (20) 0.003 > 300 2.8 - - - - 
MRS2179 80 > 100 > 100  - - > 100 
NF449 0.8 > 100 > 100 
 
> 100 - - > 100 
Modulator EC50 values (µM)
27-31 
Ivermectin - > 30 > 30 0.25 - - > 30 
Cibacron Blue  IC50 (µM) = 
0.7 
- Potentiation Potentiation and 
block 
- - - 
1. Introduction 5 
 
 
 P2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7 
Zn
2+
 - Increase  - Increase  - -  
Ca
2+
 No effect  
 
Block  Block  - Decrease  - Decrease  
Physiology and pathophysiology 
Major cellular 
expression
32
 
Smooth 
muscle 
Neurons Pain sensing 
neurons 
Microglia Skeletal muscle Broad 
expression 
Immune cells 
Major role
32
 Neuroeffector 
transmission 
Taste, pre- and 
post-synaptic 
responses 
Bladder 
reflexes, 
Chronic pain, 
taste 
Vascular 
remodeling, 
neuropathic pain 
- - Bone 
reabsorption, 
chronic pain 
Model native cell 
type 
Vas deferens 
myocytes 
Superior 
cervical ganglia 
(SCG) and 
myenteric 
plexus neurons 
Small dorsal 
root ganglion 
(DRG) neurons 
Macrophages Skeletal 
myocytes 
- Monocytes, 
macrophages 
microglia 
KO available ?
32
 Yes Yes Yes Yes - - Yes 
Major disease 
indication 
Male 
infertility 
- Bladder 
function, pain 
Neuropathic 
pain 
- - Arthritis, brittle 
bones, pain 
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1.1.1.1.1. Homomeric P2X2 receptor 
 
Homomeric P2X2 receptors are widely distributed throughout the peripheral and central 
nervous system, and on many non-neuronal cell types, where they play a role in sensory 
transmission and modulation of synaptic function.
23
 
P2X2 channels are the only homomeric P2X subtype potentiated by acidic conditions; they are 
also potentiated by Zn
2+
, but inhibited by other divalent cations at high concentrations. The 
P2X2 receptor can be activated with ATP (3), ATPγS, and 2-MeSATP (7) which are the most 
potent agonists, with similar EC50 values.
21, 33-36
 
Ap4A is the only diadenosine polyphosphate capable of gating P2X2 channels (EC50 = 15.2 
µM).
37,38
 There are no known selective or highly potent antagonists for P2X2 (Table 1). 
PPADS, TNP-ATP and reactive blue-2 are equipotent antagonists for P2X2, while suramin 
has a tenfold lower potency than these antagonists.
23 
 
 
  
Figure 3. Chemical structures of common P2X agonists. 
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1.1.1.1.2. Homomeric P2X3 and heteromeric P2X2/3 receptors 
 
P2X3 and P2X2/3 channels are predominantly localized on peripheral and central terminals of 
unmyelinated C-fiber and thinly myelinated Aδ sensory afferents, where they mediate sensory 
neurotransmission. P2X3 and P2X2/3 channels are pharmacologically similar, they are 
selectively gated by α,β-MeATP (8). These channels differ, however, in their desensitization 
kinetics and in their sensitivity to extracellular ions. α,β-MeATP (8) shows high affinity for 
homomeric native and recombinantly expressed P2X3 channels with a rapidly desensitizing 
inward current (pEC50=5.7–6.3).
21,36,39-43 
 
When α,β-MeATP (8) was tested side-by-side in the same assay systems with ATP (3) and 2-
2-MeSATP (7), 3 and 7 have been shown to be slightly more potent than α,β-MeATP.21,23,36 
BzATP (9) is the most potent agonist at homomeric P2X3 channels, with the concentration 
required to elicit half-maximal responses being approximately five-fold lower than that 
required for ATP or 2-MeSATP.
21, 36
 
 
A series of acyclic nucleotides based on the adenine skeleton and bearing in the 9-position a 
phosphorylated four-carbon chain was evaluated on rat P2X3 receptors (Figure 3, 10).
44
 The 
results showed that certain acyclic nucleotide analoges are partial agonists on P2X3 receptors. 
This is an interesting property which can depress the function of P2X3 receptors, whose 
activation is believed to be involved in a number of chronic pain conditions including 
neuropathic pain and migraine.
44
 
 
IP5I (20) blocked α,β-MeATP-evoked P2X3 responses in a concentration-dependent manner 
with an IC50 value in the micromolar range and it is a noncompetitive antagonist which binds 
to a site at the desensitized conformation of P2X3 receptors. 
45
 
 
The heteromeric P2X2/3 channel shares many of the activation characteristics of homomeric 
P2X3 including selective gating by α,β-MeATP (8) and a similar rank order of agonist 
potencies.
21,41,46
 However, the key difference is that α,β-MeATP-evoked inward currents 
through recombinant or natively expressed (nodose ganglion neurons) P2X2/3 channels are 
slowly desensitizing.
39,41 
 
The activation of P2X3 and P2X2/3 channels by α,β-MeATP (8) is sensitive to inhibition by 
TNP-ATP (16). Nanomolar concentrations of TNP-ATP (16) can inhibit α,β-MeATP-evoked 
1. Introduction  8 
 
 
inward currents and Ca
2+
 influx in cell lines expressing recombinant rat P2X3 (pIC50 = 9.0) 
and P2X2/3 (pIC50 = 8.3–8.5) channels,
47,48
 representing an approximately 1,000-fold or 
greater selectivity over the homomeric P2X2 receptors. α,β-MeATP (8) evoked currents 
through natively expressed rat P2X3 (DRG neurons) and P2X2/3 (nodose ganglion neurons) 
channels are also inhibited by TNP-ATP (16) with pIC50s of 9.1–9.5 and 7.7, respectively.
40,49
 
 
Figure 4. Chemical structures of P2X antagonists with multiple acidic functional groups 
leading to poor in vivo pharmacokinetic properties. 
 
 
A-317491(15) is a non-nucleotide competitive antagonist of P2X3 and P2X2/3 receptor 
activation. A-317491 (15) blocked recombinant human and rat P2X3 and P2X2/3 receptor-
mediated calcium flux (Ki = 22-92 nM). RO-3 (Figure 5, 17) is identified as an antagonist for 
P2X3 receptors (pIC50-7.0, IC50: 0.1 µM) and P2X2/3 receptors (pIC50=5.9, IC50: 1 µM). RO-4 
(18) is a potent, selective and drug-like dual P2X3/P2X2/3 antagonist for the treatment of 
pain.
50
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1.1.1.1.3. Homomeric P2X4 receptors 
P2X4 subunits are widely distributed within neuronal and non-neuronal tissues. P2X4 channels 
localized on activated microglia have been implicated in chronic inflammatory and 
neuropathic pain. Homomeric P2X4 channels generally produce a slowly desensitizing inward 
current in response to ATP (3).
23
 
 
The rat P2X4 receptor is different from other P2X channels due to its relative insensitivity to 
classic, non-selective P2X antagonists, such as suramin (11) and PPADS (13), even at high 
concentrations of 100–500 μM.51-53 It has been reported that suramin (11), PPADS (13), and 
cibacron blue at some concentrations can potentiate ATP-evoked currents in rat and mouse 
P2X4.
54-56
  
 
 
 
 
Figure 5. Commonly used P2X antagonists: Nucleotides related to the structure of ATP: 
TNP-ATP is an antagonist. RO-3 and RO-4 are a selective antagonist with improved “drug-
like” properties (e.g., oral bioavailability, improved metabolic stability);benzofuro-1,4-
diazepin-2-one (selective P2X4 antagonist); dinucleotide Ip5I. 
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However, the rat P2X4 may be uniquely insensitive as moderate sensitivity of the human 
P2X4 has been reported for several antagonists, including PPADS (13) (human P2X4 
pIC50=4.6–5.0; rat P2X4 pIC50 < 3.3), suramin (11) (human P2X4 pIC50 = 3.7; rat P2X4 pIC50 < 
3.3), bromphenol blue (human P2X4 pIC50 = 4.1; rat P2X4 pIC50 < 3.5), and cibacron blue 
(human P2X4 pIC50 = 4.4; rat P2X4 pIC50 = 3.9), and the mouse P2X4 has also been reported 
to be inhibited by PPADS (13) at a concentration of 10 µM with a potency similar to that seen 
at the human P2X4.
13,52 
The lack of selective P2X4 antagonists has hindered the 
pharmacological validation of the role for P2X4 receptors in pain. 5-(3-bromophenyl)-1,3-
dihydro-2H-benzofuro-[3,2-e]-1,4-diazepin-2-one (Figure 5, 19) was shown to block P2X4-
mediated currents expressed in Chinese hamster ovary cells with an IC50 value of 0.5 µM.
22
  
 
Neuropathic pain is characterized by pain hypersensitivity to innocuous stimuli (tactile 
allodynia) that is nearly always resistant to known treatments such as non-steroidal anti-
inflammatory drugs or even opioids. Some antidepressants are effective for treating 
neuropathic pain. However, the molecular mechanisms are not well understood. Paroxetine 
exhibited inhibition of calcium influx via rat and human P2X4 receptors, with IC50 values of 
2.45 µM and 1.87 µM, respectively. The inhibition on P2X4 receptors may clarify the 
analgesic effect of paroxetine, and it is possible that some antidepressants clinically used in 
patients with neuropathic pain show antiallodynic effects, at least in part via their inhibitory 
effects on P2X4 receptors.
57
 
1.1.1.2. P2Y receptors 
 
Metabotropic P2Y receptors (P2YRs) consist of 308–379 amino acids, with a mass of 41–53 
kDa after glycosylation. They possess tertiary structures with seven transmembrane domains, 
an extracellular N-terminus and an intracellular C-terminus. Basic residues near the 
extracellular surface may be involved in ligand binding and coordination of the polyphosphate 
chain of the endogenous ligands.
11
  
 
Eight different subtypes have been cloned (Table 2) of the P2Y(1,2,4,6,11-14) receptor family. The 
missing numbers represent either non-mammalian orthologs or receptors having some 
sequence homology to P2Y receptors but without functional evidence of responsiveness to 
nucleotides.
11
 
Based on phylogenetic and structural considerations (i.e., protein sequence), P2Y receptors 
can be subdivided into at least two groups by a relatively high level of sequence difference 
(Figure 6):
6
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1) P2Y1-like receptors including P2Y1, P2Y2 , P2Y4, P2Y6, P2Y11 
2) P2Y12-like receptors including P2Y12, P2Y13 and P2Y14.  
 
 
 
Figure 6. A phylogenetic tree (dendrogram) showing the relationships among the current 
members of the P2Y receptor family. The P2Y receptors can be divided into two subgroups, 
shown with green and blue backgrounds. Sequences were aligned using CLUSTALX, and the 
tree was built using the TREEVIEW software.
6
 
 
Pharmacologically the P2Y receptors can be subdivided into four groups:
11
 
 Adenine nucleotide-activated receptors sensitive to ADP (2) and ATP (3). This group 
includes P2Y1, P2Y12, and P2Y13, and P2Y11 (which has been reported to also respond 
to UTP (5)
57
);
 
 
 uracil nucleotide-receptors; this group includes P2Y4 and P2Y6 responding to either 
UDP (4) or UTP (5);  
 Mixed selectivity receptors (human and rodent P2Y2, rodent P2Y4 and, may be, P2Y11); 
and 
 Receptors activated by the sugar nucleotides UDP-glucose and UDP-galactose (P2Y14). 
 
P2Y receptor subtypes can also form heteromeric complexes,
58
 and recently, adenosine A1 
receptors have been shown to form a heteromeric complex with P2Y1 receptors.
60,61 
Dopamine D1 and adenosine A1 receptors have also been shown to form functionally 
interactive heteromeric complexes.
62
 Only recently hetero-oligomerization between P2Y1 and 
P2Y11 receptors has been described.
63 
An interesting functional consequence of the interaction 
between the P2Y11 receptor and the P2Y1 receptor was found: it promotes an agonist-induced 
internalization of the P2Y11 receptor. This is remarkable because the P2Y11 receptor 
expressed alone is not able to undergo endocytosis.
63
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Table 2. Overview of P2Y receptors subtypes
5,6&64
 
Subunit Amino 
acids 
Agonist 
 
Signal 
transduction 
In vitro test systems Main distribution 
 
Main functions 
 
Radioligand 
binding studies 
Functional studies 
P2Y1 373 ADP Gq, PLC 
 
 
 
 
[
3
H]MRS2279; 
[33P]MRS2179 
 
IP3 accumulation and 
[Ca2+]i mobilization 
Epithelial and 
endothelial cells, 
platelets, immune 
cells, osteoclasts, glial 
cells 
  
Smooth muscle relaxation & 
mitogenic actions; 
platelet shape change & 
aggregation; bone 
resorption  
P2Y2 376 UTP, 
ATP 
Gq, PLC None IP3 accumulation and 
[Ca2+]i mobilization  
Immune cells, 
epithelial and 
endothelial cells, 
kidney tubules, 
osteoblasts, astrocytes 
  
Vasodilatation through 
endothelium & 
vasoconstriction through 
smooth muscle; mitogenic 
actions; mediates surfactant 
secretion; 
epithelial cell Cl– secretion; 
bone remodelling 
P2Y4 365 UTP Gq, PLC None IP3 accumulation and 
[Ca2+]i mobilization 
 
Endothelial and 
epithelial cells, 
intestine, pituitary, 
brain  
Regulates epithelial Cl– 
transport; vasodilatation 
through endothelium; 
mitogenic actions 
  
P2Y6 328 UDP Gq, PLC None 
 
 
 
 
 
 
IP3 accumulation and 
[Ca2+]i mobilization 
 
Some epithelial cells, 
placenta, T cells, 
thymus, spleen, 
kidney, activated 
microglia  
NaCl secretion in colonic 
epithelium; role in epithelial 
proliferation 
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P2Y11 371 ATP Gs, cAMP 
Gq, PLC 
None 
 
cAMP measurement; 
[Ca2+]i mobilization; 
IP3 accumulation 
 
Spleen, intestine, 
brain, granulocytes 
  
Role in maturation & 
migration of dendritic cells; 
granulocytic differentiation  
P2Y12 342 ADP Gi, cAMP 
 
[
33
P]2-MeSADP; 
[
3
H]PSB-0413 
cAMP measurement in 
stably transfected cells; 
cAMP measurement in 
platelets 
Platelets, glial cells, 
spinal cord 
  
Platelet aggregation; role in 
dense granule secretion  
P2Y13 333 ADP Gi, cAMP 
 
[
33
P]2-MeSADP  IP3 measurement in 
1321N1 astrocytoma 
cells that express 
recombinant receptor; 
cAMP measurement; 
[
35
S] GTPγs binding 
 
Spleen, brain, lymph 
nodes, bone marrow, 
liver, pancreas, heart 
  
Function largely unknown, 
but present in both the 
immune system and brain  
P2Y14 338 UDP-
glucose 
Gi, cAMP 
 
None cAMP measurement 
 
Placenta, adipose 
tissue, stomach, 
intestine, discrete brain 
regions, spleen, lung, 
heart, bone marrow, 
peripheral immune 
cells 
Chemoattractant receptor in 
bone marrow hematopoietic 
stem cells; dendritic cell 
activation 
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1.1.1.2.1. P2Y1 receptors 
 
The P2Y1 receptor is coupled to Gαq, thus receptor activation leads to an increase in 
intracellular IP3 levels and the release of Ca
2+ 
from intracellular stores ([Ca
2+
]i). ADP (2, Ki = 
0.92 µM) is the physiological agonist for this receptor and 2-MeSADP (18) is more potent 
than the parent compound with a Ki value of 0.0099 µM.
65,66
 
  
The most potent agonist known for P2Y1 is the N-methanocarba analog of 2-MeSADP which 
is called MRS2365.
67
 ATP (3) is a partial agonist at the P2Y1 receptor 
68
 and so at low levels 
of receptor expression will act as an antagonist.
69,70
 MRS2179 (2'-deoxy-N
6
-methyladenosine 
3',5'-bisphosphate) is a highly selective and potent antagonist at P2Y1 receptors with 
antithrombotic activity (IC50 = 330 nM),
71,72 
and MRS2279 (2-chloro-N
6
-methyl-(N) 
methanocarba-2'-deoxyadenosine-3',5'-bisphosphate) is a competitive antagonist at P2Y1 
receptors (pKB = 8.1, KB = 7.94 nM ).
73
 
 
Binding studies showed that [
3
H]MRS2279 bound specifically to the human P2Y1 receptor, 
with a KD of 3.8 nM. The binding was displaced by 2-MeSADP (18) > ADP (2) = 2-meSATP 
(7) > ATP (3) and by MRS2279 = MRS2179 > adenosine-3'-phosphate-5' -phosphosulfate 
(A3P5PS).
65,66
 
 
 
 
Figure 7. Chemical structures of selected P2Y receptor agonists. 
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1.1.1.2.2. P2Y11 receptors 
 
The human P2Y11 receptor is distinguished from the other P2Y receptor subtypes by the 
following characteristics: 
1) the natural agonist ATP (3) has a low potency for it; and 
2) it is dually coupled to PLC and adenylyl cyclase stimulation;  
3) there is no rodent ortholog of P2Y11.  
This means that this receptor subtype is quite different from the other members of the family. 
At the recombinant human P2Y11 receptor, the rank order of potency with which nucleotides 
increase either cAMP or IP3 is ARC67085MX (20) ≥ ATPγS ≈ BzATP (9) > ATP (3) > ADP 
(2).
74-76
 
 
The EC50 of ATP is in the 5 to 100 µM range, whereas in the same expression systems (i.e., 
1321N1 or CHO cells), the EC50 characterizing the activation of the other P2Y subtypes by 
their respective ligands is in the 10 to 500 nM range. Suramin (10) behaves as a competitive 
antagonist of the human P2Y11 receptor with a Ki close to 1 µM.
75
 P2Y11 receptor antagonists 
derived from suramin exhibit nanomolar potency. NF157 (12a) has a Ki value of 0.0447 µM 
at the P2Y11 receptor and displays selectivity over P2Y1, P2Y2, P2X2, P2X2, P2X3, P2X4, and 
P2X7 receptors.
58
 
 
Activation of P2Y11 receptors leads to an increase of both cAMP and IP3. The use of various 
pharmacological tools, inhibition of PLC or prostaglandin synthesis, chelation of intracellular 
calcium, and down-regulation of PKC showed that the cAMP increase is not an indirect 
consequence of rises in IP3, [Ca
2+
]i, and PKC activity.
76,77
 
 
Proteinkinase C (PKC) activation plays some role and amplifies the stimulation of adenylyl 
cyclase. In addition, it has been reported that UTP (5) acts via the human P2Y11 receptor to 
induce an IP3-independent Ca
2+
 mobilization that is sensitive to pertussis toxin (PTX) 
inhibition, but the ATP (3) response is unaffected.
78
  
 
1.1.1.2.3. P2Y12 receptors 
 
ADP is the natural agonist of this receptor. For diphosphates, the rank order of agonist 
potency in all cases reported is 2-MeSADP (18) >> ADP (2) > ADPγS. In platelets there have 
been reports that ATP (3) and a wide range of its triphosphate analogs behave as antagonists 
of ADP (2) which induces adenylyl cyclase inhibition.
79
 This has been confirmed: ATP (3) 
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and its triphosphate analogs are antagonists of the P2Y12 receptor both in human and mouse 
platelets, provided care is taken to remove contaminants and to prevent enzymatic production 
of ADP (2) or 2-MeSADP (18).
80
 
 
The P2Y12 receptor is mostly expressed in the megakaryocyte/platelet lineage in which it is 
the molecular target of the active metabolite of the antiplatelet drug clopidogrel (25).
6
 This 
metabolite covalently binds cysteine residues of the extracellular loops resulting in inhibition 
of ligand binding.
81
 
 
Ticlopidine (24) and clopidogrel (25) are efficient antithrombotic drugs of the thienopyridine 
family of compounds. CS-747 or prasugrel (26) is a third antithrombotic thienopyridine 
recently approved as a drug.
82
 Clinical studies using clopidogrel (25) demonstrate a 
significantly reduced risk of peripheral artery disease, myocardial infarction, ischemic stroke, 
or vascular death compared with aspirin therapy.
83
  
 
Potent direct competitive antagonists which are all ATP analogs at P2Y12 receptors have also 
been described including ARC69931MX (21), also named cangrelor, as well as other AR-C 
compounds (Figure 8).
84 
 
 
 
Figure 8. Chemical structures of common P2Y12 ligand. 
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Unlike clopidogrel (Plavix TM) (25), which is a pro-drug, cangrelor (21) is an active drug not 
requiring metabolic conversion.
84
 Phase II studies of intravenous AR-C69931MX (21) in 
patients with acute coronary syndromes show that this agent has a rapid onset of action, 
rapidly achieving steady-state inhibition of platelet aggregation with a half-life of only a few 
minutes.
83,85
 The nonphosphorylated AZD6140 (23) is an orally active compound currently 
under clinical evaluation. To increase oral bioavailability, the structure of AZD6140 (23) was 
modified from ARC109318 (22).
86
 
 
P2Y12 knockout mice seem normal, but they exhibit prolonged bleeding times, and their 
platelets aggregate poorly in response to ADP and display a reduced sensitivity to thrombin 
and collagen.
87 
 
 
 
Figure 9. Thienopyridines and their active metabolites. 
 
1.1.1.2.4. P2Y13 receptors 
 
ADP (2) and Ap3A are naturally occurring agonists of the P2Y13 receptor. When 
contaminating ADP (2) was enzymatically removed and testing was performed over a short 
period, ATP (3) behaved as a weak partial agonist.
88
 The relative potencies of ADP (2) and 2-
MeSADP (18) differed according to the assays used. 2-MeSADP was more potent than ADP 
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in competing with [
33
P]2-MeSADP on intact 1321N1 cells expressing human P2Y13 and in  
stimulating binding of [
35
S]GTPγS to membranes of the same cells, whereas ADP was more 
potent than 2-MeSADP (18) on the rat P2Y13.
89
 In CHO-K1 cells expressing human P2Y13, 
ADP (2) and 2-MeSADP (18) produced an equipotent inhibition of cAMP accumulation.  
These results suggest that the P2Y13 receptor might exist in multiple active conformations 
characterized by differences in affinity for 2-MeSADP (18) versus ADP (2), kinetics, and 
preference for G proteins.
89
 
 
The effect of clopidogrel (25) as antithrombotic is mediated by an active metabolite. That 
metabolite has been shown to inhibit the binding of [
33
P]2-MeSADP to human P2Y12 with an 
IC50 of 100 nM,
90
 but it had no effect on human P2Y13 up to 2 µM.
88
 
AR-C69931MX (Cangrelor) (21) which is an antagonist of the human P2Y12 receptor with an 
IC50 value of 2.4 nM is also an antagonist of human and rat P2Y13 receptors in nanomolar 
concentrations.
84
 Two other P2Y12 antagonists, Ap4A and 2-MeSAMP, are also antagonists of 
the P2Y13 receptor.
88
 
The P2Y13 receptor is primarily coupled to a Gi/o protein.  Effects of ADP mediated by the 
recombinant P2Y13 receptor were inhibited by PTX. Furthermore ADP results in: 
 increased binding of [35S]GTPγS,  
 inhibition of cAMP formation,  
 ERK1/2 phosphorylation,  
 and accumulation of IP3 in cells co-expressing Gα16.
88,91
 
However, increased cAMP formation was observed at high ADP (2) concentrations and that 
may be as a result of promiscuous coupling to Gs. This phenomenon has also been observed 
with other recombinant Gi/o-coupled receptors, such as the α2-adrenergic receptor.
91
 Further 
evidence for the coupling to Gi/o derives from the measurement of [Ca
2+
]i increases in HEK 
cells co-expressing various chimeric G proteins.
92 
Major problems in investigations at P2 receptors are:
5
  
1) the lack of selective ligands (agonists and antagonists) for the majority of P2 
receptor subtypes,  
2) the frequently moderate degree of purity of commercial nucleotides,  
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3) the fast degradation of nucleotides by a number of phosphate-hydrolyzing ecto-
enzymes,  
4) phosphorylation by ecto-kinases; the enzyme pattern varies in different cell types, 
tissues and organs.  
5) A further problem constitutes the fact that cells can release nucleotides when they 
are being stressed, e.g. by physical movement (stirring, shaking), subsequent to 
change of incubation medium, or by changes of the pH value.
92,94
 ATP (and other 
nucleotides) may be released from the cells via connexins, maxi-channels, p-
glycoproteins or specific transporters. Efforts are currently under way to elucidate 
the mechanisms of ATP release and possible reuptake in various cellular systems.
95
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1.1.2. P1 receptors 
 
There are four subtypes of P1 receptors that have been cloned, A1, A2A, A2B, and A3.
20,96&97 
The P1 adenosine receptors are coupled to G proteins. They contain seven transmembrane 
(TM) domains of hydrophobic amino acids. Each TM is composed of 20–27 amino acids 
(Figure 10) connected by three extracellular loops and three intracellular ones. The NH2 
terminus of the protein lies on the extracellular side, and the COOH terminus lies on the 
cytoplasmic side of the membrane. The first crystal structure of a human A2A adenosine 
receptor bound to an antagonist was recently identified.
98
 The intracellular segment of the 
receptor interacts with the appropriate G protein, with subsequent activation of the 
intracellular signal transduction mechanism.  
 
 
Figure 10. Membrane receptors for extracellular adenosine: the P1 family of receptors for 
extracellular adenosine are G protein-coupled receptors (S-S; disulfide bond).
20 
 
 
The summary of the pharmacological properties of the mammalian adenosine receptors and 
their subtypes are summarized in table 3.  
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Table 3: Pharmacological properties of mammalian adenosine receptors
64, 99-101
 
 
Subtypes Amino 
acid 
Signal 
transduction 
Agonist Antagonist In vitro test systems Main 
distribution 
 
Main 
functions Radioligand 
binding studies 
Functional 
studies 
Agonist 
radioligand 
Antagonist 
radioligand 
A1 326 Gi , Go CPA, 
CCPA, 
S-ENBA, 
GR7 9236, 
CVT-510 
DPCPX,  
WRC-0571 
PSB-036 
 
[3H]CCPA, 
[3H]PIA, 
[3H]NECA* 
 
[3H]DPCPX GTP-shift 
cAMP 
Brain, spinal 
cord, testis, 
heart, 
autonomic 
nerve terminals 
Sedation, 
anticonvulsive, 
anxiolytic; 
cardiac 
depression 
A2A 328 GS, Golf CGS 
21680, 
HENECA 
ATL-146e, 
CVT-3146 
SCH420814, 
ZM241385, 
KW-6002, 
MSX-2, 
MSX-3, 
MSX-4 
[3H]NECA*, 
[3H]CGS21680 
 
[3H]SCH58261, 
[3H]MSX-2, 
[3H]ZM241385 
cAMP Brain 
(striatum), 
heart, lungs, 
spleen 
 
Facilitates 
neurotransmissi
on; smooth 
muscle 
Relaxation 
A2B 409 GS, Gq Bay 60-
6583, 
MRS3997 
 
MRS 1754, 
MRS 1706, 
PSB 1115, 
Enprofylline, 
MRE 2029-
F20, PSB-
603 
 [3H]MRS 1754, 
[3H]PSB 298, 
[3H]PSB 603 
cAMP, Ca2+ 
assay 
Large intestine, 
bladder, mast 
cells 
 
Role in allergic 
and 
inflammatory 
disorders; 
vasodilatation 
A3 318 Gi, Gq 2-Cl-IB-
MECA, 
IB-MECA, 
VT 160 
 
MRS 1220, 
VUF 5574, 
MRS 1523, 
MRS 1191, 
VUF 8504, 
PSB-10, 
PSB-11 
[3H]NECA*, 
[125I]AB-MECA 
[3H]MRE-
3008F20, 
[3H]PSB-11 
cAMP Lung, liver, 
brain, testis, 
heart 
 
Facilitates 
release of 
allergic 
mediators; 
cardio- & 
cytoprotective 
 
* non-selective. 
1. Introduction 22 
 
 
1.1.3. P0 Receptors 
 
The recently discovered adenine receptors (AdeRs) belong to the family of purinergic 
receptors, referred to as P0 receptors.
5 
Adenine has been identified as the endogenous ligand 
of an orphan rat Gi protein-coupled receptor by a reverse pharmacology approach.
102
 The 
highest expression of mRNA for this receptor is in the small neurons of the dorsal root 
ganglia, pointing out that the AdeRs plays a role in nociception, and adenine may be a 
neuronal signalling molecule.
102
 The in vivo experiments showed that spinally administered 
adenine facilitated electrically-evoked neuronal responses in a rat model of inflammation 
indicating a pronociceptive role of adenine in nociceptive sensory transmission.
103
 Rat AdeR 
mRNA was also detected at lower expression levels in brain cortex, hypothalamus, lung, 
peripheral blood leukocytes, and ovaries.
102
 Binding sites for [
3
H]adenine were detected in 
brain cortical and striatal membrane preparations,
104 
and in synaptosome-rich fractions.
103 
In 
in vitro studies at cultured rat cerebellar Purkinje cells adenine showed concentration-
dependent neurotrophic effects; it was the most potent compound among a series of 
physiological nucleobases, nucleosides and nucleotides.
106,107
 Recent studies demonstrating 
the specific binding of [³H]adenine to membrane preparations provided further evidence for 
the expression of the adenine receptor in rat neuronal tissues as well as a number of cell lines 
of neuronal origin.
104  
 
It was shown that adenine exhibited a Gi protein-mediated and A1 adenosine receptor-
independent inhibitory effect on Na
+
-ATPase activity in the basolateral membranes of the 
proximal tubule isolated from adult pig kidneys, thus adenine appears to be involved in renal 
function.
108
 Increased plasma adenine concentrations have been observed to correlate with the 
progress of chronic renal failure in humans
109
 confirming the significance of adenine in renal 
function.
108
  
 
Functional experiments showed that the rat Ade1R expressed in Chinese hamster ovary 
(CHO) cells
102
 is coupled to adenylate cyclase via Gi protein.  
 
A mouse ortholog (mMrgA10), but no human ortholog, of rat Ade1R could be identified by 
sequence analysis and comparison.
102
 Adenine receptors are expressed in high density in the 
rat brain and native cell lines. Functional coupling to inhibition of adenylate cyclase has been 
found in a native cell line (NG108-15).  
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RT-PCR experiments indicated that NG108-15 cells do not express a rat, but a mouse mRNA 
sequence encoding for an adenine receptor.
104
 The mouse sequence found in mouse brain and 
NG108-15 cells is clearly distinct from the mouse ortholog (mMrgA10) of the rat adenine 
receptor.
110
 
 
Furthermore, there is evidence for the existence of human AdeR, since human cell and tissue 
membrane preparations have shown high affinity binding sites for [
3
H]adenine.
104
 Active and 
passive transport systems for nucleobases have been described to exist in various species 
including mammals.
111,112
 A saturable transport system for adenine across basolateral 
membranes of the sheep choroid plexus has been characterized.
113
 Recently, it was shown that 
[
3
H]adenine is taken up into primary cultured rat cortical neurons via a saturable Na
+
-
independent mechanism indicating that efficient mechanisms for the removal of adenine from 
the extracellular fluid exist. Such systems are required for limiting the duration of receptor 
activation.
114  
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1.2. Radioligand binding studies 
 
Radioligand binding assays are important tools which are used for mapping the distribution of 
receptors in different areas of the body, as well as the effects of physiological conditions on 
the expression of the receptors, and to evaluate ligands for a specific receptor. The radioligand 
is a radioactively labelled compound which can interact with a receptor.
115
 Natively expressed 
and cloned receptors have been used in radioligand binding studies for the characterization of 
ligands.  
 
1.2.1. Basic concepts in receptor binding studies 
 
 
The basis of the receptor binding study is the binding of a ligand (L) to the receptor (R) to 
form a ligand-receptor complex (LR). The unbound ligand is identified as Free which means 
the amount of ligand that is free and able to interact with the receptor, while the amount of 
ligand bound to the examined receptor is defined as Bound. Radioligand binding studies are 
based on a chemical equilibrium process (Figure 11) that is defined by the law of mass action. 
 
Receptor (R) +  Ligand (L) Ligand Receptor Complex (LR)
k+1
k-1
 
 
Figure 11.  Ligand-receptor complex (LR) which is formed as a result of ligand binding 
between the receptor (R) and the ligand (L). 
 
 
The binding of a ligand (L) to a receptor (R) to form a ligand-receptor complex (LR) is 
describing in general a reversible binding phenomena. At equilibrium or steady state, the rate 
of the forward reaction equals the rate of a reverse reaction (not a static process). It is viewed 
as a kinetic process of a ligand moving toward and away from receptors at different states. 
 
The equilibrium binding constant is defined as an association binding constant (KA) or as a 
dissociation binding constant (KD). In biological chemistry this equilibrium is expressed in 
terms of the dissociation reaction KD rather than the association reaction KA. The KD is 
obtained by a rearrangement of the law of mass action (equation 1). 
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Equation 1. The law of mass action, where KD is the dissociation equilibrium constant, [L] is 
the concentration of the unbound ligand, [R] the concentration of the unbound receptor and 
[LR] the concentration of the receptor-ligand complex. 
 
KD is a measure of the affinity of a ligand for a receptor and is equal to k-1 / k+1, where k+1 is 
the rate constant for association and k-1 is the rate constant of dissociation, [L] is the 
concentration of the unbound ligand, [R] the concentration of the unbound receptor and [LR] 
the concentration of the receptor-ligand complex (equation 1).  
 
At equilibrium, when the concentration of the ligand equals the KD, half of the receptors are 
occupied. If the receptors have a high affinity for the ligand, the KD will be low, as it will take 
a low concentration of ligand to bind half of the receptors, while if the KD is large it means 
the receptor has a low affinity for the ligand.  
 
The law of mass action is not valid under all conditions. It can only be used under certain 
conditions:  
 
1. all receptors are equally accessible for the ligand; 
2. all receptors are either free or bound by the ligand; 
3. not more than one affinity state exists; 
4. binding is reversible;  
5. neither ligand nor receptor is altered by binding. 
 
1.2.2. Basic types of receptor binding experiments 
1.2.2.1. Saturation experiments 
 
The saturation experiments measure, at equilibrium, the specific radioligand binding at 
various concentrations of the radioligand, which are used to determine the affinity 1/KD of a 
radioactive ligand for a receptor and the Bmax of the receptor in specific tissues or samples. 
Such experiments are based on the one binding site equation (equation 2).  
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Equation 2. Binding equation, where Bound is the concentration of the drug-receptor complex, Free is the 
concentration of the free radioactive ligand, KD is the affinity of the radioactive ligand for the receptor and Bmax 
is a measure of the density of the receptor in that tissue. 
 
These experiments are called saturation experiments because at higher radioligand 
concentrations all the binding sites are occupied (saturated) by a radioactive ligand. In a 
typical saturation experiment, the radioligand concentration should be between 1/10 and 10 
times the possible KD (Figure 12).
116
 
 
 
Figure 12. Typical graph of a saturation hyperbole. 
 
 
Specific versus non-specific binding 
 
Unfortunately, radioactive ligands bind also to other sites (non specific sites) than to those of 
interest. The whole amount of the radioactive ligand bound is referred to as total binding, 
whereas the specific binding is the difference between the total binding and the non-specific 
binding.  
 
Specific binding (S) = Total binding (TB) – Non-specific binding (NS) 
 
The non-specific binding sites may be receptors in the same family or in other receptor 
families which recognize similar chemical structures, other constituents of the tissue (they 
could be trapped in the lipid membrane) as well as the assay tools, such as glass fibre filters 
and test tubes.  
 
The non-specific binding must be determined in each experiment. If it exceeds 50%, the 
experiment cannot be considered reliable. The optimal result should be between 10% and 
Free 
[RL] 
 Specific binding 
K D 
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30%.
117,118
 To reduce non-specific binding, a very clean membrane homogenate should be 
used, the filtration time should be optimized, filter can be “pre-soaked” before the filtration 
and finally the right radioligand concentration (1/10 KD - 10 KD) should be used. 
 
1.2.2.2. Competition experiments 
 
In competition experiments the affinity of an unlabelled ligand for the receptor can be 
determined indirectly by measuring its ability to compete with the binding of a known 
radioactive ligand to its receptor. In the experiment, a fixed concentration of the radiolabeled 
ligand is used against different concentrations of the unlabelled ligand which compete with 
the radioligand for the binding to the receptor,
116
 leading to a decrease in the concentration of 
the free receptor and accordingly the concentration of radioligand receptor complex.
116
 
 
From the experiment, the concentration of the unlabelled ligand that inhibits the binding of 
the radioactive ligand by 50 % (IC50 value) is determined.  
 
The value of the IC50 depends on:  
 
 the affinity of the radioactive ligand for the receptor; 
 optimization of the radioactive ligand concentration which should ideally be 
approximately 0.8 times the KD.  
 
If a higher concentration of the radioactive ligand is used, then higher concentrations of 
unlabelled ligand will be required to inhibit the binding of the radioactive ligand, and 
accordingly the value of Cheng-Prusoff correlation (equation 3) will be quite large. If a lower 
radioactive ligand concentration is used, it may lead to no sufficient binding and therefore no 
reliable data can be obtained.
116
 
 
The dissociation constant (Ki) for an unlabeled ligand (agonist or antagonist) for the receptor 
is obtained from the competition experiment. If the Ki value is low, the affinity of unlabeled 
ligand for the receptor will be high. The Ki value can be obtained from the IC50 value using 
Cheng-Prusoff equation (equation 3). 
 
 
 
Equation 3. Cheng-Prusoff equation 
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Where L is the concentration of the radioactive ligand used and KD is the affinity of the 
radioligand for the receptor.
119
 
 
1.2.2.3. Kinetic experiments 
1.2.2.3.1. Dissociation rate  
 
A dissociation binding experiment measures the “k-1” or koff for a radioligand dissociating 
from the receptor. The aim of dissociation experiments is to:  
 
 fully characterize the interaction of the ligand and the receptor; 
 confirm that the law of mass action applies; 
 help to design the experimental protocol.  
 
If the dissociation is fast, the filtration and washing of the samples should be quick so that 
negligible dissociation occurs. Lowering the temperature of the buffer used to wash the filters, 
or using another method such as centrifugation might be done. While, if the dissociation is 
slow, the filtration of the samples can be done more slowly. 
 
To perform a dissociation experiment, first, the ligand and receptor are allowed to bind to 
equilibrium. At that point, the further binding of the radioligand to the receptor should be 
blocked. After initiating the dissociation, the binding is measured over time (typically 10-20 
measurements) to determine how rapidly the ligand dissociates from the receptors.
120
 
 
1.2.2.3.2. Association rate  
 
Association binding experiments are used to determine the association rate constant. This is 
useful to characterize the interaction of the ligand with the receptor. It is also important as it 
allows the determination of how long it takes to reach equilibrium in saturation and 
competition experiments. In this method, the radioligand is added and specific binding at 
various time intervals is measured.  
 
The observed rate constant (kob) is determined from the association experiment (equation 4), 
and it is a measure of how quickly the incubation reaches equilibrium, and it depends on three 
factors: 
 
o the association rate constant, this needs to be determined;   
o the concentration of radioligand;  
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o the dissociation rate constant.  
 
 
 
Equation 4. Association rate constant where the kob is determined from the experiment 
 
At equilibrium, the rate of the forward binding reaction equals the rate of the reverse 
dissociation reaction. If the radioligand dissociates quickly from the receptor, equilibrium will 
be reached faster, but there will be less binding at equilibrium. If the radioligand dissociates 
slowly, equilibrium will be reached more slowly and there will be more binding at 
equilibrium.
120
 
 
The analyses of association experiments assume: 
 no ligand depletion. A small fraction of the radioligand binds to receptors, so the 
concentration of free radioligand equals the amount you added and does not change 
over time; 
 no cooperativity; 
 the binding is for a specific receptor. 
 
1.2.2.3.3. Combining association and dissociation data 
 
Once the values of k-1 and k+1 were separately determined, the KD can be calculated from the 
combination of them (equation 5).   
 
 
 
Equation 5. Combining association and dissociation data, KD obtained by k-1 and k+1. 
 
If binding follows the law of mass action, the KD calculated this way should be the same as 
the KD calculated from a saturation binding curve. 
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1.3. G protein-coupled receptors 
 
G protein-coupled receptors (GPCR) are a family of proteins which plays an important role in 
signal transduction in the cells. GPCRs have grown to be one of the most important areas of 
research in the pharmaceutical industry. Analysis has indicated that ~ 45% of currently 
marketed medicines are targeted to this type of receptors.
121,122 
 
 
GPCRs interact with heterotrimetric G proteins. The Gα proteins regulate the activity of the 
GPCRs. Guanosine diphosphate (GDP) binds to Gα proteins in their inactive state, in which 
they are non-covalently associated with the Gβγ subunits and a corresponding GPCR.  
 
 
 
Figure 13. Receptor-mediated G protein activation. The interaction of an endogenous ligand 
with its cell surface receptor (R) facilitates the coupling of the activated receptor (R*) with 
intracellular heterotrimeric G proteins. The R*-G protein coupling promotes the exchange of 
GDP for GTP on the Gα-subunit. Gα-GTP then dissociates from Gβγ and R*. Both subunits are 
free to modulate the activity of a wide variety of intracellular effectors. Termination of the 
signal occurs when the γ-phosphate of GTP is removed by the intrinsic GTPase activity of the 
Gα-subunit, leaving GDP in the nucleotide binding pocket on Gα. Gα-GDP then reassociates 
with Gβγ and the cycle is complete.
123
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The activation of GPCR leads to allosteric conformational changes in the receptor, leading to 
exchange of GDP from the Gα subunit for guanosine triphosphate (GTP) and dissociation of 
the G protein heterotrimeric subunits. The Gβγ form a single subunit which performs various 
functions independently of the Gα constituent (Figure 13). The G protein cycle is completed 
by the hydrolysis of the GTP bound to the Gα subunit by its intrinsic GTPase activity. Thus, 
the Gα subunit returns to the original state, which leads to reassociation again with the Gβγ 
subunits and finally binding of the heterotrimer to the GPCR (Figure 13).
124
 
The Gα subunit nomenclature is used to classify GPCRs with regard to their primary signal 
transduction pathway. There are 16 forms of α subunits known, which have been grouped into 
4 subclasses (Figure 14):  
1. Gαi which leads to decreased cAMP though the inhibition of adenylate cyclase, 
2. Gαq which leads to a rise in intracellular calcium by activating the PLC pathway,  
3. Gαs-coupled receptors lead to increased levels of cAMP via the adenylate cyclase 
pathway and 
4. Gα12 interacts with Cl
–
 channels. 
 
The dissociated βγ subunit can also modulate several signaling pathways, including 
stimulation or inhibition of adenylate cyclases, activation of phospholipases, and regulation of 
potassium and calcium channels.
125 
 
 
Figure 14. The principle mechanisms involved in different G protein signalling pathways. Gs 
and Gi proteins are coupled to adenylate cyclase (AC) whereas Gq is coupled to phospholipase 
β (PLCβ) and inositol-1,4,5-trisphosphate (IP3) production. In addition βγ affects activity of 
phosphoinositol-3-kinaseγ (PI3Kγ) as well as certain ion channels.126 
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GPCR signalling is a multistep process composed of: 
 agonist binding,  
 conformational change of the receptor leading to G protein activation and  
 subsequent coupling to intracellular secondary messenger mechanisms.  
 
Each of these three steps gives possibilities for the development of a screening strategy:  
 
1. The first point in the process that could be used is the binding of a ligand to the receptor. 
If suitable tracer compounds are available a variety of approaches could be exploited 
for developing a screening assay.  
2. The second step that could be exploited is agonist-mediated stabilization of the receptor 
in an active conformation resulting in nucleotide exchange (GTP for GDP) on 
      an associated hetero-trimeric G protein. This step could be exploited for screening       
            purposes using GTPγS binding technologies.  
3. The third step depends on the type of G protein coupled to receptor.126 
 
In principle the simplest assay is competition binding, however, this has the disadvantage that 
it primarily addresses the initial event, potentially missing receptor regulation through 
allosteric mechanisms. A functional assay where a receptor functions through its cognate G 
protein offers the best choice for identifying all compounds that alter receptor function.
126
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1.4. Functional studies 
 
Functional assays are used for the following purposes: 
 they facilitate early and direct pharmacological characterization of compounds; 
 they expedite the separation of antagonist and agonist compounds and 
 enable the identification of novel compounds such as allosteric modulators, weak-
affinity and high-potency agonists.
127  
 
In in vitro screening there are several methods used to quantify functional effects at a number 
of points along the GPCR signalling cascade. In the following chapters, selections of the 
commonly used methods are reviewed.
128
 
 
1.4.1. Regulation of intracellular 3′,5′-cyclic adenosine monophosphate levels 
 
The production of cAMP is controlled through the adenylyl cyclase (AC) family of enzymes, 
which convert adenosine triphosphate (ATP) to cAMP and inorganic diphosphate (Figure 15). 
These enzymes are activated or inhibited by direct interaction with G protein α-subunits and, 
for some isoforms, with Ca
2+
 and calmodulin.
129, 130
 
 
 Following Gs-coupled GPCR activation, agonists exert a positive effect on AC catalysis. 
The produced cAMP is able to bind to protein kinases in the cell, initiating 
phosphorylation events that regulate target enzymes and transcription factors.  
 Following Gi-coupled receptor activation, Gαi is activated and a negative effect is 
exerted on the enzyme.  
 
Degradation of cAMP is controlled by the cAMP phosphodiesterase (PDE) enzymes, which 
catalyse the hydrolysis of the 3′-ester bond of cAMP to form 5′-adenosine monophosphate 
(AMP). There are various PDE isoforms, which are involved in the breakdown of either 
cAMP or cGMP. There are several mechanisms which lead to activation of PDE enzymes. 
The most widely observed mechanism for activation of the cAMP PDEs is phosphorylation 
by cAMP-dependent protein kinases. The cAMP PDE enzymes act as an important negative-
feedback system on the receptor-mediated signalling cascade, regulating the extent of changes 
in intracellular cAMP concentrations.
131
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Figure 15. Ligand-receptor interaction and intracellular regulation of cAMP levels. 
 
1.4.1.1. Quantitative analysis of 3′,5′-cyclic adenosine monophosphate levels  
 
1.4.1.1.1. Accumulation assays 
 
 Radiometric competitive binding assays 
 
These are the most widely used techniques for cAMP measurement. These methods follow a 
general principle, in which changes in intracellular cAMP are detected by the competition 
between cellular cAMP and a labelled form of cAMP for binding to an anti-cAMP antibody 
or anther cAMP-binding protein.  
 
 Non-radiometric assays 
Examples for these types of assays are the application of fluorescence polarization (FP)
132 for 
detection of cAMP. Time-resolved fluorescence resonance energy transfer (TR-FRET) has 
also been applied to the measurement of cAMP as well as homogeneous time-resolved 
fluorescence (HTRF). 
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Three new technologies have been developed which aim to provide non-radiometric high-
sensitivity assays:
128  
 
1. ALPHA screen (amplified luminescent proximity homogeneous assay), 
2. an enzyme complementation technology and 133 
3. electrochemiluminescence detection.  
 
The selection of a given technology might also require evaluation of other parameters, such as 
detection limits, cost and the number of addition steps.
128
 
 
 
1.4.1.1.2. Reporter-gene assays for 3′,5′-cyclic adenosine monophosphate detection 
 
A reporter gene is a sequence of DNA whose product is synthesized in response to activation 
of the signalling cascade under investigation. The DNA sequence consists of a promoter, 
where transcription factors bind to control transcription, a reporter gene and a transcription 
stop signal. The choice of promoter element dictates the sensitivity and specificity of the 
reporter. The reporter must have:
134
 
 low basal expression and a large transcriptional response following receptor activation,  
 offer a unique property to the cell system being studied,  
 have a short half-life to minimize basal accumulation and 
 be easily measurable by simple, cheap assays.  
 
Reporter-gene assays follow a general principle, in which receptor-mediated changes in 
intracellular cAMP concentrations are detected through changes in the expression level of a 
particular gene (the reporter), the transcription of which is regulated by the transcription factor 
cAMP response-element binding protein (CREB) binding to upstream cAMP response 
elements (CREs) (Figure 16).
134
 
 
Several protocols and different numbers of CREs are used for reporter assays. The choice of 
reporter gene and the particular method for measuring activity of that reporter gene must be 
done carefully. Although all reporter genes share common properties in that they are absent 
from the cell type of interest and a small number of active molecules are required for 
detection, they represent the most significant factor when considering which assay system to 
choose.
128
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Figure 16. A schematic diagram showing how, after stimulation of the GPCR and 
dissociation of the G protein subunits, the major G protein families signal by the different 
intracellular second messenger pathways to communicate with nuclear promoter elements. (a) 
Gαs-coupled receptors stimulate AC, which synthesizes cAMP from ATP. In contrast Gαi-
coupled receptors inhibit AC and so reduce cAMP formation. (b) The βγ subunits from Gαi 
and other G proteins are able to activate the MAP kinase pathways and PLCβ. (c) GPCRs 
coupled to the Gαq family of G proteins stimulate PLCβ, which cleaves membrane 
phospholipids to produce IP3, which mobilizes intracellular calcium, and DAG, which 
activates PKC. (d) Second messenger pathways then activate a range of effector systems to 
change cell behaviour; in many cases this includes the regulation of gene transcription. The 
dotted line shows a more indirect pathway. MAPK, MAP kinase, MEK, MAP kinase kinase; 
P, phosphate; PIP2, phosphatidylinositol-4, 5-bisphosphate.
134
 Abbreviations, cAMP response 
element (CRE), serum response element (SRE), activator protein 1 (AP-1) nuclear factor of 
activated T cells response element (NFAT-RE). 
 
Various reporter genes have been used in in vitro and in vivo studies, including:
134-137
 
 β-galactosidase, 
 green fluorescent protein (GFP), 
  luciferase,  
 β-lactamase.  
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Luciferase enzymes have shorter half-lives than β-galactosidase and GFP, providing some 
advantage and making them a popular choice in screening assays.
138
 
 
The most commonly used luciferase enzyme is that from the firefly (Photinus pyralis), which 
catalyzes the oxidation of luciferin to produce oxyluciferin and light (Figure 17). The 
advantage of using this particular enzyme is that there are various reagents available to detect 
these effects. Some of these reagents can prolong the life time of the light emitted, making it 
detectable for several hours and improving automation compatibility. However, it is noted that 
luciferin analogues, which are present in the compound collection, will interfere with the 
assay in spite of reagent choice.128 
 
 
 
 
Figure 17. Schematic representation of the luciferase reporter-gene technologies. Cells 
containing the luc gene under the control of cAMP regulatory elements (CREs) are incubated 
with agonist. Following this receptor activation, increases in cAMP activate the cAMP-
dependent protein kinase (PKA), which then phosphorylates the transcription factor CRE-
binding protein (CREB). Phosphorylated CREB binds to the CREs, mediates transcription and 
functional luciferase is created. However, the cells need to be lysed to detect the activity of 
the luciferase enzyme. Following this lysis and addition of substrate, the enzyme catalyses a 
mono-oxygenation reaction, which produces oxyluciferin and light (550–570 nm) that can be 
measured. The light produced is naturally short-lived; however, reagents are available that 
prolong this lifetime, making it suitable for automated high-throughput screening.
128
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The sea pansy (Renilla reniformis) luciferase enzyme, which catalyses the oxidation of 
coelenterazine to coelenteramide and light (480 nm), can also be used as a reporter. It has 
been used in conjunction with the firefly enzyme as a means of controlling well-to-well 
variations or simultaneous screening of two different targets.
139
 
 
Recently, the family of luciferase enzymes has been reviewed, highlighting key residues that 
are involved in both substrate binding and bioluminescence colour.
140
 This could give us 
valuable information for the development of improved luciferase reagents that produce stable 
signals at alternative wavelengths and minimizing the potential for compound interference. 
 
The cell lines most commonly used in reporter-gene assays are Chinese hamster ovary cells 
(CHO) and human embryonic kidney cells (HEKs).  
 
Table 4. Advantages and disadvantages of accumulation and reporter-gene systems
128 
 
  
       Accumulation assays 
 
 
      Reporter gene assays 
 
Advantage Some technologies have been 
successful with membranes  that 
can reduce the impact of false-
positives (for example: FP) 
 
Molecular biology not required if  
endogenous receptors are used 
 
 
Might be more physiologically  
relevant than  reporter systems 
(e.g. β2-adrenoceptor)141 
Amplification might mean greater 
sensitivity to weak agonism 
 
Assays are generally cheaper than 
accumulation assays 
 
Assays are compatible with standard 
plate readers and automation  
 
Tissue-culture resource might be less 
than whole-cell accumulation assay 
 
 
 
Disadvantage 
 
Might be less sensitive to weak  
agonism 
 
 
Some technologies might require  
a specific reader 
 
Misleading data might arise due to  
large changes in cAMP producing  
small changes in raw data 
 
Accumulation technologies are 
generally more  expensive than 
reporters 
 
Amplification means that the compound 
activity detected might not be 
physiologically relevant 
 
Molecular biology required 
 
 
Misleading data might arise due to 
inducible cAMP early repressor (ICER) 
or accumulation assay receptor 
desensitization142,143 
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There are some factors that should be considered (Table 4) in order to indicate whether an 
accumulation or reporter-gene technology is more suitable for a certain test system. For 
example, if an agonist is required, a reporter-gene system might be more sensitive, through 
maximizing the potential of identifying activities. However, if a membrane-based 
accumulation assay can be developed, it might minimize the tissue culture resource required 
and could potentially minimize false-positives that would be observed as a result of 
downstream activity of compounds.
128 
 
 
1.4.1.2. General remark for 3′,5′-cyclic adenosine monophosphate assays (accumulation or 
reporter) 
 
The following points must be taken in consideration during the performance of cAMP assays: 
 
1. Tolerance to organic solvents such as dimethylsulphoxide (DMSO), which is tolerated 
in the order of 1–10% for the cAMP assays mentioned before.128 
2. In order to detect the negative regulation of AC by Gi-coupled GPCRs, the system must 
first be active. This is achieved by using the direct chemical modulator of AC,   
forskolin. The EC50 value for forskolin is different depending on the type of cell used 
and might also vary dependent on the type of assay format (that is, accumulation 
versus reporter gene).
144 
Thus, it is important to determine the potency of forskolin for 
the system of choice. Also, forskolin can stimulate cells to produce changes in cAMP 
that are much greater than would be generated by receptor-mediated action.  Therefore, 
care for evaluation of the concentrations used is required to ensure that optimum 
sensitivity is obtained.  
3. Breakdown of cAMP by PDEs can also affect the data that are produced in assays that 
measure the AC pathway. For example, PDE inhibitors could appear as false-positives 
in a screen for agonists of a Gs-coupled GPCR. To control for such effects, the non-
selective PDE inhibitor isobutylmethylxanthine (IBMX) can be included in the buffer. 
Dependent on the system, this might significantly increase basal levels of cAMP, but 
might also improve the observed potency of forskolin;
145
 therefore, the effect of 
addition of IBMX on the assay sensitivity should be fully evaluated. 
 
1.4.2. Measurement of intracellular calcium or inositol 1,4,5-trisphosphate levels (IP3) 
 
Activation of Gq-coupled receptors leads to release of calcium from intracellular [Ca]i stores 
through the generation of IP3 as a consequence of PLC activation (Figure 14 and 16). 
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Functional assays of Gq-coupled receptors can be performed using both the IP3 or calcium 
signal and are consequently cell-based screening strategies. 
 
The detection of calcium can be achieved by fluorescent dyes and technologies such as 
fluorimetric imaging plate readers (FLIPR).
146
 For example, in living cells, small, cell-
membrane permeable molecules, such as fluorescent dyes can be used, which change their 
fluorescent properties after binding of Ca
2+
 (Figure 18). As high-throughput screening (HTS) 
test, this assay presents several advantages:
138,147,148
  
 
(1)  it is a sensitive nonradioactive fluorescence-based assay; 
(2)  it can be miniaturized to a 384 well plate level; 
(3)  it is easy to perform and can be automated; 
(4)  it provides a positive signal over the background.  
 
The FLIPR technology is extensively used for high throughput screening even through 
fluorescent compounds can potentially interfere with the assay.
126 
 
In addition, it can be also used to study Gi-coupled receptors by using chimeric or 
promiscuous G proteins. These G proteins enable the system to be switched to the PLC/Ca
2+
 
pathway or the stimulatory AC/cAMP pathway.
149-151
However, such strategies also need to be 
used with care because these alternative G proteins do not couple effectively to all receptor 
types, which can lead to either an altered pharmacological profile or to no signal being 
detected.
151-152
 
 
An alternative approach is to use the aequorin technology. The use of the photoprotein 
aequorinwas reported as a sensitive detector of increases in [Ca
2+
]i levels.
153, 154
  Apoaequorin 
is a 21-kDa photoprotein, isolated from the jellyfish Aequorea victoria, which forms a 
bioluminescent complex when linked to the chromophore cofactor coelenterazine. The 
binding of [Ca
2+
]i to this complex results in an oxidation reaction of coelenterazine, followed 
by the production of apoaequorin, coelenteramide, CO2, and light (469 nm), which can be 
detected by luminometry.
155 
 
The calcium detection technologies provide one of the principal methods for Gq-coupled 
receptor screening.
126 
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Figure 18. The fluorescent dye enters cells as a membrane-permeable acetoxymethyl (AM) 
ester. Once inside the cell, the fluorescent dye is hydrolyzed by intracellular esterases. The 
cell membrane-impermeable, negatively charged form of the fluorescent dye is now capable 
of binding with Ca
2+
.
156
  
 
Alternatively there are several methods for the screening of IP3 levels. These methods are all 
cell-based and are a mixture of homogeneous and non-homogenous techniques. These 
methods should have rapid termination of the assay, a factor that introduces significant 
technical difficulties. 
 
Practical experience has shown that calcium detection methodologies provide more robust 
assay options than those used to measure IP3 accumulation. The measurement of IP3 is 
necessary only when studying receptor inverse agonism.
126
 
 
1.4.3. Measurent of extracellular signal-regulated kinase 1/2 levels (ERK1/2) 
 
Current methods employed in GPCR screening programs measure various cellular signaling 
events. As already described the most widely used include measuring the formation of cAMP, 
IP3, and intracellular Ca
2+ 
mobilization. cAMP assays are useful when the receptors are 
known to couple to Gi or Gs pathways, although they are limited in the irability to screen an 
orphan or Gq-coupled receptors. Ca
2+
 mobilization assays are widely used to measure 
activation of Gq-coupled receptors or in cell lines transfected with chimeric G proteins, which 
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redirect the normal signaling pathway through PLC and Ca
2+
 mobilization. Although this 
technology is widely used, it requires specialized instrumentation, and there are several 
limitations. The receptor must be Gαq coupled or be transfected with a chimeric G protein. The 
signal to baseline, and thus the dynamic range of the response, is often poor, and the time of 
flux is often brief, affording only a small window of time for measuring response. Finally, 
data output can be large due to the kinetic nature of the assay measurements forming large 
data sets.
157
  
 
Because of these potential limitations, it is desirable to have another assay target as a 
measurement of cellular GPCR agonists and antagonists. The potential for using the 
phosphorylation of p42/44 MAP kinase (mitogen-activated protein kinase) (extracellular 
signal-regulated kinases 1 and 2 ERK1/2) as a measure of GPCR activation became apparent in 
studies using COS-7 cells transfected with constitutively active mutants of Gαs, Gαq, or Gβγ. 
Transfection with these signaling mutants resulted in sustained activation of ERK1/2
158,159
 and 
demonstrated, at least in COS-7 cells, that activation of ERK1/2  was possible from a variety of 
GPCR signaling inputs.  
 
The ERK1/2 cascade can be activated by a variety of different GPCRs, and the complex set of 
signaling pathways that are generated by GPCR stimulation converges at ERK1/2, despite 
coupling to different G protein subclasses (Figure 19). Recent evidence has shown that these 
pathways are separated functionally by the presence of distinct pools of active ERK1/2 
throughout the cell.
160
 Thus, activation of a GPCR in any given cell type may result in ERK1/2 
phosphorylation, and although the activated pool is located in the plasma membrane, focal 
adhesions, nucleus, or cytoplasm, ERK1/2 can be used to measure the functional outcome of 
receptor stimulation. 
 
Until recently, the use of ERK1/2 activation as a measurement for GPCR activation has not 
been possible because a cell-based high throughput assay has not been available. Recent 
higher throughput assays for the detection of intracellular ERK1/2 phosphorylation include 
electrochemiluminesence-based (Meso-Scale Discovery [MSD]) and infrared fluorescence-
based (LICOR) detection systems. Using such detection systems, a 384-well ERK-based 
assay for the detection of agonist mediated dopamine D2 and D3 receptors has been 
described.
161
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Figure 19. G protein–coupled receptor (GPCR) signaling pathways via ERK1/2. ERK1/2 can be 
activated by GPCRs, which couple to different protein subclasses and transduce the signal by 
different pathways. Functional separation of these signals is achieved by spatially distinct 
pools of ERK1/2 within the cell.
160 
 
Common techniques for the detection of ERK1/2, Western blotting or enzyme-linked 
immunosorbent assay (ELISA), are laborious and are medium throughput at best. The 
SureFire™ cellular ERK1/2 assay measures activation of ERK1/2 in a high-throughput format 
that is performed in 384-well microplates and can be fully automated with standard robotics. 
The assay was used to measure endogenous levels of ERK1/2 phosphorylation in both 
transiently and stably transfected cell lines expressing Gq-coupled receptors and to measure 
the activation of endogenous GPCR receptor activation in several cell lines as well. The 
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measurements of GPCR activation indicated that ERK1/2 activation is pharmacologically 
similar to previously established responses as measured by other assay formats.
157
 
 
The serum response element (SRE) is activated by MAP kinases
162,163
 which are activated by 
mitogenic signals from a number of receptors. At the SRE, a complex forms between the 
serum response factor and a ternary complex factor (e.g. Elk-1). A MAP kinase 
phosphorylates the ternary complex factor to allow the complex to initiate transcription. The 
βγ subunits from Gi proteins have been shown to activate this pathway via Ras-dependent 
MAP kinase activation
159,164,165
 (Figure 16 and 19). Stimulation of MAP kinases via Gq-
coupled receptors results mainly from PKC activation.
159,164,166
 Recent studies using SRE 
based reporter genes include investigation of the muscarinic M1 receptor,
167
 Edg3 and Edg5 
receptors for lysophosphatidic acid
168,169
 and α1-adrenoceptors.170 
 
ERK activation is related to the activation of the SRE-pathway.
171
 The dopamine D2-receptor 
which is a Gi-coupled receptor has been previously shown to couple to the SRE-
pathway.
172
The native P2Y12-receptor mediates an activation of the extracellular signal-
regulated protein kinase ERK
173,174 
and recombinant hP2Y12 was shown to activate the ERK 
through coupling to the SRE-pathway.
 175
 There is no information known about activation of 
the extracellular signal-regulated protein kinase ERK for the adenine receptors.   
 
pSRE-Luc is designed for monitoring the induction of the serum response element (SRE)
 
in a 
reporter gene assay. pSRE-Luc is designed to measure the binding of transcription factors to 
SRE, providing a direct measurement of activation for this pathway.
176
 pSRE-Luc contains the 
firefly luciferase (luc) gene from Photinus pyralis.
177
 After transcription factors bind SRE, 
transcription is induced and the reporter gene is activated. For example, the addition of serum 
or growth factors to the cell-culture medium induces the binding of transcription factors to 
SRE, which initiates transcription of the luciferase reporter gene. Luciferase is a highly 
sensitive enzymatic reporter that can be assayed by any standard luciferase-detection method, 
which provides quantitative data on induction levels. The pSRE-Luc vectors can be 
transfected into mammalian cells by any standard method.  
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1.4.4. β-Arrestin assays  
 
ß-Arrestin assays are high-throughput screening assays for monitoring GPCR activation 
following ligand stimulation, without an imaging instrument, fluorescent protein tag, or 
radioactivity. This assay method provides a suitable format for HTS automated screening. 
This GPCR assay system provide the means for discovering new therapeutic leads for known 
GPCRs and to potentially de-orphanize novel GPCRs with a high a sensitivity, 
specificity.
178,179
 
 
1.4.4.1. Principle of ß-arrestin assay  
 
GPCR activity can be monitored by detecting the interaction of arrestin with the activated 
GPCR using enzyme fragment complementation.  In this system, the β-galactosidase enzyme 
is split into two inactive fragments.  When these fragments are fused to two proteins that 
interact, the interaction of the two proteins forces the complementation of the fragments to 
restore enzyme activity. The figure 20 shows the system as applied to measuring GPCR 
activation.  The larger portion of β-gal, termed ∆ω, is fused to the C-terminus of β-
arrestin.  The smaller complementing fragment of β-gal, the ∆α, is expressed as a fusion 
protein with the GPCR of interest at the C-terminus.  Upon activation, the GPCR is bound by 
β-arrestin.  The interaction of β-arrestin and the GPCR forces the interaction of ∆α and ∆ω, 
thus allowing complementation of the two fragments of β-gal and the formation of a 
functional enzyme capable of hydrolyzing substrate and generating a fluorescence signal 
(Figure 20).
178,179 
 
This assay eliminates interference from endogenous receptors on the parental cells because it 
measures a signal that is specifically generated by the tagged receptor and is immediately 
downstream of receptor activation.
179
 
 
In general these important factors must be taken into consideration in the design of assays: 
1) the low costs of assay development and assay reagents;  
2) the ease of use and suitability of the assay format for automation; 
3) the generation of an assay end-point suitable for miniaturization into 96-, 384-,1536-
well and smaller microplate formats; 
4) the generation of a suitable signal ratio in the assay to enable the rapid identification of 
any compound with activity.  
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An ideal assay would involve few requirements, no plate-to-plate transfers or washing steps, 
and would be suitable to full automation. 
 
 
 
Figure 20. The inactive β-gal deletion mutants, ∆α and ∆ω are fused to the carboxyl terminus 
of a GPCR and β-arrestin 2, respectively. Fusion proteins are stably expressed in cells 
following retroviral infection and clone selection. Interaction of ligand-activated GPCR with 
β-arrestin 2 drives complementation of the β-gal mutant fragments.178 
 
1.5.  Retroviral gene transfer technology principle  
 
Current retroviral gene transfer technology is based on the coordinated design of packaging 
cell lines and retroviral expression vectors.
180,181
To develop a packaging cell line, the viral gag, 
pol, and env genes are stably integrated into the genome of the packaging cell line. The 
separate introduction and integration of the structural genes minimizes the chances of 
producing replication-competent virus due to recombination events during cell 
proliferation.
182,183 
Retroviral expression vectors provide the packaging signal Ψ+, 
transcription and processing elements, and a target gene. The viral env gene, expressed by the 
packaging cell line, encodes the envelope protein. Viral envelopes are classified according to 
the receptors used to enter host cells. For example,  
1. ecotropic viruses can recognize a receptor found only on mouse and rat cells;  
2. amphotropic viruses recognize a receptor found on a broad range of mammalian cell 
types;  
3. dualtropic viruses recognize two different receptors found on a broad range of 
mammalian cell types;  
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4. a pantropic packaging cell line provides a major advancement in retroviral gene transfer, 
as this cell line produces viruses that can infect both mammalian and non-mammalian 
cells.
183 
Using this cell line, virions are pseudo-typed with the envelope glycoprotein 
from the vesicular stomatitis virus (VSV-G). Unlike other viral envelope proteins, 
VSV-G mediates viral entry through lipid binding and plasma membrane fusion.
184
 
 
Stable expression of the VSV-G envelope protein is toxic; thus, the packaging cell line only 
contains the viral gag and pol genes. Virus is produced by transiently cotransfecting a 
retroviral expression vector and pVSV-G into a pantropic packaging cell line. 
 
 
 
Figure 21. Virus production in packaging cell lines. The gag, pol and env genes required for 
viral production are integrated into the packaging cells genome. The vector provides the viral 
packaging signal, commonly denoted Ψ+, a target gene, and drug-resistance marker. 
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Once a packaging cell line is transfected with a retroviral expression vector that contains a 
packaging signal, the viral genomic transcript containing the target gene and a selectable 
marker are packaged into infectious viruses within 48–72 h. Antibiotic selections are used to 
select cells that stably express the integrated vector. Stable virus-producing cells can be frozen 
and used in later experiments. Virus produced by both transient and stable transfections can 
infect target cells and transmit target genes; however, it cannot replicate within target cells 
because the viral structural genes are absent. 
 
In this study an amphotropic retrovirus packaging cell line (GP+envAm12) was used. This 
amphotropic retrovirus packaging cell line was constructed in which the gag, pol, and env 
genes of the helper virus are separated on two different plasmids. A plasmid containing the 
moloney murine leukemia virus gag and pol genes was transfected into NIH 3T3 cells, and a 
plasmid containing the 4070A amphotropic env gene was transfected into one of the resulting 
clones which produced a high level of reverse transcriptase. A clone producing a high level of 
amphotropic env protein (GP+envAm12) was then isolated.
185
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2. Scope of investigation 
 
The purinergic receptor family represents very important targets for the discovery of new 
drugs for the treatment of various diseases via activation or blockade of those receptors. 
Therefore the goals of the present study were: 
 construction of recombinant cell lines expressing purine receptor subtypes 
 assay development in: 
 native tissues and cells 
 recombinant cells 
In order to develop assays for compound testing such as: 
 radioligand binding assay at membranes and living cells  
 functional assays via measurement of: 
 cAMP accumulation, 
 measurement of intracellular Ca2+ levels  
 the ERK signaling pathway coupled receptors.  
And subsequent 
 screening of compound libraries 
 detailed characterization of selected compounds 
 analysis of their structure-activity relationships 
 investigation of species differences  
 and characterization of purinergic receptors in tissues and cells of various species.  
 
In particular, the present study focuses on the newly discovered adenine receptors. 
 
2.1. Adenine receptors (P0 receptors) 
 
2.1.1. Human adenine receptors 
 
Purinergic receptors are divided into two families, P1 receptors activated by nucleosides and 
P2 receptors activated by nucleotides.
2
 The P0 receptors (adenine receptors) have recently 
been discovered and identified as a third member of the purinergic receptor family.
5 
Adenine 
has been identified as the endogenous agonist for the adenine receptors.
102
 Two adenine 
receptor subtypes were identified, rat Ade1R, its mouse ortholog MrgA10 and mouse Ade2R. 
Radioligand binding studies at membranes of human astrocytoma 1321N1 cells revealed that 
a human ortholog of the rAde1R appears to exist.
104
 The human adenine receptor was also 
detected in Jurkat T cells and HEK293 cells.
186
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In HEK293 cells, the adenine receptor is expressed in very high density with a single high-
affinity binding site.
186
 The affinity of the physiological agonist adenine for human adenine 
receptors in membrane preparation of HEK293 cells showed a Ki value of 47.1 nM
186 
which 
was in a good agreement with that obtained for adenine receptors in rat cortical membrane 
preparations (Ki value of 29.2 nM).
104 
In the present study, our goal was to characterize the 
human adenine receptors in intact HEK293 cells using different radioligand binding studies 
including saturation, competition and kinetic experiments and subsequently compare the 
obtained results with those obtained with membrane preparations of HEK293 cells. The 
results will provide information about the behavior of the human adenine receptors in 
HEK293 cells under more physiological conditions. To investigate whether the human 
adenine receptors in HEK293 cells are Gi- or Gs-coupled, we plan to functionally characterize 
the human adenine receptors in the HEK293 cells using cAMP accumulation assays. In 
addition, adenine-induced ERK signalling will be investigated and a luciferase reporter gene 
assay is to be established useful for high-throughput screening in native HEK293 cells as well 
as in recombinant 1321N1 astrocytoma cells. 
 
In order to fully characterize the adenine receptors in different cells or tissues and to 
understand its physiological role, potent ligands, agonists and antagonists, must be developed. 
Therefore we aimed to search for potent ligands via screening of compound libraries based on 
modifications of the physiological agonist adenine, in various positions, either commercially 
available compounds or newly synthesized compounds, using radioligand binding assays. An 
important goal was to study their structure-activity relationships at the adenine receptors of 
human HEK293 cells and rat cortical membrane preparations and to analyze any species 
differences of the adenine receptor in human and rat. For the most potent compounds, 
functional assays were to be performed in order to know if they functioned as agonists or 
antagonists. cAMP assays had to be established using (a) a radioactive cAMP binding assay 
and (b) a cAMP luciferase gene reporter assay. In addition, we aimed to study the selectivity 
of the most potent compounds against the adenosine receptors.   
 
2.1.2. Mouse adenine receptors 
 
The mouse adenine receptor sequence found in mouse brain and NG108-15 cells, which is 
clearly distinct from the mouse ortholog (mMrgA10) of the rat adenine receptor, (mAde2R), 
was recently cloned.
104 
In this study, we aimed at functionally characterizing the cloned 
mAde2R receptor in order to know whether it is coupled to Gi or Gs proteins. In addition, we 
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planned to screen the most potent ligands of the purinergic receptors in order to distinguish 
the properties of the newly cloned adenine receptor from the other members of the purinergic 
receptor family.    
 
2.1.3. Hamster (CHO cells) and rat (PC12 cells) adenine receptors 
 
The studying of the effect of species differences and expression levels of AdeRs in different 
mammalian cell lines is very important for the characterization of the adenine receptors. For 
this reason we aimed at characterizing adenine receptors natively expressed in Chinese 
hamster ovary cells (CHO K1) and endogenous rat adenine receptors in pheochromocytoma 
cells (PC12 cells) using cAMP functional studies to determine the coupling of adenine 
receptors natively expressed in these cell lines. In addition we planned to determine the 
adenine receptor density in PC12 and CHO cells using radioligand binding studies.  
 
In addition to the main project, which focused on adenine receptors, other goal was to 
establish cell-based assays for several other members of the purinergic receptor family 
including adenosine A2A and A2B, P2Y1, P2Y11, P2Y12, P2Y13, P2X2, P2X3 and P2X4 
receptors. 
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3. Results and discussion 
 
3.1. Human adenine receptors  
 
3.1.1. Pharmacology and test systems for the human adenine receptors 
 
Radioligand binding studies at membranes of human astrocytoma 1321N1 cells revealed that 
a human ortholog of the rAde1R appears to exist.
104
 The human adenine receptor was also 
detected in Jurkat T cells and HEK293 cells, which is in agreement with the expression of 
adenine receptors in porcine kidneys.
186
 In HEK293 cell membranes the adenine receptor was 
found to be expressed in very high density (Bmax value of 8.18 pmol/mg protein) with a single 
high-affinity binding site.
186
 In competition studies, the physiological agonist adenine showed 
a Ki value of 29.2 nM for adenine receptors in rat cortical membrane preparations,
102 
and a Ki 
value of 47.1 nM for human adenine receptors in membrane preparation of HEK293 cells.
186 
The Ki value of adenine for human adenine receptors in membrane preparations of HEK293 
cells was in good agreement with the determined KD value obtained in saturation assays (44.1 
nM).
186
In the present study we characterized human adenine receptors in more detail. 
 
3.1.1.1. Radioligand binding studies
 
3.1.1.1.1. [
3
H]Adenine saturation experiments (saturation experiments for whole cells) 
 
Intact HEK293 cells were used for saturation studies. [
3
H]Adenine saturation experiments 
exhibited two binding sites with a KD1 value of 92.4 ± 4.7 nM and a Bmax1 value of 1.882 ± 
0.075 pmol/mg of protein, and a second site with a KD2 value of 4.15 ± 0.5 M and a Bmax2 
value of 0.381 ± 0.095 pmol/mg of protein (n = 2, Figure 22). We conclude that [
3
H]adenine 
labelled two binding sites one with high affinity and a second one with low affinity. The 
receptor density is quite high with a Bmax in the picomolar range for the high affinity site. 
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Figure 22. Saturation of [
3
H]adenine binding to adenine receptors in HEK293 cells. The mean 
± S.E.M of two independent experiments, performed in duplicate at room temperature, is 
shown.  
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3.1.1.1.2. Kinetic studies at whole HEK293 cells 
 
Association kinetics were performed by measuring the specific binding of [
3
H]adenine (15 
nM) at different time points between 2 and 240 min after addition of [
3
H]adenine. Nonspecific 
binding was determined by the addition of 100 µM adenine. 
 
Dissociation studies. Cells were first incubated with [
3
H]adenine (15 nM) for 60 min. 
Specific binding was then measured at 2–120 min after the addition of  100 µM adenine. 
 
Results of kinetic studies (Figure 23A) showed that [
3
H]adenine bound to HEK293 whole cell 
rapidly, and the steady state appeared to be reached after 15 min and sustained for at least 200 
min (Kobs= 0.263 ± 0.046 min
-1
). The binding was slowly reversed by the addition of adenine 
in a final concentration of 100 µM, with 30% of dissociation being evident after 60 min 
(Figure 23B). A kinetic KD value could not be determined and the law of mass action did not 
apply to the system. An explanation for the observed unusual kinetics could be that the 
adenine receptor undergoes a conformational change after binding of [
3
H]adenine; an initial 
low affinity conformation may be converted to a high-affinity conformation for adenine upon 
binding. A similar phenomenon had been already observed at rat brain cortical membrane 
preparations.
186
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Figure 23. The kinetics of [
3
H]adenine binding (15 nM) to HEK293 cells at 23°C. (A) 
representative association curve for specific [
3
H]adenine (15 nM) binding to HEK293. (B) 
Representative dissociation curve obtained by the addition of 100 µM unlabeled adenine to 
equilibrated specific binding of [
3
H]adenine (15 nM) to HEK293 cells (n = 3). 
 
3.1.1.1.3. [
3
H]Adenine competition assays   
The binding site of adenine receptors in HEK293 cells was further characterized using 
competition assays. HEK293
 
cells (3 x 10
5
) were incubated with 15 nM [
3
H]adenine as a 
radioligand. Inhibition curves were determined using different concentrations of adenine.  
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Nonspecific binding was determined with 100 µM adenine. The results showed that adenine 
exhibits an affinity of 3.44 µM in whole cell binding assays which means a 73-fold lower 
affinity than in competition assays using adenine and membrane preparations of HEK293 
cells (Figure 24). It was also considerable lower than the KD value determined in saturation 
assays (see 3.1.1.1.1.). 
 
The difference between the results from whole cell binding studies and binding assays at 
membrane preparation of HEK293 cells may be due to the fact that the intact cells have a 
machinery for quickly and efficiently removing physiological receptor agonists, in this case 
adenine, by degradation or cellular uptake, to limit their actions. However, little is known so 
far about the extracellular metabolism of adenine. Transporter proteins for adenine have been 
described, which may contribute to the removal of adenine from the extracellular 
compartment.
111, 113 
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Figure 24. Competition of [
3
H]adenine binding (15 nM) to adenine receptors in HEK293 cells 
(intact cells); Ki = 3.44 ± 1.46 µM from three independent experiments performed at room 
temperature.  
 
The binding sites for [
3
H]adenine detected in HEK293 cell membranes showed similar 
properties as in  brain cortex. Therefore, this cell line can be used as a model for studying 
natively expressed adenine receptors. 
 
As a next step the coupling of adenine receptors to adenylate cyclase was to be studied. 
Therefore functional studies were performed.  
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3.1.1.2. Functional studies 
 
3.1.1.2.1. cAMP accumulation assays at human adenine receptors in HEK293 cells 
 
It had been shown before that adenine receptors in human HEK293 cells are coupled to Gs 
protein and therefore adenine leads to an increase in intracellular cAMP in a dose-dependent 
manner with an IC50 value of 4.72 µM.
186
 However cAMP assays performed at human 
adenine receptors in HEK 293 cells in our hands suggested that two distinct subtypes of 
adenine receptors might exist in this cell line (Figure 25A). Another explanation could be that 
the adenine receptors in HEK 293 cells might couple to inhibition as well as to activation of 
adenylate cyclase depending on the test conditions, i.e. the concentration of adenine used for 
receptor stimulation. 
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Figure 25. (A) The figure shows the amount of intracellular cAMP-accumulation by adenine 
(0.001–100 µM). (B) Stimulation of adenylate cyclase activity by adenine in HEK293 cells 
after incubation of cells with PTX (100 ng/ml). The figure shows the concentration-dependent 
stimulation of intracellular cAMP-accumulation by adenine (0.01–1 µM). The EC50 value was 
0.372 µM (n = 1). 
 
To further test this assumption, the effect of pertussis toxin (PTX) on adenine receptors in 
HEK293 was studied. Cells were pre-treated with PTX (100 ng/ml) over night before the 
cAMP assay was performed. Pertussis toxin is inhibiting the signal transduction via Gi-
coupled GPCRs by catalyzing the ADP ribosylation of the α-subunit of the G protein. 
Therefore the Gα subunit remains in its GDP-bound inactive state and is not able to inactivate 
the adenylate cyclase. Pertussis toxin has no effect on the stimulatory Gs proteins. By 
inactivating the Gi- coupling of the adenine receptor we only see the stimulatory effect of 
adenine as shown in figure 25B.   
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We conclude that adenine receptors in HEK293 cells are coupled to stimulation of adenylate 
cyclase, which is seen at low concentrations, via Gs, and to inhibition of adenylate cyclase 
(Gi) at high concentrations.  
 
However, the coupling of adenine receptor to the Gs pathway is relatively weak if we compare 
the produced amount of cAMP/well to that produced in case of adenosine A2A and A2B 
receptors expressed in CHO cells. Using the same test system both, adenosine A2A and A2B 
receptors, showed amounts of cAMP not less than 20 pmol/well when stimulated with the 
agonist NECA at a concentration of 1 µM. In comparison the maximal effect induced by 
adenine in HEK293 is at least 5-fold weaker. 
 
3.1.1.2.2. Investigation of extracellular signal-regulated kinase (ERK) phosphorylation 
induced by human adenine receptors in HEK293 cells 
 
The detected coupling of human adenine to adenylate cyclase in HEK293 was not strong 
using cAMP accumulation assays. Therefore, a further functional study was performed in 
order to study the pharmacological properties of this receptor in HEK293 cells, using an 
ERK-phosphorylation assay. To investigate whether adenine has any effects on this 
downstream target, we performed a luciferase assay using SRE-LUC as a reporter gene for 
human adenine receptors in HEK293 cells. SRE is located in the promoter region of the c-Fos 
gene and plays a major role in regulation of c-Fos gene transcription.  
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Figure 26. Increases in SRE-dependent luciferase expression upon addition of different 
concentrations of adenine in HEK293 cells (% of basal activity). The EC50 value was 21.5 ± 
2.1 nM (n=3). 
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In the luciferase assay, adenine induced the SRE-LUC reporter gene expression in a dose-
dependent manner with an EC50 value of 21.5 ± 2.1 nM (Figure 26). Because adenine could 
induce SRE-LUC reporter gene expression, it also influenced the phosphorylation of ERK. 
Our studies provide new insights into the activation of the ERK signaling pathway via adenine 
receptors.  
 
Recently, by use of a luciferase gene reporter assay it was shown that the human P2Y12 
recombinantly expressed in CHO stimulates the ERK-pathway upon receptor activation via 
SRE-dependent gene expression; this pathway was shown to be pertussis toxin sensitive.
175 
The human P2Y12 receptor expressed in CHO Flp-In cells showed an increase of ca. 50-60% 
of basal increases in SRE-dependent luciferase expression activity.
175 
Similar results were 
now obtained with the adenine. At a concentration of 10 µM a 57 ± 16% increase in SRE-
dependent luciferase was observed. From the above data, we conclude that the human adenine 
receptors in HEK293 cells leads to stimulation of ERK-pathway that is comparable with the 
reported signal of the human P2Y12 receptor inducing ERK1/2 phosphorylation. It should be 
noted that the EC50 value of adenine determined in ERK phosphorylation assay (21.5 nM) was 
much lower than that determined in the cAMP assay (372 nM). 
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3.1.2. Structure-activity relationships of adenine derivatives at human and rat adenine 
receptors 
 
It had been shown in studies that even only small modifications at the adenine structure led to 
a major reduction or loss of affinity for the rAde1R. For example, 1-, 3-, 6-, 7-, or 9-methyl-
adenine exhibited Ki values in the micromolar range at the rAde1R compared with nanomolar 
affinity for adenine.
104
 
 
As already pointed out, there is evidence showing that adenine may play a role in human and 
pig renal function.
108
 Consistent with these observations, we detected a specific binding site 
for [
3
H]adenine in HEK293 cell membrane preparations (Figure 27A). Homologous 
competition experiments with adenine versus [
3
H]adenine (10 nM) at HEK293 cell 
membranes yielded a Ki value of 47.1 nM, which is very similar to the Ki value of 29.2 nM 
obtained for adenine at rat brain cortical membrane preparations (Figure 27B). 
 
We subsequently performed competition experiments to investigate the structure-activity 
relationships of selected adenine derivatives at the high-affinity adenine binding site in 
HEK293 cell membranes. Experimental conditions for the HEK membranes were the same as 
for the rat receptor preparations. The determined competition curves for the most active 
adenine derivatives are collected in figure 28 and affinities are compared with those 
determined for the rAde1R at rat brain cortical membrane preparations using [
3
H]adenine (10 
nM) as a radioligand.
104
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Figure 27. (A) Non-specific and specific binding of 10 nM [
3
H]adenine to HEK293 cell 
membrane preparations (100 µg protein, n = 3; error bars represent SEM values); (B) 
Homologous competition experiments with adenine vs. [
3
H]adenine (10 nM) at membrane 
preparations of rat brain cortical membrane, and HEK293 cell membrane preparations, 
respectively. Data points are means ± SEM of three experiments performed in triplicates at 
room temperature. 
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It has clearly been shown that [
3
H]adenine is a suitable radioligand for the labelling of AdeR 
if bacterial contaminations (which can also bind [
3
H]adenine) in the applied buffer solutions 
are avoided.
187
 A series of compounds was investigated in radioligand binding studies at 
membrane preparations of human embryonic kidney HEK293 cells in order to assess their 
affinity for human adenine binding sites.  
 
Table 5. Comparison of affinities of adenine and adenine derivatives for human and rat 
adenine receptors determined in radioligand binding studies using membrane preparations 
(modification at position 1 and 2). 
 
 
 
Compound     R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a 
HEK293 cells Rat brain cortex 
1 Adenine    ___ 0.0471  0.0292  
0.0034 
2 1-Propyladenine 
 
>> 100
 
(15 ± 5)
a
 >> 100
186
  
(12 ± 5)
a
 
3 2-Aminoadenine 
    
1.23  0.49 4.95  0.75
186
 
4 2-Azidoadenine 
      
> 100 (35  4)
a
 3.18  0.67
186
 
   aPercent inhibition ± SEM of radioligand binding at 100 µM.  
 
A comparison of the affinities of adenine and three adenine derivatives for the human adenine 
receptors in membrane preparations of HEK293 cells adenine showed that the affinities and 
the rank order of potency were similar to those at the adenine receptor expressed in rat brain 
cortex. (Table 5) The exception was 2-azidoadenine (4) which showed affinity for adenine 
receptors expressed in rat cortical membranes with a Ki value of 3.18 µM, whereas it showed 
no measurable affinity for the human receptors in membrane preparations of HEK293 cells. 
 
The introduction of an oxo-function in position 8 of adenine (6) resulted in increased Ki 
values (110 µM and 27 µM) in both test systems in comparison with the parent compound 
adenine. Substituents in the 8-position with alkyl- and arylsulfanyl residues (8-11) diminished 
the affinity for the rat adenine receptors in cortical membrane preparation at a concentration 
of 30 µM when compared to 8-thioadenine (Ki = 2.77 µM).
102
 The 8-phenylsulfanyl adenine 
(11) showed affinity in the micromolar range (Ki = 34.8 µM) for the human adenine receptors 
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in a membrane preparation of HEK293 cells while the 8-alkylsulfanyl residues (8-10) 
abolished affinity in the same test system. 8-Azidodenine (5) and 8-benzylaminoadenine (12) 
were able to displace [
3
H]adenine binding with affinities in the micromolar range in both test 
systems (Table 6).  
 
Table 6. Comparison of affinities of adenine derivatives with modifications at position 8 for 
human and rat adenine receptors determined in radioligand binding studies using membrane 
preparations. 
 
 
 
Compound        R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
 
HEK293 cells Rat brain cortex 
5 8-Azidoadenine 
(HPLL 92) 
    ___ 11.2 ± 2.8  6.37 ± 0.74
186
 
6 8-Oxoadenine 
 (TB 34) 
    ___ 110 ± 4  27.0 ± 6.5
186
 
7 TB 32 (PSB-09032) 
    
0.0341 ± 0.0088  6.51 ± 1.92
186
 
8 TB 37 
    
>> 100 (9 ± 2)
a
 >> 30 (10 ± 6)
b
 
9 TB 38 
    
>> 100 (24 ± 1)
a
 >> 30 (0 ± 6)
b
 
10 TB 39 
    
> 100 (46 ± 2)
a
 >> 30 (0 ± 4)
b
 
11 TB 45                                  
    
34.8 ± 8.1  >> 30 (0 ± 2)
b
 
12 
 
TB 25 
    
32.9 ± 2.9  6.67 ±  1.03
186
 
aPercent inhibition ± SEM of radioligand binding at 100 µM; bPercent inhibition ± SEM of radioligand binding 
at 30 µM. 
 
8-Aminoadenine (7) exhibited a Ki value of 0.0341 µM at the human binding site and thus 7 
was more potent than adenine itself (Ki = 0.0471 µM). Compound 7 was 190-fold more potent 
at the human as compared to the rat binding site and therefore shows high species-selectivity. 
Modifications at position 8 of adenine (Table 7) such as 8-(1-piperidinyl)adenine (13), 8-(1-
piperazinyl)adenine (15), and 8-dimethylaminoadenine (16) led to higher AdeR affinities than 
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bulky, lipophilic residues. However, 8-(1-pyrrolidinyl)adenine (14) showed no measurable 
affinity for the human adenine receptors in membrane preparations of HEK293 cells at a 
concentration of 100 µM while its Ki value at the rAde1R was 42.5 ± 2.5 µM.  
 
Table 7. Comparison of affinities of adenine derivatives with modifications at position 8 for 
human and rat adenine receptors determined in radioligand binding studies using membrane 
preparations. 
 
 
 
Compound R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a
 
HEK293 cells Rat brain cortex 
13 ANR 425 
 
31.7 ± 4.8  3.94 ± 0.87  
14 ANR 429 
             
> 100 (18 ± 3)
a
 42.5 ± 2.5 
15 ANR 426 
    
27.4 ± 4.6  3.27 ± 0.12  
16 ANR 430 
             
34.1 ± 3.2  2.30 ± 0.28  
17 TB 35 
 
>> 100 (22 ± 7)
a
 >> 100
186 
 
(16 ± 11)
a
 
18 TB 40 
        
7.21 ± 1.37  >> 100
186 
 
(23 ± 1) 
19 TB 41 
 
12.2 ± 1.8  18.2 ± 5.0
186
 
20 TB 42 
 
≥ 100 (46 ± 1)a >> 30 (19 ± 2)b 
aPercent inhibition ± SEM of radioligand binding at 100 µM; bPercent inhibition ± SEM of radioligand binding 
at 30  µM. 
 
Phenyl, 3-trifluoromethoxyphenyl, and phenylethynyl substitution (17, 18, and 20) resulted in 
a total loss of affinity for rat adenine receptors in rat cortical membrane preparations.  
 
8-Benzylaminoadenine (12) and 8-styryladenine (19) exhibited an affinity in the low 
micromolar range. 8-Styryladenine (19) showed nearly the same affinity in both species. 
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  Table 8. Comparison of affinities of adenine derivatives with modifications at position 9 for 
human and rat adenine receptors determined in radioligand binding studies using membrane 
preparations. 
 
 
 
Compound R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a 
HEK293 cells Rat brain cortex 
21 9-Methyladenine 
 
ca. 100 (44 ± 7)
a
 17.5 ± 2.96
186
 
22 9-Cyclopentyladenine 
 
ca. 100 (50 ± 8)
a
 43.5 ± 7.44
186
 
23 TB 33 
 
ca. 100 (57 ± 2)
a
 49.1 ± 11.7
186
  
24 TB 68 
 
ca. 100 (58 ± 3)
a
 45.1 ± 0.3
c
 
25 TB 66 
 
≥ 100 (41 ± 2)a 75.1 ± 8.1  
26 TB 64 
 
> 100 (44 ± 4)
a
 ≥ 250 (46 ± 3)b 
27 TB 62 
 
>> 100 (0 ± 4)
a
 > 250 (28 ± 6)
b
 
28 AAla 
 
6.23 ± 1.81  10.7 ± 1.11
186
 
29 Apr acid 
APalpha acid  
18.5 ± 5.6 20.5 ± 0.42
186
 
30 EA 6203 
 
5.49 ± 1.42 2.98 ± 0.16
186
 
aPercent inhibition ± SEM of radioligand binding at 100 µM; bPercent inhibition ± SEM of radioligand binding 
at 250 µM.
 cData from Dr. Anke Schiedel. 
 
Introduction of the electron-withdrawing trifluromethoxy group in the m-position of 8-
phenyladenine (18) led to increased affinity for human adenine receptors in membrane 
preparation of HEK293 cells (Ki = 7.21 µM) compared to the unsubstitued rigid phenyl ring, 
but still had a much lower affinity than the parent compound adenine (Ki = 44.7 nM). The 
enhanced affinity of the trifluoromethoxyphenyl derivative, compared to the unsubstituted 
phenyl compound, was probably due to its electron withdrawing property. 
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9-Methyladenine (21) and 9-cyclopentyladenine (22) showed no measurable affinity at the 
human adenine receptors. 9-Phenethyladenine (23) exhibited low affinity (Ki = 49.1 µM), 
whereas the introduction of one or two basic nitrogen atoms to the 9-substituent could result 
in positive or negative effects on the affinity, depending on the position of the basic function. 
Both, the piperazine derivative 27 and the 4-pyridyl derivative 26 showed no measurable 
AdeR affinity. 3-Pyridylethyl-substituted adenine 25 showed a slight increase in affinity (Ki = 
75.1 ± 8.1 µM) at rAde1R. Compound 24, featuring a nitrogen atom in the ortho-position, had 
a quite similar affinity (Ki = 45.1 µM) like the corresponding pyridyl derivatives 25 and 26. 
The morpholinyl derivative 30 also showed good AdeR affinity in the low micromolar range 
(Table 8). The Ki values of 28 and 29 indicated that the introduction of polar functions at 
position 9 of adenine positively affected the AdeR binding affinity. The 9-substituted adenine 
derivatives bearing polar substituents (28, 29 and 30) showed almost identical affinities for 
the human and the rat binding sites. All other 9-substituted compounds were weaker at human 
binding sites than at the rat adenine receptor. 
 
At position N
6
 of adenine, introduction of a methyl group was tolerated by human adenine 
receptors (31, Ki value of 22.6 µM), whereas ethyl (32), phenyl (33), benzyl (34) and hexyl 
(35) residues resulted in a very weak affinity. A small polar substituent as in compounds 36 
and 37 led to an increase in affinity for AdeR (Ki values of 0.500 µM and 1.38 µM, 
respectively). Compounds 36 and 37 exhibited higher affinity (4–19-fold) for the rat AdeR 
than for the human adenine binding site (Table 9). Dimethylation of the amino group (38) 
abolished affinity in both test systems, indicating that a hydrogen bond donor (N-H) in that 
position was probably required for binding to the receptor, similarly as in adenosine 
receptors.
188
 
 
Compounds 39, 41 and 42 with relatively large ring structures showed higher affinity for the 
human adenine receptors than N
6
-hexyladenine. Thus, this position can probably tolerate 
bulky substituents with particular ring structures, but not larger, non-polar residues. N
6
-(4-
fluorobenzyl)adenine (41) showed higher affinity with a Ki value of 13.8 µM compared with 
N
6
-benzyladenine (34) in both test systems. This improvement in the affinity is a result of the 
introduction of fluorine atom at the benzyl residue. 
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Table 9. Comparison of affinities of adenine derivatives with modifications at N
6
 for human 
and rat adenine receptors determined in radioligand binding studies using membrane 
preparations (part I).  
 
 
 
Compound R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a 
HEK293 cells Rat brain cortex 
31 N
6
-Methyladenine 
 
21.6 ± 3.2  3.64 ± 0.36
186
 
32 N
6
-Ethyladenine 
(TB 20)  
ca. 100 (60  2)
a
 16.4 ± 2.89
186
 
33 6-Anilinopurine 
  
>> 100 (26 ± 9)
a
 
 
65.3 ± 5.98
186
 
 
34 
 
N
6
-Benzyladenine 
 
 
>> 100 (28 ± 5)
a
 
 
113 ± 10.2
186
 
 
35 
 
6-n-Hexyladenine 
 
 
>> 100 (22 ± 8)
a
 
 
 
73.3 ± 4.34
186
 
 
 
36 
 
 
N
6
-Hydroxyadenine 
(ANR 427) 
 
 
9.53 ± 1.79  0.500 ± 0.104  
37 N
6
-Aminoadenine 
(ANR 428)  
17.5 ± 1.7  1.38 ± 0.10 
38 N
6
-Dimethyladenine 
 
___ >> 100 (10 ± 5)
a
 >> 100
186
  
(11 ± 2)
a
 
39 N
6
-Furfuryladenine 
(Kinetine) 
 
8.02 ± 1.65  26.7 ± 5.50
186
 
40 trans-Zeatin 
 
 
2.06 ± 1.12  22.6 ± 2.11
186
 
41 HPLL047 
 
 
13.8 ± 1.1 14.9 ± 3.35 
186
 
aPercent inhibition ± SEM of radioligand binding at 100 µM. 
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The N
6
-hydroxypentenyl-substituted adenine derivative trans-zeatin (40), acytokinin 
(phytohormone), was 10-fold more potent at human adenine receptors than at rat adenine 
receptors (Ki value of 2.06 µM vs. Ki value of 22.6 µM). The N
6
-azidoadenine (43) showed 
lower affinity for human adenine receptors with a Ki value of 25.4 µM compared with 8-
azidoadenine (5) but was still better than 2-azidoadenine (4). 
 
Table 10. Comparison of affinities of adenine derivatives with modifications at N
6
 for human 
and rat adenine receptors determined in radioligand binding studies using membrane 
preparations (part II). 
 
 
 
Compound R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a
 
HEK 293 cells Rat brain cortex 
42 HPLL046 
 
28.2 ± 1.9 6.73 ± 1.98
186
 
43 6-Azidoadenine 
  
25.4  1.6 8.49  0.47
186
 
44 TB 21 
 
ca. 100 (58 ± 1)
a
 23.9 ± 1.80  
45 TB 200 
 
≥ 100 (40 ± 6)a ≥ 100 (21 ± 4)a 
46 TB 201 
 
 >> 100 (19 ± 3)
a
 
 
ca. 100 (58 ± 9)
a
 
 
47 TB 202 
 
> 100 (26 ± 5)
a
 
 
≥ 100 (46 ± 4)a 
 
48 TB 203 
 
>> 100 (8 ± 5)
a
 
 
≥ 100 (49 ± 1)a 
 
   aPercent inhibition ± SEM of radioligand binding at 100 µM. 
 
Adenine derivatives (Table 10) bearing aminoalkyl and N-t-boc-aminoalkyl substituents at 
position N
6
 (45, 46, 47, and 48) exhibited no measurable AdeR affinity, whereas ethyl and 
hydroxyethyl substitution at that position (32 and 44) was still somewhat tolerated (Ki values 
of 16.4 µM and 23.9 µM, respectively). Interestingly, the corresponding N
6
-acetyl-substituted 
adenine 49 showed a higher affinity (Ki = 2.85 µM) than the corresponding alkyl derivative, 
consistent with previous observations, that benzoyl substitution at position N
6
 was better 
tolerated than benzyl substitution.
104
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  Table 11. Comparison of affinities of adenine derivatives with modifications at N
6
 for human 
and rat adenine receptors determined in radioligand binding studies using membrane 
preparations (part III). 
 
 
 
Compound R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a 
HEK 293 cells Rat brain cortex 
49 TB 23 
 
0.515 ± 0.066  2.85 ± 0.59
186
 
50 TB 93 
 
0.302 ± 0.032  0.403 ± 0.061  
51 TB 74 
 
 
0.719 ± 0.081  0.334 ± 0.031  
52 TB 96 
 
 
2.68 ± 0.37  3.39 ± 0.56  
53 TB 155 
 
12.0 ± 2.2  3.85 ± 0.05  
54 TB 158 
 
14.3 ± 2.4  2.21 ± 0.41  
aPercent inhibition ± SEM of radioligand binding at 100 µM. 
 
Our results indicated that N
6
-acylation is more favorable in terms of increased AdeR affinity 
than N
6
-alkylation. Most of the investigated N
6
-substituted adenine derivatives, for example 
compounds 36 and 37, exhibited higher affinity for the rat AdeR than for the human adenine 
binding site. Exceptions were compounds 39 and 40, but the affinity was still in the 
micromolar range. N
6
-Acetyladenine (49) was 5.5-fold more potent at adenine receptors in 
HEK293 cell membranes (Ki = 0.515 µM) as compared to the rat receptor (Ki = 2.85 µM). 
 
On the basis that N
6
-acylation of adenine is tolerated, the synthesized tBoc-protected N
6
-ω-
aminoacyladenine derivatives 50-54 were tested at human and rat adenine receptors. The 
glycyl- and alanyl-derivatives 50 and 51 showed high affinity for both, human and rat adenine 
receptors with Ki values in the nanomolar range (Table 11). Increasing the chain length (52) 
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and alkylation of the protected nitrogen atom of the glycyl derivatives (53 and 54) resulted in 
reduced affinity in both test systems. 
 
Table 12. Comparison of affinities of adenine derivatives with modifications at N
6
 for human 
and rat adenine receptors determined in radioligand binding studies using membrane 
preparations (part IV).  
 
 
 
Compound R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a 
HEK293 cells Rat brain cortex 
55 TB 156 
 
 
5.47 ± 1.28  0.949 ± 0.135  
56 TB 159 
 
7.70 ± 2.40  2.93 ± 0.40  
57 TB 183 
 
ca. 100 (44 ± 6)
a
 11.8 ± 0.8 
58 TB 184 
 
19.7 ± 0.7 1.56 ± 0.026 
59 TB 196 
 
42.1 ± 1.8 9.02 ± 0.55 
60 TB 197 
 
17.4 ± 3.2 
 
9.07 ± 0.80 
aPercent inhibition ± SEM of radioligand binding at 100 µM. 
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The N
6
-ω-aminopropionyl-substituted adenine derivatives 55-60 were tested at adenine 
receptors (Table 12). The introduction of a methyl group at the protected nitrogen atom (55) 
resulted in moderate affinity with a Ki value in the low micromolar range (Ki = 5.47 µM and 
Ki = 0.949 µM, respectively) for human and rat adenine receptors. Quite similar results were 
shown by the introduction of an ethyl group at the protected nitrogen atom, while introduction 
of propyl, hexyl, benzyl and phenethyl substituents (57-60) somewhat decreased or abolished 
the affinity for adenine receptors in both species.  
 
  Table 13. Comparison of affinities of N
6
-substituted adenine derivatives for human and rat 
adenine receptors determined in radioligand binding studies using membrane preparations 
(part V). 
 
 
 
Compound R
1
 Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a 
HEK293 cells Rat brain cortex 
61 TB 73 (PSB-09073) 
 
0.0526 ± 0.0034  0.0215 ± 0.0056  
62 TB 162 (PSB-08162) 
 
1.83 ± 0.09  0.292 ± 0.056  
63 TB 165 
 
1.34 ± 0.48 
 
  
0.508 ± 0.163  
64 TB 187 
 
 
6.85 ± 2.17  
 
1.29 ± 0.24  
 
65 
 
TB 198 
 
 
3.27 ± 1.23  0.852 ± 0.131  
66 
 
TB 199 
 
 
6.93 ± 0.83  
 
2.12 ± 0.07  
67 
 
TB 97 (PSB-09097) 
  
0.174 ± 0.045  0.0805 ± 0.0030  
aPercent inhibition ± SEM of radioligand binding at 100 µM. 
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In general, the N-boc-protected derivatives bearing relatively bulky and lipophilic substituents 
still exhibited relatively high affinities with Ki values in the nanomolar or low micromolar 
range. This fact illustrated that there is obviously much space for voluminous substituents at 
position 6 offering a high potential for further modifications at the exocyclic amino group of 
adenine. The binding results for free amines (61-67) which were obtained by removal of the 
tBoc group of compounds shown previously in table 11 and 12 are collected in table 13. The 
removal of protecting groups (Table 13) clearly resulted in compounds with higher affinity for 
adenine receptors in comparison with the protected compounds. Thus, the introduction of a 
basic amino group at the N
6
-acyl substituent yielded adenine derivatives that were well 
tolerated by adenine binding sites.  
 
In addition these derivatives showed somewhat higher affinity for the rat than the human 
adenine receptors. Compounds 64-66, in which bulky and lipophilic substituent were 
introduced, were able to displace [
3
H]adenine from its binding sites at both species with Ki 
values varying from the nanomolar range or low micromolar range. The most potent adenine 
receptor ligand of this series was compound 61 exhibiting an even higher affinity for rat 
adenine receptors (Ki value of 21.5 nM) than the natural ligand adenine itself (Ki value of 29.2 
nM). In addition, compound 61 showed similar affinity for human adenine receptors with a Ki 
value of 52.6 nM compared with the endogenous ligand adenine (Ki = 44.6 nM). Therefore 
compound 61 represents the most potent adenine receptor ligand that has been described so 
far. The butyryl analogue of compound 61, compound 67 also showed high affinity for both, 
rat and human, adenine receptors (Ki values of 80.5 nM and 174 nM, respectively). In general, 
substitution in the 8-position (amino, dimethylamino, piperidinyl, piperazinyl), or in the 9-
position (2-morpholinoethyl) with basic residues, or introduction of polar substituents at the 
6-amino function represented the best modifications, whereas bulky and lipophilic 
substituents at all positions, or alkyl substitution at N
9
 were not well tolerated.  
 
The compounds were additionally investigated in binding studies at human embryonic kidney 
(HEK293) cells, which also express a high-affinity adenine binding site. Structure-affinity 
relationships at the human cell line were similar to those at the rat Ade1R, but not identical. 
The N
6
-acetyladenine (49, Ki rat: 2.85 µM; Ki human: 0.515 µM) and 8-aminoadenine (7, Ki 
rat: 6.51 µM; Ki human: 0.0341 µM) were much more potent at the human as compared to the 
rat binding site, while compounds 61 and 67 showed high affinity for both human and rat 
adenine receptors with Ki values in nanomolar range.  
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Figure 28. Inhibition of [
3
H]adenine binding (10 nM) by selected adenine derivatives to (A-
C) membrane preparations of HEK293 cells, and (D and E) to rat brain cortical membrane 
preparations. Data points represent means ± SEM of three separate experiments each 
performed in triplicate at room temperature. 
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Table 14. Comparison of affinities of aza- and deazapurines for human and rat adenine 
receptors determined in radioligand binding studies using membrane preparations. 
 
Compound Structure Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3)
a 
HEK 293cells Rat brain cortex 
68 8-Azaadenine 
 
 
>> 100 (7 ± 5)
a
 >> 100 
 (21 ± 9)
 186
 
69 AAG 14 
 
 
8.61 ± 2.57 10.6 ± 2.66
186
 
70 AAG 223 
 
 
17.1 ± 3.6  6.81 ± 2.35
186
 
71 AAG 225 
 
 
> 100 (31 ± 3)
a
 > 100 (21 ± 9)
a
 
72 AAG 226 
 
> 100 (20 ± 5)
a
 >> 100 (0 ± 5)
a
 
73 
 
AAG 227 
N
N
H
N
NH2
 
>> 100 (0 ± 3)
a
  > 100 (39 ± 8)
a
 
aPercent inhibition ± SEM of radioligand binding at 100 µM. 
 
All tested deazapurines (Table 14) were much less active at the AdeR than the physiological 
ligand adenine (Ki value of 0.0292 µM). The 7- and 9-deazapurines 71, 72, and 73 showed no 
significant affinity for the AdeR at concentrations up to 100 µM, whereas the 1- and 3-
deazapurines 69 and 70 exhibited AdeR affinities in the low micromolar range (> 200-fold 
decrease in affinity). This result indicated that the presence of a hydrogen bond acceptor at 
position 7 is essential for AdeR affinity. Interestingly, a similar effect was previously 
observed for 7-deazaadenosine at adenosine receptors (AdoRs), the 7-deazaadenosine being 
only weakly active or inactive at A1, A2A, and A3 AdoR. 3-Deazaadenosine had exhibited 
somewhat higher affinity for AdoR in the micromolar range.
189
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Table 15. Comparison of affinities of some adenine-related structures for human and rat 
adenine receptors determined in radioligand binding studies using membrane preparations. 
 
Compound Structure Ki ± SEM [µM] vs. [
3
H]adenine 
(n=3) 
HEK 293 cells Rat brain cortex 
74 2-Aminopurine 
 
>> 100 (5 ± 1)
a
 > 100  
(39 ± 8)
 186
 
 
75 5-Amino-4-imidazole 
carboxamide 
 
> 100 (32 ± 8)
a
 19.0 ± 0.47
186
 
76 4,6-
Diaminopyrimidine 
 
>> 100 (16 ± 6)
a
 >> 100  
(22 ± 7)
186
 
78 Guanine 
 
>> 100 (24 ± 5)
a
 3.33 ± 2.14
186
 
79 8-Azido-2- 
fluoroadenine 
 
>> 100 (22 ± 4)
a
 17.5 ± 8.34
186
 
80 1,N
6
-Ethenoadenine 
 
>> 100 (11 ±  6)
a
 
 
34.4 ± 8.12
186
 
81 Guanosine 
 
>> 100 (20 ± 4)
a
 >> 100  
( 5 ± 3)
190
 
82 2´-Deoxyadenosine 
 
>> 100 (29 ± 4)
a
 11.0 ± 0.55
186
 
   aPercent inhibition ± SEM of radioligand binding at 100 µM. 
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The best tolerated deazaadenosine derivatives in these studies had been the 1-deaza 
compounds which was similarly potent as the corresponding adenosine derivatives.
189
In 
contrast, the N
1
, as well as the N
3
, are quite important for high AdeR affinity and appear to 
strongly contribute to receptor binding probably as hydrogen bond acceptors (Table 15).
 
8-
Azaadenosine had been found to possess no affinity for adenosine receptors,
191
 likewise 8-
azaadenine (68) also showed no measurable affinity for the AdeR at concentrations up to 100 
µM. 
 
 
It was described before that 2-fluoroadenine showed affinity for human and rat adenine 
receptors in the nanomolar range (Ki= 940 nM, and 620 nM, respectively).
186
 The introduction 
of an azido group in position 8 of 2-fluoroadenine resulted in 8-azido-2-fluoroadenine (79). 
Compound 79 showed no measurable affinity for the human adenine receptor at 100 µM and 
the activity was decreased by 28-fold at the rat adenine receptors, whereas 8-azidoadenine (5) 
showed affinity for the human adenine receptors in the micromolar range. 1,N
6
-Ethenoadenine 
(80) is a tricyclic adenine derivative in which the nitrogen atoms in position 1 and N
6
 are 
connected by the formation of an imidazole ring. It exhibited no significant binding affinity 
for the adenine receptor at a high concentration of 100 µM, thus the connection of two 
nitrogen atoms is not well tolerated for adenine binding sites.  
 
5-Amino-4-imidazole carboxamide (75), 4,6-diaminopyrimidine (76), guanine (78), 
guanosine (81) and 2´-deoxyadenosine (82) showed no effects on [
3
H]adenine binding. In 
addition, 2-aminopurine (74) was not able to inhibit [
3
H]adenine binding at a concentration of 
100 µM. It is concluded that the 6-amino group of adenine is important for adenine binding to 
the membrane receptors and the 2-amino group impedes adenine binding to the [
3
H]adenine-
binding site. 
 
Based on the results of binding studies of many adenine derivatives at membrane preparations 
of both, rat and HEK293 cells, we conclude that human embryonic kidney (HEK293) cells 
and rat brain cortex express binding sites for adenine with similar but not identical structure-
activity relationships. Differences in binding affinities may be due to species differences 
and/or could be explained by the existence of different adenine receptor subtypes. The latter 
explanation is more likely since no highly homologous gene (> 80% sequence identity) could 
be identified in the human genome database.  
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3.1.2.1. Investigation of agonistic properties of adenine and adenine derivatives at the rat 
adenine receptor  
 
3.1.2.1.1. cAMP accumulation assays  
 
In order to investigate whether the potent rAde1R ligands identified in this study were 
agonists or antagonists we performed functional studies with selected compounds. Thus, 
1321N1 astrocytoma cells were stably transfected with the sequence for the rAde1R using a 
retroviral expression system.
192
 Adenine at 1 µM concentration inhibited isoproterenol-
induced cAMP formation in a dose-dependent manner with a maximal inhibition of about 35-
40% and an IC50 value of 8.29 ± 2.69 nM (Figure 29B). Selected adenine derivatives were 
tested for their effects to inhibit isoproterenol-induced cAMP accumulation. In order to obtain 
a full AdeR-activating effect, high concentrations of test compounds (ca. 100 x Ki value; 50 
µM, 250 µM or 500 µM) were applied. Compound 13 (8-(1-piperidinyl)adenine) was tested at 
a lower concentration (30 µM, ca. 8-fold Ki, see Figure 29A) since at 250 µM concentration it 
had led to a complete inhibition of cAMP production in a preliminary experiment (not 
shown), likely due to an AdeR-independent effect. 
 
All compounds investigated showed agonistic effects at rAde1R expressed in astrocytoma 
cells as shown in figure 29A. 8-(1-Piperidinyl)adenine (13), 8-aminoadenine (7) and 9-(2-
morpholinoethyl)adenine (30) showed about the same efficacy as adenine. 8-
Dimethylaminoadenine (16) was even more efficacious than the physiological agonist 
showing 137% of the maximal effect of adenine. In contrast, N
6
-hydroxyadenine (36, 51% 
efficacy), N
6
-acetyladenine (49, 77% efficacy) and 8-(1-piperazinyl)adenine (15, 52% 
efficacy) were partial agonists in the applied test system.  
 
Compounds 49 and 15 were and in the presence of additionally tested for antagonistic effects. 
Concentration-response curves for adenine were obtained in the absence 10 µM (ca. 3-fold Ki 
value) of 49, or 15, respectively.  Curves for adenine in the presence of 49 in comparison with 
adenine alone are shown in figure 29B.  Both compounds, 49 and 15, had no statistically 
significant effects on the IC50 value or the efficacy of adenine indicating that they did not 
behave as antagonists in this test system. Taken together, the results from functional studies 
showed that minor structural modifications can have a significant impact on functional 
properties of the adenine derivatives. 
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Figure 29. (A) Inhibition of isoproterenol-stimulated cAMP accumulation by adenine and 
selected adenine derivatives in 1321N1 astrocytoma cells stably expressing the rAde1R. 
Cellular cAMP production was increased by preincubation with 3 nM isoproterenol for 10 
min at 37 °C; data are given as percentage of the mean increases in cellular cAMP levels in 
the presence of isoproterenol alone (% of control, n=3). Adenine and compound 13 were 
tested at 1 µM and 30 µM, respectively. Compounds 49, 15, 16 and 30 were tested at 250 µM 
(100-fold Ki value). Compounds 36 and 7 were tested at 50 µM and 500 µM, respectively. 
*p=0.0151; ** p<0.01; *** p<0.0001 indicates statistically significant differences from 
control (isoprenaline); # p<0.01; ## p=0.0032 indicates statistically significant differences 
between maximal effect of adenine and effect of test compound at high concentration. (B) 
Concentration-dependent inhibition of isoprenaline-stimulated intracellular cAMP 
accumulation in the absence and in the presence of compound 49 (10 µM). An IC50 value of 
8.29 ± 2.69 nM was determined for adenine (n=5). The presence of 49 (10 µM, 3-fold Ki) did 
not show any significant effect on the IC50 value or the efficacy of adenine (n=3). 
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3.1.2.1.2. cAMP-dependent luciferase assay 
In order to examine the functional properties of the most potent adenine receptor ligands 
identified in radioligand binding studies, we measured the Gi protein-mediated effects of 
compounds 50, 55, 61, 62, 63, 65, 67, and adenine (1) on isoproterenol-stimulated cAMP 
production by a luciferase luminescence assay, a gene reporter assay. These experiments were 
performed with 1321N1 astrocytoma cells stably transfected with the rat adenine receptor. 
The results are illustrated in figure 30. 
 
This experiment showed that compounds 61, 63, 65, 67, 55 and 50 represent adenine receptor 
agonists, whereas compound 62 exhibited no significant effect on isoproterenol-induced 
cAMP dependent luciferase assay (Figure 30). The agonistic properties of compound 61 were 
further confirmed by its concentration-dependent inhibition of the isoproterenol-stimulated 
cAMP dependent signal in a luciferase assay (Figure 31).  
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Figure 30. Inhibition of isoproterenol-stimulated cAMP-dependent luciferase assay by 
adenine and selected adenine derivatives in 1321N1 astrocytoma cells stably expressing the 
rAde1R. Applied concentrations: adenine and 61: 1 µM (n = 3); 63, 65, 67, 55, 62: 10 µM (n 
= 3); 
***
P < 0.0001;
 **
P = 0.004 (65);
 **
P = 0.0026 (55). Data are given as percentages of the 
mean increases in cellular cAMP levels in the presence of isoproterenol alone (control).  
 
Adenine (1) and 61 both inhibited the maximal cAMP amount produced by 30 - 35 % with 
IC50 values of 3.18 ± 1.51 nM and 28.4 ± 4.3 nM, respectively (Figure 31). 
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Figure 31. Inhibition of isoproterenol-stimulated cAMP dependent-luciferase assay in 
1321N1 astrocytoma cells stably expressing the rAde1R by different concentrations of (A) 
adenine, and (B) compound 61. IC50 values: 3.18 ± 1.51 nM (adenine) and 28.4 ± 4.3 nM (61). 
Data points represent means ± SEM of three separate experiments each performed in triplicate. 
 
The functional studies revealed that compounds 61, 63, and 65 exhibited the strongest 
inhibitory effects on cAMP production with the same maximal effect as adenine (30% 
inhibition). Therefore, these compounds constitute full agonists (Figure 30).  
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Figure 32. Inhibition of the isoproterenol-stimulated cAMP-dependent signal in a luciferase 
assay by different concentrations of adenine in the absence (▲) and in the presence (■) of 
compound 62 (10 µM) in 1321N1 astrocytoma cells stably expressing the rAde1R (n=3). Data 
points represent means ± SEM of three separate experiments each performed in triplicate. A 
Kb value of 0.165 µM was calculated. 
 
The adenine derivatives 67, 55, and 50 were found to be partial agonists, whereas compound 
62 showed only a slight, non-significant decrease in cAMP formation, indicating that N
6
-(3-
methylaminopropionyl)adenine 62 might be an adenine receptor antagonist. To further 
investigate the antagonistic properties of 62, we monitored the inhibitory effect of the natural 
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agonist adenine on the cAMP formation in the absence (Figure 32, ▲) and in the presence 
(Figure 32, ■) of 62. In the absence of 62, adenine exhibited an EC50 value of 3.70 nM, 
whereas in the presence of 62 the dose-response curve of adenine was shifted to the right 
(EC50 = 71.5 nM). The calculated Kb value was 0.165 µM. This result revealed, that N
6
-(3-
methylaminopropionyl)adenine (62) represents the first adenine receptor antagonist described 
so far. 
 
3.1.2.2. Extracellular signal-regulated kinase (ERK) phosphorylation assay 
 
The rAde1R expressed in 1321N1 astrocytoma cells was functionally characterized by 
analyzing the effects of receptor activation on the receptor-mediated inhibition of cellular 
cAMP production and cAMP response element (CRE)-dependent luciferase expression. Later 
on the receptor-mediated activation of the serum response element (SRE)-directed luciferase 
expression was also determined. There is no information available so far about activation of 
the extracellular signal-regulated protein kinase ERK mediated by the adenine receptors. The 
dopamine D2-receptor which is a Gi-coupled receptor has been previously shown to couple to 
the SRE pathway.
171,172
 The native P2Y12-receptor mediates an activation of the extracellular 
signal-regulated protein kinase (ERK)
173,174 
and recombinant human P2Y12 was shown to 
activate the ERK through coupling to the SRE-pathway.
175
 ERK phosphorylation was 
investigated by a gene reporter assay measuring SRE-dependent luciferase activity in 
astrocytoma cells stably transfected with the rat adenine receptor (rAde1R).  
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Figure 33. (A) The non-transfected 1321-N1 astrocytoma cells showed no change in SRE-
dependent luciferase expression in the presence of adenine. (B) Increases in SRE-dependent 
luciferase expression upon addition of different concentrations of adenine to 1321-N1 
astrocytoma cells expressing rAde1R. 
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For this purpose, 1321N1 astrocytoma cells expressing rAde1R were transiently transfected 
with the pSRE-luc vector. In cells transfected with the pSRE-luc vector alone, adenine (0.1 
nM to 0.1 mM) showed no response. In contrast, adenine (0.1 nM to 0.1 mM) increased the 
SRE-dependent luciferase expression by about 50% with an EC50 concentration of 60.6 ± 7.7 
nM in cells expressing rAde1R (Figure 33). Similar increases were observed using compound 
61, and an EC50 value of 1.87 ± 0.99 nM was determined (Figure 34). 
This experiment revealed that adenine receptors are also involved in the regulation of kinase 
pathways. 
 
0
20
40
60
80
100
10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4
[61], M
%
 S
R
E
-d
ir
e
c
te
d
 l
u
c
if
e
ra
s
e
e
x
p
re
s
s
io
n
 (
%
 o
f 
b
a
s
a
l 
a
c
ti
v
it
y
)
-10
10
30
50
70
90
110
10 -10 10 -9 10 -8 10 -7 10 -6 10 -5
[adenine], M
%
 S
R
E
-d
ir
e
c
te
d
 l
u
c
if
e
ra
s
e
e
x
p
re
s
s
io
n
 (
%
 o
f 
b
a
s
a
l 
a
c
ti
v
it
y
)
A B
 
Figure 34. Increases in SRE-dependent luciferase expression upon addition of different 
concentrations of adenine in 1321-N1 astrocytoma cells expressing rAde1R (% of basal 
activity) (A) adenine, and (B) compound 61. EC50 values: 60.6 ± 7.7 nM (adenine) and 1.87 ± 
0.99 nM (61) (n=3). 
  
Therefore, we present here a new lead structure for adenine receptor agonists based on the 
properties of compound 61. N
6
-acylation of adenine was obviously the best tolerated 
modification by the rat adenine receptor. A basic terminal amino group further enhanced the 
potency. A distance of three carbon atoms between the N
6
-nitrogen atom and the terminal 
amino group turned out to be optimal. Moreover, methylation of the amino group led to the 
first adenine receptor antagonist 62. 
 
Table 16 showes a comparison of Ki and EC50 values determined for adenine and the synthetic 
agonist 61 obtained in different assays. The compounds appear to be pathway-specific. In 
contrast to the physiological agonist adenine, compound 61 is more potent and efficacious in 
activation the ERK pathway than in inhibition of adenylate cyclase.  
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Table 16. Comparison of affinities of adenine and compound 61 at different test systems. 
 
Compound 
 
 
Radioligand binding 
studies 
Functional studies 
using rAde1R expressed in 1321-N1 
astrocytoma cells  
Rat brain cortex Ki ± SEM 
[nM] vs. [
3
H]adenine 
(n=3) 
cAMP-assay 
IC50 ± SEM [nM]  
(n=3) 
ERK-pathway 
EC50 ± SEM [nM] 
(n=3) 
Adenine 29.2 ± 3.4 3.18 ± 1.51 60.6 ± 7.7 
61 21.5 ± 5.6 28.4 ± 4.3 1.87 ± 0.99 
 
Further evaluation of both compounds (adenine and 61) in other test systems or other cell 
lines may provide more information about the functional properties of adenine and compound 
61.  
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3.1.3. Investigation of the affinity of selected adenine derivatives for rat adenosine A1 
and A2A receptors 
 
Certain adenine derivatives had previously been described to be antagonists at adenosine 
receptors. As a next step we therefore wanted to study the affinity of the most potent adenine 
derivatives at adenosine receptors in order to assess the compounds, selectivity for adenine 
receptors. The adenine derivatives were investigated in radioligand binding studies at rat brain 
striatal adenosine A2A receptors using the antagonist radioligand [
3
H]MSX-2 ([
3
H]3-(3-
hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine, 84 Ci/mmol).
193
 The 
affinity for the adenosine A1 receptor subtype was assessed by performing radioligand binding 
studies at rat brain cortical membranes using [
3
H]CCPA ([
3
H]2-chloro-N
6
-
cyclopentyladenosine, 48.6 Ci/mmol),
194
 as a radioligand.  
 
The result showed that the majority of the tested N
6
-substituted adenine derivatives (Table 17) 
was not able to displace [
3
H]MSX-2 (1 nM) from rat brain striatal (adenosine A2A receptor) at 
a concentration of 100 µM. Similar results were obtained for N
6
-substituted adenine 
derivatives (table 17) at adenosine A1 receptors in rat brain cortical membranes, at which the 
compounds mostly showed no measurable affinity at a concentration of 100 µM. Moderate 
affinity was seen with N
6
-aminoadenine (37) (Table 18) which was able to displace [
3
H]MSX-
2 from rat brain striatal membranes by 59 % at 100 µM concentration. Compound 37 showed 
an inhibition value of 44 % for binding of [
3
H]CCPA to rat brain cortical membranes. 
Compounds 62 and 63 showed inhibition values of 48 % for [
3
H]MSX-2 from rat brain 
striatal (adenosine A2A receptor). This means that the expected Ki values would be around 100 
µM. 
 
8-(1-Piperazinyl)adenine (15) and 8-dimethylaminoadenine (16) exhibited similar inhibition 
values for adenosine A2A receptor in rat brain striatal (46 %). Compounds 15 and 16 showed 
no measurable affinity at both adenosine A1 and A2A receptor subtypes (see table 18). 8-(1-
Piperidinyl)adenine (13) showed inhibition values of 46 % and 42 % for adenosine A1 
receptors at rat cortical membranes, and adenosine A2A receptors at rat striatal membranes, 
respectively (Table 18) indicating moderate affinities.  
 
Compounds 13, 15, 16, 37, 62 and 63 exhibited affinities for adenosine A1 receptors at rat 
cortical membranes and A2A receptor at rat striatal membranes above 100 µM, and therefore 
the compounds can be considered selective for adenine receptors in comparison with 
adenosine receptors (table 17 and 18). 
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Table 17. Comparison of affinities of selected adenine derivatives for adenosine A1 and 
adenosine A2A receptors with human and rat adenine receptors determined in radioligand 
binding studies using membrane preparations. 
 
Compound Structure Ki ± SEM [µM] (or % inhibition at 100 µM) (n=3)
 
Adenosine 
A1 receptor 
(rat brain 
cortical 
membranes) 
[³H]CCPA 
Adenosine 
A2A 
receptor 
(rat brain 
striatal 
membrane) 
[³H]MSX-2 
HEK cells 
membranes  
[3H]adenine 
Rat brain 
cortex 
membranes 
[3H]adenine 
67 TB97 
(PSB-
09097) 
 
 
>> 100  
(21 ± 9) 
>> 100 
(33 ± 13) 
0.174 ± 
0.045 
0.0805 ± 
0.0030 
61 TB73 
(PSB-
09073) 
 
 
>> 100  
(15 ± 10) 
 
>> 100  
(26 ± 6) 
 
0.0526 ± 
0.0034 
0.0215 ± 
0.0056 
62 TB 162 
(PSB-
08162) 
 
>> 100  
(16 ± 12) 
 
> 100  
(48 ± 4) 
 
1.83 ± 
0.09 
0.292 ± 
0.056 
63 TB 165 
 
>> 100  
(18 ±10) 
 
> 100  
(48 ± 5) 
 
1.34 ± 
0.48 
0.508 ± 
0.163 
64 TB 187 
 
>> 100  
(23 ± 9) 
 
>> 100  
(29 ± 9) 
 
6.85 ± 
2.17 
1.29 ± 0.24 
66 TB 199 
 
>> 100  
(11 ± 9) 
 
>> 100  
(10 ± 7) 
 
6.93 ± 
0.83 
2.12  ± 0.07 
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Table 18. Comparison of affinities of selected adenine derivatives for adenosine A1 and 
adenosine A2A receptors with human and rat adenine receptors determined in radioligand 
binding studies using membrane preparations. 
Compound Structure Ki ± SEM [µM] (or % inhibition at 100 µM) (n=3)
 
Adenosine 
A1 receptor 
(rat brain 
cortical 
membrane) 
[³H]CCPA 
Adenosine 
A2A receptor 
(rat brain 
striatal 
membranes) 
[³H]MSX-2 
HEK cells 
membranes  
[3H]adenine 
Rat brain 
cortex 
membranes 
[3H]adenine 
36 ANR427 
 
 
>> 100  
(27 ± 8) 
>> 100 
 (21 ± 3) 
9.53 ± 
1.79 
0.500 ± 
0.104 
37 
 
ANR428 
 
 
≥ 100  
(44 ± 6) 
≥ 100  
(59 ± 7) 
17.5 ± 
1.7 
1.38 ± 0.10 
15 ANR426 
 
 
>> 100  
(24 ± 10) 
≥ 100  
(46 ± 15) 
27.4 ± 
4.6 
3.27 ± 0.12 
16 ANR430 
 
 
 
>> 100  
(28 ± 4) 
≥ 100  
(46 ± 10) 
34.1 ± 
3.2 
2.30 ± 0.28 
13 ANR425 
 
 
≥ 100  
(46 ± 3) 
≥ 100  
(42 ± 8) 
31.7 ± 
4.8 
3.94 ± 0.87 
30 EA 6203  
 
n.d >> 100  
(19 ± 6) 
5.49 ± 
1.42 
2.98 ± 0.16 
n.d. = not determined 
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3.1.4. Characterization of the mouse adenine receptor (mAde2R) 
 
The adenine receptor sequence found in mouse brain and NG108-15 cells, which is clearly 
distinct from the mouse ortholog (mMrgA10) of the rat adenine receptor, was cloned by Prof. 
Ivar von kügelgen. Non-transfected human 1321N1 astrocytoma cells possess binding sites 
for adenine
104
 but do not respond upon addition of adenine (0.1 and 1 µM) with a decrease in 
cAMP formation in the absence and presence of isoproterenol used to stimulate the cellular 
cAMP accumulation. The lack of any effect of adenine confirms the absence of an 
endogenous inhibitory receptor for adenine in 1321N1 astrocytoma cells. Therefore, human 
1321N1 astrocytoma cells are suitable for a pharmacological characterization of a 
recombinant inhibitory receptor for adenine.  
 
3.1.4.1. cAMP accumulation assay at the mAde2R 
The receptor was expressed in human 1321N1 astrocytoma cells in order to analyze the 
pharmacological properties of the mouse receptor. In 1321N1 cells stably expressing the 
mouse receptor adenine (1 nM to 1 µM) inhibited the isoproterenol-induced cAMP formation 
in a concentration-dependent manner with a half maximal concentration (IC50) of 8 nM (95 % 
confidence interval: 3-23 nM) and a maximal inhibition by about 40 % (Figure 35A). 
Similarly, the analogue 2-fluoroadenine caused a concentration-dependent inhibition of cAMP 
production with an IC50 concentration of 15 nM (95 % confidence interval: 7-30 nM) and a 
maximal inhibition by about 60 % (Figure 35B).  
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Figure 35. (A) Inhibition of isoproterenol-stimulated cAMP accumulation by adenine (IC50 = 
8 nM, 95 % confidence interval: 3-23 nM) and (B) 2-fluoroadenine (IC50 = 15 nM, 95 % 
confidence interval: 7-30 nM) in 1321N1 astrocytoma cells stably expressing the mouse 
adenine receptor. Cellular cAMP production was increased by addition of isoproterenol 3 nM 
for 10 min at 36.5 °C; data are given as percentages of the mean increases in cellular cAMP 
levels in the presence of isoproterenol alone (% of control; average increase in cAMP levels 
by 15.3 ± 1.3 pmol cAMP per well; n = 17). Means ± SEM from five to 21 experiments.** 
indicates significant differences from corresponding control. 
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The recombinant mouse adenine receptor analyzed shows similar pharmacological properties 
as the adenine receptor endogenously expressed in the mouse neuroblastoma x rat glioma 
hybrid cell line NG108-15 (which in fact expresses the mouse but not the rat sequence).
104 
Both the native and the recombinant receptor couple to inhibition of adenylate cyclase activity 
via pertussis toxin sensitive G proteins.
104,110
 Adenine acted as an agonist at the native 
104
 and 
at the recombinant receptor.
110
 In addition to adenine, the adenine derivative 2-fluoroadenine 
was active at the native receptor in NG108-15 cells
104 
as well as at the recombinant mouse 
receptor.
110
  
 
In comparison to the results obtained at the recombinant mouse adenine receptor expressed in 
astrocytoma cells (IC50 = 8 nM) and at membranes from NG108-15 cells (IC50 = 21 nM),
104
 a 
higher IC50 value of 2.5 µM for the adenine-induced inhibition of forskolin-stimulated cAMP 
production had been determined in intact NG108-15 cells.
104
  
 
3.1.4.2. Radioligand binding assays 
 
As a next step a suitable system for performing radioligand binding assays at the mAde2R 
was established. NG108-15 cell membranes natively expressing the mouse adenine receptor 
had previously been shown to exhibit specific binding of [
3
H]adenine.
104 
However, this cell 
line may not only express one adenine receptor subtype, but also further adenine receptor 
subtypes or other specific binding sites that are labelled by [
3
H]adenine. 1321N1 astrocytoma 
cells recombinantly expressing the mouse adenine receptor were also not suitable for binding 
assays since non-transfected 1321N1 astrocytoma cells also express specific binding sites for 
[
3
H]adenine.
104
 Although a series of cell lines were tested, including CHO and HEK cells, all 
tested mammalian cell lines natively express specific binding sites for [
3
H]adenine. In contrast, 
the non-mammalian cell line Sf21 insect cells did not show any specific binding of 
[
3
H]adenine.
110
 
 
The novel mouse adenine receptor was subsequently expressed in Sf21 insect cells using the 
baculovirus expression system by Bernt Alsdorf and Dr. Anke Schiedel (group of Prof. 
Müller).
110 
Saturation experiments with [
3
H]adenine (0.75 - 150 nM) and membrane 
preparations of infected Sf21 cells showed a single high affinity binding site with a KD value 
of  113 ± 17 nM, and a Bmax value of 1.98 ± 0.39 pmol/mg protein was determined (n=3) 
(Figure 36). The KD value was slightly higher to that previously determined for the rat adenine 
receptor in brain cortical membranes.  
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A comparison of the affinities of adenine and other adenine derivatives for the recombinant 
mouse adenine receptor showed that the affinities and the rank order of potency were similar 
to the mouse adenine receptor natively expressed in NG108-15 cells and the adenine receptor 
expressed in rat brain cortex (Table 19). 
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Figure 36. Saturation curve of [
3
H]adenine binding to membranes prepared from S21 insect 
cells expressing the mouse adenine receptor.  KD and Bmax values were 113 ± 17 nM and 1.98 
± 0.39 pmol/mg protein (n=3). The result shown represents one of three independent 
experiments, each performed in duplicates.  
 
The rank order of potency was: adenine (1) > 2-fluoroadenine (84) > 7-methyladenine (85) > 
1-methyladenine (83) >> N
6
-benzyladenine (34) > N
6
-dimethyladenine (38). The latter two 
compounds did not show any affinity at the mouse receptor and only negligible affinity at a 
concentration of 100 µM for the rat receptor. The synthesized compounds 49, 61 and 67 
showed affinity in the low micromolar range for native mouse adenine receptors at membrane 
preparation of NG108-15 cells. Similar results were obtained with the mouse adenine receptor 
expressed in Sf21 insect cell membranes. IC50 values determined in radioligand binding 
studies were generally several-fold higher than IC50 values obtained in functional cAMP 
assays due to the amplification of the signal mediated by a GPCR by the intracellular 
signalling transduction pathway. The same differences between IC50 values determined in 
radioligand binding and functional studies has previously been observed for the recombinant 
rat adenine receptor expressed in CHO cells.
102
 
 
Affinities of adenine, selected adenine derivatives, as well as other substances known to 
activate GPCRs, at the mouse adenine receptor expressed in Sf21 insect cell membranes were 
determined and compared with those for the adenine receptor expressed in NG108-15 mouse 
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neuroblastoma x rat glioma cell membranes and the affinities determined in rat brain cortical 
membrane preparations (Figure 37, Table 19). The unsubstituted adenine showed the highest 
affinity in all three test systems exhibiting Ki values in the nanomolar range (IC50 = 63.7 nM 
for the mouse receptor in Sf21 cells, 54.9 nM in NG108-15 cells, Ki = 29.2 nM in rat brain 
cortex).  
 
Table 19. Comparison of affinities of adenine and selected compounds for mouse and rat 
adenine receptors determined in radioligand binding studies using membrane preparations. 
 
Compound Structure IC50 or Ki value ± SEM [µM] 
 (or % inhibition at 100 µM) 
Mouse 
recombinant 
receptor 
expressed in 
Sf21 cells 
NG108-15 
cells 
 
Rat 
brain 
cortex 
 
1 Adenine 
 
 
0.0737 ± 
0.0129110 
0.0549 ±  
0.0422 
0.0292 ± 
0.0033  
83 1-Methyladenine 
 
 
 
≥ 100  
(62 ± 7) 
 
≥ 100  
(60 ± 4) 
 
29.3 ± 
9.3186 
84 2-Fluoroadenine 
 
 
1.279 ± 
0.139 
0.304 ± 
0.097 
0.622 ± 
0.144104 
34 N6-Benzyladenine 
 
 
>> 100 
(12 ± 12)  
 
>> 100 
(8 ± 12) 
 
> 100 
(30 ± 3)186 
 
38 N6-
Dimethyladenine 
 
 
>> 100 
(0 ± 8) 
 
>> 100 
(0 ± 6) 
 
>> 100 
(11 ± 2)186 
 
49 TB 23 
 
 
7.51 
 
 
7.69 ± 
2.99 
 
 
2.85 ± 
0.59186 
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61 TB 73 (PSB-
09073) 
 
3.51 ± 
1.39190 
 
 
 
3.53 ± 
0.55 
 
 
0.025 ± 
0.006 
 
67 TB 97 (PSB-
09097) 
 
0.375 ±  
0.128190 
 
0.273 ± 
0.035 
 
0.094 ± 
0.003 
 
85 7-Methyladenine 
 
5.76 ±1.02 1.447 ± 
0.440 
4.13 ± 
1.08186 
86 NECA 
 
 
 
 
 
>> 100 
(28 ± 1)  
 
>> 100 
(7 ± 1) 
 
>> 100 
(10 ± 2)186 
 
87 ADP 
 
 
>> 100 
(28 ± 3)  
 
≥ 100 
(50 ± 5)  
 
≥ 100 
(51 ± 3)186 
 
88 ATP 
 
 
>> 100 
(14 ± 1)  
 
≥ 100 
(61 ± 4) 
 
> 100 
(39 ± 7)186 
 
89 Caffeine 
 
>> 100 
(0 ± 1)  
 
>> 100 
(0.4 ± 1)  
 
>> 100 
(2 ± 1)186 
 
 
The rank order of potency for the mouse receptor expressed in Sf21 cells was: adenine (1) > 
N
6
-(4-aminobutyryl)adenine (67) > 2-fluoroadenine (83) > N
6
-(3-aminopropionyl)adenine 
(61) > 7-methyladenine (85) > N
6
-acetyladenine (49) > 1-methyladenine (83) >> N
6
-
benzyladenine (34) > N
6
-dimethyladenine (38). The same rank orders of potency were 
observed for NG108-15 cellular membranes and rat brain cortical membranes. All other tested 
substances (NECA, ADP, ATP and caffeine) were inactive (Table 19). 
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In conclusion, a novel receptor for the purine nucleobase adenine from mouse brain was 
pharmacologically characterized. The low sequence identity with the previously described rat 
adenine receptor (76 %) suggests that the new receptor is not a species homologue but rather a 
distinct receptor subtype. Since human cells also posses specific binding sites for adenine
104
 
the existence of a receptor for adenine in human tissues seems to be very likely. However, a 
human sequence encoding for an adenine receptor has yet to be identified. The rat adenine 
receptor discovered
102
 and the mouse adenine receptor characterized in the present study 
appear to be members of a new, possibly larger family of receptors for purine nucleobases.  
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Figure 37. Competition curves for adenine and adenine derivatives at membranes from 
NG108-15 cells, natively expressing the mouse adenine receptor (A) and Sf21 cells 
recombinantly expressing the mouse adenine receptor (B).  
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3.1.5. Investigation of adenine receptors natively expressed in Chinese hamster ovary 
cells (CHO K1)  
It had previously been reported by our group that adenine receptors were natively expressed in 
CHO cells. Adenine in a concentration-dependent manner stimulated d intracellular cAMP 
accumulation with an IC50 value of 0.43 ± 0.24 µM in native CHO cells indicating the 
presence of a hamster adenine receptors.
186
 Here we aimed to furthers study adenine receptors 
natively expressed in CHO-K1 cells and to compare results of the coupling of adenine 
receptors in CHO-K1 with those present in CHO flp-in cells.  
3.1.5.1. Accumulation cAMP assay for CHO K1 and CHO flp-in cells 
The function of adenine receptors in CHO K1 and CHO flp-in cells was assessed by analyzing 
the activity of cellular adenylate cyclase activity. Cellular cAMP production was stimulated 
by the addition of 5 µM forskolin.  
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Figure 38. Inhibition of adenylate cyclase activity of adenine receptor in intact (A) CHO K1 
cells and (B) CHO flp-in cells. Cellular cAMP production was stimulated by 5 µM of 
forskolin. The figure shows the concentration-dependent inhibition of intracellular cAMP 
accumulation by adenine (1 nM – 1000 nM). The IC50 value was 4.04 ± 2.7 nM for adenine 
receptors in CHO K1 cells and 23.8 ± 2.1 nM for adenine receptor in CHO flipIn cells (n = 3). 
*** indicates significant differences from corresponding control (p < 0.001) or ** (p < 0.01). 
 
The forskolin-induced cAMP production in the presence of agonists was expressed as 
percentage of the forskolin-induced cAMP production in the absence of agonists (% of 
control) (n = 3, Figure 38). The results showed that adenine receptors in CHO K1 and CHO-
flp-in cells are coupled to inhibition of adenylate cyclase with IC50 values of 4.04 ± 2.7 nM 
and 23.8 ± 2.1 nM, respectively. An explanation of the 6-fold lower IC50 value of adenine in 
CHO K1 cells as compared to CHO-flp-in cells could be a lower receptors expression in the 
latter cell line. 
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3.1.5.2. [
3
H]Adenine saturation experiments 
For further characterization of the adenine receptors in CHO K1 cells saturation binding 
studies were performed using membrane preparations of CHO K1 cells and [
3
H]adenine 
(0.75-150 nM). 
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Figure 39. Saturation of [
3
H]adenine binding to adenine receptors in membrane preparations 
of CHO K1 cells.  
 
The results showed that CHO cells exhibited a single binding site for [
3
H]adenine with a KD 
value of 121 nM and a Bmax value of 1.536 pmol/mg of protein (n = 1, Figure 39). The 
determined KD value was quite similar to that determined at the mAde2R expressed in Sf21 
cells (KD = 113 nM). 
 
Thus, the hamster also appears to express at least one adenine receptor coupled to inhibition 
of adenylate cyclase and the expression level in CHO K1 cells was found to be high. 
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3.1.6. Homologous competition assays 
 
3.1.6.1. Principle of assay 
 
A competitive binding experiment is termed homologous when the same compound is used as 
the hot and cold ligand. Homologous competitive binding experiments have the same goals as 
saturation binding experiments which can be used to determine the affinity of a ligand for the 
receptor as well as the receptor number. In order to analyze a homologous competition 
binding curve, one needs to make the following assumptions:
120
 
 The receptor has identical affinity for the labeled and the unlabeled ligand. 
 There is no cooperativity. 
 There is no ligand depletion. The methods in this section assume that only a small  
 fraction of ligand binds. In other words the method assumes that the free concentration 
equals the concentration added. 
 There is only one class of binding sites. It is difficult to detect a second class of binding 
sites unless the number of lower affinity sites vastly exceeds the number of higher 
affinity receptors (because the single low concentration of radioligand used in the 
experiment will bind to only a small fraction of low affinity receptors). 
 
The Cheng and Prussoff equation is used to analyze a homologous competition binding curve 
in which Ki is calculated from the IC50. In this case the hot ligand has identical affinity with 
the cold ligand so that KD is the same as Ki (equation 6).
120  
 
KD = Ki = IC50 - [Radioligand]
 
Equation 6. Cheng and Prussoff equation 
 
The difference between the top and bottom plateaus of the curve represents the specific 
binding of the radioligand at the concentration used. Depending on how much radioligand is 
used, this value may be close to the Bmax or far from it. To determine the Bmax, specific binding 
is divided by the fractional occupancy (equation 7), calculated from the KD and the 
concentration of radioligand. 
Bmax =
Top - Bottom
Fractional occupancy
=
Top - Bottom
[Radioligand]
(KD + [Radioligand])
 
Equation 7. Calculation of receptor density (Bmax) 
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3.1.6.2. Homologous competition binding curves for characterization of endogenous rat 
adenine receptors in pheochromocytoma cells and human melanoma 1539 cells 
 
Radioligand binding studies were performed of membrane preparations of various cell lines. 
High affinity binding of [
3
H]adenine was found in membrane preparations of various cell 
lines, including rat pheochromocytoma (PC12) cells, human astrocytoma cells, human 
embryonic kidney cells and human melanoma 1539 cells (Figure 40).  
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Figure 40. [
3
H]Adenine binding (10 nM) to membrane preparations of rat cortex, 1321N1 
astrocytoma cells heterologously expressing rAde1R, PC12 cells, astrocytoma 1321N1 cells, 
human embryonic kideny cell (HEK293) and human melanoma 1539 cell  (100 µg of protein) 
(n=3). 
 
Competition binding assays were performed as described at adenine receptors of human 
melanoma 1539 cells and rat pheochromocytoma cell membranes using different 
concentrations of adenine as shown in figure 41. Adenine showed relatively low affinity for 
adenine receptors in human melanoma 1539 cells with an IC50 value of 341 ± 119 nM 
compared to the adenine receptors in human embryonic kidney cells (HEK293) (Ki = 44.3 
nM). The calculated KD value from the homologous competition experiments was 315 ± 104 
nM, which is much higher than the KD value calculated for the human adenine receptor in 
membrane preparation of HEK293 cells (KD = 44.7 nM).
186
 The adenine receptors density at 
membrane preparations of melanoma cells was very low with a Bmax value of 6.96 ± 1.99 
fmol/mg protein. Quite similar results were obtained for adenine receptors in membrane 
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preparations of rat PC12 cells: adenine showed lower affinity (IC50 = 489 ± 206 nM) in 
comparison with the adenine receptor in rat cortical membrane preparations (Ki = 29.2 nM). 
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Figure 41. Competition curves for adenine derivatives versus 10 nM [
3
H]adenine obtained 
(A) at membrane preparations of PC12 cells (B) at membrane preparations of melanoma cells 
(n=3). The apparent KD and Bmax values were 479 ±106 nM and 21.3 ± 5.6 pmol/mg protein 
and, IC50 489 ± 206 nM for endogenous rat adenine receptors in pheochromocytoma cells, and 
the apparent KD = 315 ± 104 nM,  Bmax  6.96 ± 1.99 fmol/mg protein and IC50 value of 341 ± 
119 nM at human melanoma 1539 cells (n = 3). 
 
The apparent KD value calculated from homologous competition experiments was 479 ± 106 
nM, while the determined KD value for adenine receptors at rat brain cortical membrane 
preparation was 27.2 nM. A high receptor density with a Bmax value of 21.3 ± 5.6 pmol/mg 
was detected in membrane preparations of PC12 cells (n = 3). 
 
Despite the low affinity for adenine, the amount of specific binding determined in radioligand 
binding studies using 10 nM [
3
H]adenine at membrane preparations from rat PC12 cells was 
higher than at human embryonic kidney cells (HEK293), human melanoma 1539 cells and rat 
brain cortical membranes (Figure 41). This can be explained by the very high expression level 
of [
3
H]adenine binding sites in PC12 cells. 
 
3.1.6.2.1. Functional studies at PC12 cells 
 
 
In order to study functional properties of rat adenine receptors in PC12 cells we measured the 
activity of adenylate cyclase in PC12 cells. cAMP reporter gene assays were performed. For 
this purpose, the pCER-luc (the cAMP responsive reporter plasmid) was transiently 
transfected into PC-12 cells using Lipofectamine 2000 as a transfection reagent. The results 
showed that adenine in a dose dependent manner affects forskolin-stimulated cAMP 
production in the luciferase luminescence assay (Figure 42). Adenine at a concentration of 
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100 µM inhibited forskolin-stimulated cAMP levels by up to 60% with an IC50 value of 12.8 
± 2.1 µM. The determined IC50 value is in the micromolar range while the rAde1R receptor 
expressed in 1321N1 astrocytoma cells had shown an IC50 value in the nanomolar range. 
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Figure 42: Inhibition of forskolin-stimulated cAMP-dependent luciferase activity by adenine 
activating endogenous rat adenine in PC12 cells. Data are given as percentages of the mean 
increases in cellular cAMP levels in the presence of forskolin alone. Adenine induced a dose-
dependent inhibition of forskolin-stimulated intracellular cAMP, reducing stimulated cAMP 
levels by up to 60%. The IC50 value was 12.8 ± 2.1 µM (mean ± SEM determined in 2 
independent experiments). 
 
One explanation for this discrepancy could be that PC12 cells express an adenine receptor 
subtype which is different from the rAde1R. An alternative explanation could be that the 
adenine receptor in PC12 cells forms heteromers with other receptor or interact with other 
proteins which modulate receptor activation. 
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3.1.6.2.2. mRNA localization studies for endogenous rat adenine receptors in PC12 cells 
In order to investigate whether PC12 cells express mRNA for the rAde1R, mRNA was 
extracted from PC12 cells.  Primers were designed as shown in table 20. 
 
 
Figure 43. PCR product experiment. Lane 2 and 3, 426 bps, are PCR product with cDNA 
from PC12 cells.  Lane 4 is PCR product with rAde1R plasmid (426 bps). Control samples 
without primers (5) or primers without plasmid (7) revealed no products. Lane 8 and 9 are 
PCR product using β-actin cDNA from PC12 cells with specific primers as control. 
 
Analysis of PCR products showed that bands 426 bps (A and B, Figure 43) were obtained 
which have the expected size of the rAde1R plasmid using the same primers 426 pbs (Figure 
43). 
 
Table 20. Information about primers used in PCR.  
 
  Sequence (5'->3') Start 
 
Stop Tm Product 
length 
Primer 
Set 1 
Forward 
primer 
rAde1R 
GGCATCGAACTTCTTTACTGC 573 593 62  
     
426 
 Reverse 
primer 
rAde1R 
CATCACGGCTCCACCTTGC 998 980 62 
Primer 
Set 2 
Forward 
-b-actin 
rat 
CCCTAAGGCCAACCGTGAAAAGAT 414 
 
 
437 
 
 
72  
 
222 
Reverse  
b-actin 
rat 
AGGTCCCGGCCAGCCAGGTC 635 
 
 
616 
 
 
70 
 
From the functional studies and primary mRNA localization studies for endogenous rat 
adenine receptors in PC12 cells, we can conclude that PC12 cells express rat adenine 
receptors. Further studies must be performed in order to determine the exact sequence for 
endogenous rat adenine receptors in PC12 cells and to compare it with the rAde1R sequence.  
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3.2. Adenosine receptors 
 
3.2.1. Evaluation of adenosine A2B receptors expressed in CHO cells 
 
3.2.1.1. Adenosine A2B receptors 
 
Adenosine A2B receptors have been generally defined as the “low affinity adenosine 
receptors” due to their lower affinity for the endogenous ligand adenosine and for some 
typical agonists, such as 5′-N-ethylcarboxamidoadenosine (NECA, 86, Table 19) by contrast 
with other AR subtypes.
195,197
Activation of adenosine A2B receptors leads to stimulation of 
adenylate cyclase and activation of phospholipase C through the coupling to Gs and Gq/11 
proteins, respectively. From a pharmacological point of view, adenosine A2B receptors are 
known as the most poorly characterized of the adenosine P1 receptors. Only very recently 
some reports about important advancement in identifying adenosine A2B receptor agonists 
with improved in vitro pharmacological profile have been published.
197
 BAY-60–6583 (90, 
Figure 44) had been characterized in CHO cells expressing recombinant human adenosine A1, 
A2A or A2B receptors.
197
The compound (90) showed EC50 values for receptor activation 
>10,000 nM for both human adenosine A1 and A2A receptors and 3 nM for the human 
adenosine A2B receptor subtype. Moreover, it showed no agonistic activity in the adenosine 
A3-Gα16 assay up to a concentration of 10 μM.
198
 BAY-60–6583 (90) has been examined as 
adenosine A2B receptor agonist for its potential in treating disorders of the coronary arteries 
and atherosclerosis,
199
 and for prophylaxis and/or treatment of ischemia-reperfusion injury
200 
and 
 
angina pectoris. In our work we aimed at developing a recombinant stable CHO cell line 
expressing the human adenosine A2B receptors. Furthermore the newly prepared cell line was 
to be used for characterizing the non-selective agonist NECA (86) and the selective agonist 
BAY-60–6583 (90). 
 
 
Figure 44. Chemical structures of the adenosine A2B agonist (nonadenosine-like, non-
nucleosidic ligand) BAY 60-6583 (90). 
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3.2.1.2. cAMP accumulation assay for CHO cells stably expressing the human adenosine 
A2B receptor 
 
The function of the human adenosine A2B receptor was assessed by analyzing the activity of 
cellular adenylate cyclase activity in CHO cells stably expressing the human adenosine A2B 
receptor. Experiments were carried out with increasing concentrations (0.001–10 µM) of the 
agonist NECA (86) and increasing concentrations (0.001–1 µM) of BAY 60-6583 (90).  
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Figure 45. (A) Stimulation of adenylate cyclase activity by the human A2B receptor expressed 
in CHO K1 cells. The figure shows the concentration-dependent stimulation of intracellular 
cAMP-accumulation by NECA (0.001–10 µM). The EC50 value was 0.035 ± 0.014 µM (n = 
3). (B) Stimulation of adenylate cyclase activity by the human adenosine A2B receptor 
expressed in CHO K1 cells. The figure shows the concentration-dependent stimulation of 
intracellular cAMP-accumulation by BAY 60-6583 (0.001–1 µM). The EC50 value was 0.016 
± 0.004 µM (n = 3). 
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Figure 46. Dose response curves of NECA (86) and BAY 60-6583 (90) obtained in cAMP 
assays with CHO cells expressing the human adenosine A2B receptor (n=3). 
 
Figure 45, A and B shows the dose-response curves for NECA and BAY 60-6583 at the 
human adenosine A2B receptor expressed in CHO cells. NECA and BAY 60-6583 exhibited 
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agonistic properties at human adenosine A2B receptors expressed in CHO cells with EC50 
values of 0.035 ± 0.014 µM and 0.016 ± 0.004 µM, respectively. From our results it can be 
concluded that both ligands acted as full agonists in this system since the maximal effect was 
very similar (see figure 46). It should be noted that the low EC50 values for both ligands 
indicate a very high A2B receptor expression level. In such systems partial agonism may not 
be detectable. 
 
3.2.2. Modification of a protein-binding method for rapid quantification of cAMP in cell-
culture supernatants  
 
 
Competitive binding assays are widely used methods for cAMP quantification in which the 
cAMP-binding properties of antibodies raised against chemically modified cAMP
201 
or 
binding of cAMP to the regulatory subunit of cAMP-dependent protein kinase
202,203
 is 
determined. When measuring cAMP with competition techniques, protein-bound tracer must 
be separated from free tracer. Separation of protein-bound cAMP from free cAMP can be 
achieved with albumin-saturated charcoal,
202
 ammonium sulfate,
204
 or by filtration over 
cellulose filters.
203
 The major disadvantages of the separation methods as presently described 
are that they are time-consuming and labor-intensive and therefore not suitable for analysis of 
large numbers of samples. Therefore we tried to apply a rapid, semiautomatic modification of 
the protein-binding method described before,
202, 205
 in which cAMP-dependent protein kinase 
from bovine adrenal cortices is used as a binding protein, and [
3
H]cAMP with a very high 
specific activity is used as a radioligand. 
 
3.2.2.1. Modified protocol  
 
In order to test the binding protein prepared from calf adrenal glands a cAMP assay was 
performed as mentioned above using A2B receptor-expressing CHO cells. cAMP levels in the 
supernatant were then quantified by incubation of an aliquot with cAMP binding protein 
prepared from calf adrenal glands (40 µg) and [
3
H]cAMP (3 nM). The samples were 
harvested by filtration through Whatman GF/B filters using a cell harvester. A parallel assay 
was performed using the cAMP binding protein from the assay kit TRK 432 from Amersham 
Biosciences, Freiburg, Germany. The results are shown in figure 47. There was good 
agreement between cAMP values obtained with the protein-binding method prepared from 
calf adrenal cortex and the commercially available kit that was used as a reference method. 
More than 500 samples could be assayed in duplicate or triplicate in less than 6 h.  
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Figure 47. Comparison of dose response curves for NECA in cAMP assays using CHO cells 
expressing the human adenosine A2B receptor: (A) filtration through Whatman GF/B filters 
using a harvester or adsorption to charcoal for separation of bound from free [
3
H]cAMP; (B) 
binding protein prepared from calf adrenals gland and binding protein from assay kit TRK 
432. 
 
In conclusion, the data presented here show that cAMP in cell-culture supernatants can be 
measured accurately with the presented modification of the protein-binding assay. The 
sensitivity of the method compared favorably with other protein-binding methods described
205 
with a sensitivity limit in the femtomole range. The major advantages of the method are:  
(i) the low cost (small volumes of tracer and reagents),  
(ii) the ease of setting up large assays with commercially available equipment 
designed for microtiter plates,  
(iii) the rapidity of the separation of bound from free tracer. It is not difficult to assay 
400-500 samples in duplicate or triplicate during a period of 6 h. 
The developed protocol which is similar to a protocol previously described by Fredholm and 
coworker
205
 has now become the standard procedure in our laboratory to measure cAMP 
accumulation. 
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3.2.3. Adenosine A2A receptor agonists 
 
3.2.3.1. cAMP accumulation assay for CHO cells stably expressing the human adenosine 
A2A receptor 
 
A newly synthesized adenosine receptor agonist PBS-0777 had showen high affinity for 
adenosine A2A receptors at rat cortical membranes with a Ki value of 44.2 ± 2.4 nM and 
selectivity over the other adenosine receptors subtypes. Further evaluation of the agonistic 
properties of PBS-0777 at adenosine A2A receptors and comparison with the non-selective 
adenosine receptor agonist NECA was done under the same conditions. 
The function of the adenosine A2A receptor was assessed by analyzing the activity of cellular 
adenylate cyclase activity in CHO cells stably expressing the human adenosine A2A receptor. 
Experiments were carried out with increasing concentrations of the agonist NECA (0.001–10 
µM) and increasing concentrations of the newly synthesized adenosine A2A receptor agonist 
PSB-0777 (0.001–1 µM) as shown in figure 48.  
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Figure 48. Stimulation of adenylate cyclase activity via the human adenosine A2A receptor 
expressed in CHO K1 cells. (A) Concentration-dependent stimulation of intracellular cAMP-
accumulation by NECA (0.001–10 µM). The EC50 value was 17.6 ± 14 nM (n=4). (B) 
Concentration-dependent stimulation of intracellular cAMP-accumulation by PSB-0777 
[0.001–10 µM]. The EC50 value was 117 ± 10 nM (n = 3). 
 
Figure 48 shows the dose-response curves of NECA and PSB-0777 at the human adenosine 
A2A receptor expressed in CHO cells (EC50 values 17.6 ± 14 nM, and 117 ± 10 nM, 
respectively). The amount of cAMP produced by compound PSB-0777 at 10 µM showed no 
significant difference compared with the amount of cAMP produced at the same high 
concentration of NECA (Figure 49 and 50). From these results it can be concluded that PSB-
0777 acts as a full agonist and has high affinity for human adenosine A2A receptors expressed 
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in CHO K1 cells. The compound showed six fold lower affinity compared with the parent 
compound NECA for human adenosine A2A receptors expressed in CHO cells.  
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Figure 49. Dose response curves of NECA (86) and PSB-0777 in cAMP assays using CHO 
K1 cells expressing the human adenosine A2A receptor (n = 3). EC50: 17.6 ± 14 nM (NECA) 
and 117 ± 10 nM (PSB-0777). 
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Figure 50.  Maximal amount of cAMP produced by stimulation with 10 µM of NECA and 
PSB-0777; the result showed no significant different and therefore PSB-0777 is a full agonist 
at human adenosine A2A receptors in this test system. 
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3.2.4. Adenosine A2A receptor antagonists 
3.2.4.1. cAMP accumulation assay at CHO cells stably expressing the human adenosine 
A2A receptor for investigation of the new adenosine A2A receptor antagonist AA-01 
The new antagonist AA-01 was to be functionally characterized in order to investigate 
whether it has an allosteric or a competitive mechanism of action. Standard A2A antagonists 
were investigated under the same conditions for comparison. 
 
CHO cells transfected with the human adenosine A2A receptor were used for this purpose. For 
experiments with antagonists, cells were incubated with different concentrations of adenosine 
A2A antagonists for 10 min before addition of the agonist NECA (1 nM - 100000 nM). Then 
the cells were incubated for 10 more minutes. Alternatively both, agonist and antagonist were 
added at the same time. As antagonists AA-01, KW6002 (istradefylline) (91) and SCH420814 
(preladenant) (92) were investigated (Figure 51). AA-01 (10 nM, 100 nM, 1 µM) showed a 
concentration-dependent shift of the concentration-response curve of NECA to the right. The 
maximal effect of NECA was significantly reduced in a concentration-dependent manner 
(Figure 52). 
 
Figure 51. Chemical structures of the adenosine A2A antagonists KW6002 (91) and 
SCH420814 (92). 
 
 
KW6002 (91) (1 µM) and SCH420814 (92) (100 nM) also shifted the concentration-response 
curve of NECA (86) to the right. The maximal effect was also decreased, although to a 
smaller extent than seen with AA-01 (Figure 52 and 53). Figure 53 shows the effect on the 
maximal NECA-induced cAMP response in the presence of antagonists.  
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Figure 52. Measurement of stimulation of adenylate cyclase activity by human adenosine A2A 
receptors expressed in CHO cells. The figure shows the stimulation of intracellular cAMP-
accumulation by NECA alone (A-C), and (A) by NECA after preincubation with different 
concentrations of AA-01 (10 nM, 100 nM and 1000 nM), (B) by NECA after preincubation 
with 100 nM SCH420814, and (C) by NECA after preincubation with 1 µM KW6002. The 
cells were incubated with antagonist for ten minutes before addition of agonist (n=3). 
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The reduction in the maximal effect by AA-01 was statistically highly significant. Table 21 
shows the EC50 values obtained for NECA (86) in the absence and in the presence of 
antagonist. 
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Figure 53. Maximal amount of cAMP released at 100 µM of NECA without and after 
preincubation with antagonists. *P values for SCH420814 (92) and KW6002 (91) are 0.0254 
and 0.0458, respectively; **P value for 10 nM of AA-01 is 0.0046 while the ***P vor 100 
and 1000 nM AA-01 value is < 0.0001. 
 
 
Table 21. EC50 values for NECA-induced cAMP accumulation without and after 
preincubation with antagonist. 
 
 
Compounds EC50 ± SEM (μM) ( n = 3 ) 
NECA (86) 0.0714 ± 0.0046 
NECA +10 nM AA-01 0.202 ± 0.065 
NECA + 100 nM AA-01 0.737 ± 0.093 
NECA + 1000 nM AA-01 16.7 ± 2.5 
NECA + 100 nM SCH420814 (92) 3.11 ± 0.87 
NECA + 1000 nM KW6002 (91) 4.54 ± 1.32 
 
Simultaneous addition of agonist and antagonist 
 
In the following experiments the antagonist was added at the same time as the agonist. AA-01 
again showed a concentration-dependent shift of the NECA (86) curve (Figure 54). The 
maximal effect of NECA (86) was not significantly reduced by the antagonist. A KB value 
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was calculated for AA-01: it was 4.14 nM (Table 22). Thus AA-01 is similarly potent as 
SCH420814 (92) (KB value 2.61 nM), which could also be characterized as a competitive 
antagonist. Co-administration of NECA (86) and KW6002 (91) led to a shift of the 
concentration-response curve for NECA (86) (Figure 56). The maximal effect of NECA (86) 
was reduced (Figure 57). The level of statistical significance, however, was low. The KB value 
for KW6002 (91) could be calculated as 22.9 ± 9.9 nM. 
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Figure 54.  NECA-induced stimulation of adenylate cyclase activity via the human adenosine 
A2A receptor expressed in CHO cells in the absence and in the presence of (A) two different 
concentrations of AA-01 (100 nM and 1000 nM) and (B) 10 nM SCH420814. Agonist and 
antagonists were added at the same time (n=3). 
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Figure 55.  NECA-induced stimulation of adenylate cyclase activity via the human adenosine 
A2A receptor expressed in CHO cells in the absence and in the presence of two different 
concentrations of AA-01 (100 nM and 1000 nM). Agonist and antagonists were added at the 
same time (n=3). 
 
Table 22. Potency of selected adenosine receptor antagonists in CHO cells transfected with 
the human adenosine A2A receptor  
 
 
Antagonist KB ± SEM (nM), n=3 Hill slop 
SCH420814 (92) 2.61 ± 1.27 1.06 ± 0.27 
AA-01 4.14 ± 3.08 0.94 ± 0.14 
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Figure 56.  NECA-induced stimulation of adenylate cyclase activity via the human adenosine 
A2A receptor expressed in CHO cells in the absence and in the presence of 100 nM KW6002. 
Agonist and antagonist were added in the same time (n=3). 
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Figure 57.  Maximal amount of cAMP produced by stimulation with 100 µM of NECA in the 
absence and in the presence of 100 nM KW6002 (coadministration) (*P values is 0.0464). 
 
 
In conclusions, AA-01 appears to be a competitive antagonist at human adenosine A2A 
receptors, like KW 6002 (91) and SCH420814 (92). The compound shows a large decrease in 
the maximal effect induced with NECA (86) when applied prior to the agonist (10 min 
preincubation). This might be due to slow dissociation from the receptor. But this would 
require further investigation, e.g. by performing kinetic studies with radiolabelled AA-01. 
Slow receptor dissociation may be pharmacologically relevant. 
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3.2.5. Interactions of Magnolia extract with adenosine A1 receptors  
The bark of Magnolia officinalis has a history of use in traditional Asian medicine for mild 
anxiety, nervousness and sleep-related problems. A proprietary combination containing 
Magnolia extract, Seditol
®
, has demonstrated effectiveness in alleviating sleep difficulties in 
an open-label clinical assessment.
206
 
In order to better understand the pharmacological targets for Seditol
®
(S), the product and its 
component extracts (Magnolia = M and Ziziphus = Z) were tested for binding affinity to a 
number of central nervous system receptors associated with relaxation and sleep. 
For this purpose, a series of different plant extracts was investigated for their affinity and 
function at adenosine receptors in radioligand binding studies (the extracts were provided by 
Dr. Koetter Consulting Services, Uttwil, Switzerland). An extract concentration of 100 µg/ml 
was used to determine the inhibition of the radioligand binding at all four adenosine receptor 
subtypes. Only extract M at A1 adenosine receptor and extracts M and S at A3 adenosine 
receptor could inhibit the respective radioligand binding by ≥ 50 % and showed therefore 
significant affinity. The radioligand binding studies showed that extract S exhibited an affinity 
for human adenosine A3 receptors (Ki= 3.65 µg/ml), while extract M showed affinities to 
both, rat adenosine A1 receptor with a Ki-value of 9.20 µg/ml and to human adenosine A3 
receptors (Ki-value of 32.0 µg/ml).
206
 This indicates that there are interactions between 
Seditol
®
, and/or one of its constituent extract of Magnolia, with the adenosine A1 receptor. 
These interactions are consistent with the reported anxiolytic and sleep-inducing activities of 
extracts of Magnolia, Ziziphus and their combination. The results provide further indications 
of the mode of action of these plant extracts. 
 
Extracts of M. officinalis bark and Z. spinosa seed are combined in a proprietary product 
called Seditol
®
 that is produced by Next Pharmaceuticals. Seditol is characterized as 
containing a minimum of 2.7% honokiol and 0.1% spinosin. Seditol is a dietary supplement, 
marketed for the improvement of sleep difficulties associated with restlessness, stress or 
anxiety. 
 
In order to fully understand the nature of interaction of Mongolia extract with adenosine A1 
receptors further testing were performed. 
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3.2.5.1. Luciferase cAMP assay 
 
The CHO K1 cells stably transfected with human adenosine A1 receptors were transiently 
transfected with pCRE-luc (cAMP response element). The reporter cells were stimulated for 
cAMP production with forskolin (4 µM) and N
6
-cyclopentyladenosine (CPA) was used as an 
adenosine A1 receptor agonist to inhibit the forskolin-stimulated cAMP production. CPA at a 
concentration of 1 µM showed about 60% inhibition of maximal cAMP produced. The 
Magnolia extract M was tested at a concentration of 10 µg/ml and 100 µg/ml completely 
inhibited forskolin-stimulated cAMP accumulation in CHO cells expressing the adenosine A1 
receptor (Figure 58).  
C
on
tr
ol
Fo
rs
ko
lin
C
P
A
 1
0 
 n
M
C
P
A
 1
00
 n
M
C
P
A
 1
 µ
M
M
 1
00
 µ
g/
m
l
M
 1
0 
µg
/m
l
C
P
A
 1
0 
nM
/ M
 1
00
 µ
g/
m
l
0
5000
10000
15000
20000
R
e
la
ti
v
e
 l
u
m
in
e
s
c
e
n
c
e
 u
n
it
 
Figure 58. Inhibition of forskolin-stimulated cAMP accumulation by CPA and plant extract 
M at different concentrations in CHO cells stably expressing the human adenosine A1 receptor 
(n=2). 
 
The extract seemed to disturb the assay system by an unknown mechanism. In the presence of 
the extract, the cells were not able to produce any cAMP after stimulation of the adenylate 
cyclase with forskolin (4 µM). 
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3.2.5.2. GTP-shift experiments 
 
As the cAMP luciferase result was considered likely to be an artifact, the functional properties 
(agonist, antagonist) of the magnolia extract M were investigated in GTP-shift experiments 
using a rat cortical membrane preparation containing adenosine A1 receptors. The magnolia 
extract showed no GTP-shift in this experiment. Results are shown in table 23 and figure 59.  
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Figure 59. GTP-shift curves (A) for the full A1 agonist CPA and (B) for the plant extract M 
to determine shifts in IC50 values in order to estimate the functional properties. Data points 
represent means of 1 or 3 independent experiments ± SEM. 
 
The full A1-adenosine receptor agonist N
6
-cyclopentyladenosine (CPA) led to 101-fold (see 
also Table 23) right word shift of IC50-value in the presence of 100 µM GTP indicating the 
maximum level for agonists. By contrast, plant extract M showed no significant shift of the 
Ki-value in the presence of GTP (P-value 0.347 in a two-tailed student´s t-test, not 
significant), indicating that plant extract M is an antagonist at adenosine A1 receptors. 
 
Table 23. GTP-shift experiment for the magnolia extract M and CPA at adenosine A1 
receptor in rat cortical membrane preparations. 
 
 
 
IC50  ± SEM 
A1 vs. [
3
H]DPCPX at rat cortex 
 
Shift 
Control + GTP (100 µM) 
Plant extract M 9.49 ± 0.47 µg/ml 12.1±1.7 µg/ml 1.2 ± 0.1 (ns) 
CPA (n = 1) 29.3 nM 2985 nM 101 
 
In conclusion, the GTP-shift and cAMP experiments with the Magnolia extract indicate that it 
may be either a week partial agonist or an antagonist.  
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Seditol
®
 showed an interaction with the adenosine A1 receptor that appears to be due to the 
constituent Magnolia extract. Adenosine A1 is known to play an important role in the 
initiation of sleep. During the day, adenosine accumulates in neurons and in the evening it is 
released into the nerve synapses where it prepares the body to enter into a relaxed state.
207
 The 
Magnolia extract was tested for adenosine A1 agonist activity. The rationale for this is that it 
was hypothesized that the Magnolia extract might act in a similar was as an extract of 
Valerian root (Valeriana officinalis L). Previously it has been reported that a valerian extract 
counteracted functional central arousal caused by the oral administration of caffeine, a 
adenosine receptor antagonist.
208 
Results with the Valerian extract indicated that it is a partial 
agonist of adenosine A1.
209,210 
The GTP-shift experiments with the Magnolia extract indicate 
that it may be either a weak partial agonist in analogy with the Valerian extract, or more likely, 
an antagonist. 
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3.3. Characterization of [
3
H]PSB-0413, the first selective radioligand for P2Y12 receptors 
 
 
ADP plays a key role in arterial thrombosis.
211
 ADP is released at sites of vascular injury and 
interacts with two G protein-coupled receptor subtypes of the P2 receptor family on platelets, 
the P2Y1 and P2Y12 receptors. The P2Y12 receptor is the target of the antithrombotic 
thienotetrahydropyridine derivatives clopidogrel and prasugrel.
212
 The platelet P2Y12 receptor 
has been extensively characterized in functional assays. However, characterization on the 
protein level has been hampered by the lacking of a selective radioligand.  
 
 
 
Figure 60. Chemical structure of [
3
H]PSB-0413, the first selective radioligand for P2Y12 
receptors.  
 
In a preliminary communication we reported on the development of [
3
H]PSB-0413 (Figure 
60) as a high affinity, subtype selective antagonist radioligand for the characterization of 
P2Y12 receptors on the protein level.
213
 
 
Here we want to complete the full characterization of [
3
H]PSB-0413 by using human P2Y12 
receptors transfected in 1321N1 astrocytoma cells. Saturation and competition experiments 
were performed at astrocytoma 1321N1 cells recombinantly expressing the human P2Y12, 
P2Y1, or P2Y13 receptor, respectively. Cell lines were prepared by retroviral transfection. 
 
3.3.1. cAMP accumulation assay for astrocytoma cells stably expressing the human P2Y12 
receptor 
 
In 1321 N1 astrocytoma cells stably expressing the human P2Y12 receptors, 2-MeSADP or 
ADP induced a dose-dependent inhibition of forskolin stimulated intracellular cAMP 
accumulation, reducing stimulated cAMP levels by up to 60–80% (Figure 61). Data are given 
as percentages of mean increases in cellular cAMP levels in the presence of forskolin alone (4 
µM). cAMP levels increased to 23 pmoles/well and were reduced to about 6–8 pmoles / well 
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in the presence of each diphosphate nucleotide. IC50 values were determined for ADP and 2-
MeSADP and found to be 1.68 ± 0.73 µM and 0.00129 ± 0.00109 µM, respectively (means ± 
SEM in 3–6 independent experiments). The rank order of potency was 2-MeSADP >> ADP. 
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 Figure 61. Inhibition of forskolin-stimulated cAMP accumulation by ADP and 2-MeSADP 
in 1321N1 astrocytoma cells stably expressing human P2Y12 receptor. cAMP production was 
stimulated with forskolin (4 µM) in the presence of IBMX (100 µM) and caffeine (10 µM). 
(A) ADP induced a dose-dependent inhibition of forskolin-stimulated intracellular cAMP 
accumulation, reducing stimulated cAMP levels by up to 60 %. The IC50 value was 1.68 ± 
0.73 µM (mean ± SEM in 3 independent experiments). (B) 2-MeSADP reduced the 
production of cAMP induced by forskolin (4 µM) up to 80%. The IC50 value was 0.00129 ± 
0.00109 µM (n= 3).  
 
3.3.2. Radioligand binding studies 
 
3.3.2.1. Saturation experiments  
 
As shown in figure 62, binding of [
3
H]PSB-0413 to 1321N1 cells expressing human P2Y12 
receptors was concentration-dependent, and the nonspecific binding measured in the presence 
of ADP (10 mM) was low and depended on the [
3
H]PSB-0413 concentration. The results 
showed two classes of binding sites one exhibiting high affinity with a KD value of 13.1 ± 1.1 
nM. The total number of binding sites (Bmax) corresponds to 61,925 ± 10,153 receptors per 
cell. The second binding site has a low affinity with a KD value of 0.229 ± 0.041 M and with a 
Bmax value of 30,737 ± 8,228 receptors per cell. 
 
The KD value for [
3
H]PSB-0413 obtained from saturation studies to intact astrocytoma cells 
was in close agreement with the KD value calculated from kinetic experiments and saturation 
studies at human platelet membranes (ca. 5 nM).
214
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Figure 62. Saturation binding studies of [
3
H]PSB-0413 to intact astrocytoma cells expressing 
the human P2Y12 receptors.  
 
3.2.2. Competition experiments  
 
The competition assays were carried out using [
3
H]PSB-0413 in a concentration of 5 nM 
using intact 1321N1 cells stably expressing human P2Y12 receptors or membrane preparations 
of the same cell line. The non-specific binding was determined using 10 mM ADP. Serial 
dilutions of test compounds were used. As shown in table 24, 2-MeSADP showed high 
affinity for human P2Y12 receptors expressed in 1321N1 cells with a Ki value of 0.00521  
0.00036 µM. ADP itself showed a Ki value of 2.32 ± 0.58 µM (Figure 63). Quite similar 
results were obtained with membrane preparations of astrocytoma 1321N1 cells expressing 
human P2Y12 receptors (Figure 63 and Table 24). IC50 values determined in radioligand 
binding studies for the human P2Y12 receptor expressed in 1321N1 astrocytoma cells were 
similar to IC50 values obtained in functional cAMP assays. The rank order of potency in 
competition assays at P2Y12 receptors natively expressed in human platelets was 2-MeSADP 
(4.88 nM) >> ADPβS (4.11 µM) > ADP (17.6 µM). Similar affinities were observed at human 
P2Y12 receptors expressed in astrocytoma 1321N1 cells. ADP showed an affinity of 2.32 µM 
in whole cell binding assays with a 23-fold lower affinity than in competition assays using 
membrane preparations of 1321N1-astrocytoma cells expressing the human P2Y12 receptors 
(Ki 0.00979 µM) (Figure 63 and Table 24). 
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Table 24. P2Y12 receptors affinities, expressed as Ki values, of selected P2Y12
 
receptor 
ligands determined at membrane preparations of blood platelets natively expressing the 
human P2Y12 receptors and whole 1321N1 cells expressing the human P2Y12 receptors.  
 
                                                                         
                         Ki (or IC50) ± SEM [µM] vs. [
3
H]PSB-0413 (n=3) 
 
Compound Membrane preparation  
of 1321N1-astrocytoma 
cells expressing the 
human P2Y12 receptors 
Whole 1321N1 cells 
expressing the human 
P2Y12 receptors 
Membrane 
preparation of blood 
platelets natively 
expressing the human 
P2Y12 receptors
214
 
ADP 0.0979 ± 0.0049 2.32 ± 0.58 17.6  0.7 
ADP S 1.120 2.33 ± 0.83 4.11  1.17 
2-MeSADP 0.00340 ± 
0.00156 
0.00521  0.00036 0.00506  0.00010 
ATP S 4.54 ± 0.29 n.d. 13.2  0.2 
AR-C67085 0.00579 ±  
0.00331 
n.d. 0.00241  0.00025 
n.d. (not determined) 
 
The reason for this difference may be due to degradation or cellular uptake of ADP in the 
intact cells and accordingly the available amount for receptor activation is reduced. ADP is 
metabolically unstable and metabolized by ectonucleotidases (ENTPDases) which leads to a 
decrease in the extracellular concentrations of ADP.
11
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Figure 63. Competition curves for ADP and ADP derivatives vs. 5 nM [
3
H]PSB-0413 
obtained at: (A) intact astrocytoma 1321N1 cells recombinantly expressing the human P2Y12 
receptors. (B) Membranes preparation of astrocytoma 1321N1 cells recombinantly expressing 
the human P2Y12 receptors.  
 
Besides the P2Y12 receptor, there are 2 more subtypes of P2 receptors that are stimulated by 
ADP, P2Y1, and
 
P2Y13. AR-C67085 was developed as an antagonist at P2Y12 receptors
 
in 
nanomolar concentrations and it was suggested that it may
 
also act as an antagonist at P2Y13 
receptors in micromolar concentrations.
88
 Therefore, the binding affinity of the newly 
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synthesized structurally similar [
3
H]PSB-0413 as a radioligand for P2Y12 receptors was 
studied at human P2Y13 receptors expressed in 1321 N1 astrocytoma cells, human P2Y1 
receptors expressed in astocytoma cells and at non-transfected astrocytoma cells. The results 
are shown in figure 64. 
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Figure 64. Specific binding of  3 nM of [
3
H]PSB-0413 at human P2Y12, human P2Y13 and  
human P2Y1 receptors expressed in 1321N1 cells and non-transfected astrocytoma cells (n=3).  
 
 
As shown in figure 65, astrocytma cells expressing the human P2Y12 receptors showed the 
highest binding affinity for [
3
H]PSB-0413. Human P2Y13 receptors, human P2Y1 receptors 
and non-transfected astrocytoma cells showed very low specific binding of the radioligand. 
 
In summary, the human P2Y12 receptors were stably expressed in astrocytoma 1321N1 cells 
using a retroviral vector (pLXSN) and characterized in radiolgand binding and functional 
studies. [
3
H]PSB-0413 is the first selective high affinity radioligand for P2Y12 receptors. The 
new radioligand will allow the setting up of a high-throughput screening assay to identify new 
receptor agonists and antagonists. 
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3.4. Characterization of 1321N1 astrocytoma cells stably expressing the human P2Y13 
receptor 
 
Human P2Y13 receptors were expressed in 1321N1 astrocytoma cells in order to be used in 
measurement of the [
3
H]PSB-0413 radioligand subtype selectivity. To proof the expression, 
functional characterization of the produced cell lines were performed. 
 
3.4.1. cAMP accumulation assay in 1321N1 astrocytoma cells stably expressing the human 
P2Y13 receptor 
 
As shown in figure 65, ADP produced an inhibition of forskolin (4 µM)-induced 
accumulation of cAMP in 1321N1 astrocytoma cells stably expressing the human P2Y13 
receptor. The IC50 value of ADP was 0.00747 ± 0.00291 nM (mean ± S.E.M. of two 
independent experiments), whereas the published data for human P2Y13 receptor transfected 
into CHO K1 cells showed for ADP an IC50 value of 0.07 ± 0.14 nM. This means that in our 
case the human P2Y13 receptor is highly expressed in 1321N1 astrocytoma cells. The 
inhibition of forskolin-stimulated cAMP production was 47 ± 5 % at a maximal concentration 
of 10 nM of ADP. 
 
In the literature, the reversal of that inhibition at higher concentrations, as well as an 
enhancement of cAMP accumulation after pertussis toxin pretreatment, and a greater potency 
of 2-MeSADP have been reported. These effects are explained by a promiscuous coupling to 
Gs, which has been observed with several other Gi-coupled receptors as well.
88,89
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Figure 65. 1321N1 astrocytoma transfected cells were incubated with ADP for 10 min in the 
presence of 4 µM forskolin. The data represent the mean ± S.E.M of triplicate experimental 
points obtained from one experiment that was representative of two separated experiments. 
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Our results at the human P2Y13 receptor recombinantly expressed in1321N1 astrocytoma cells 
are in agreement with the reported data. Inhibition of adenylyl cyclase mediated by the P2Y13 
receptor was confirmed in recombinant 1321N1 cells. We conclude that the human P2Y13 
receptor was successfully expressed in 1321N1 astrocytoma cells and was used to study the 
selectivity of [
3
H]PSB0413.  
 
3.5. Principle of measurement of intracellular Ca
2+
 levels 
 
Ester derivatives of fluorescent indicators and chelators bearing carboxylic acid residues are 
uncharged molecules that can permeate cell membranes (Figure 66). Once inside the cell, the 
esters are cleaved by nonspecific esterases, resulting in a charged form that leaks out of cells 
far more slowly than its parent compound. Frequently, hydrolysis of the esterified groups is 
essential for binding of calcium ions resulting in fluorescence. A dispersing agent like 
Pluronic
®
 F-127 may be used because of the relatively insolubility of esters in aqueous 
solutions.  
 
After addition of agonists Gq-coupled receptors or ion channels can be activated leading to an 
increase in the intracellular calcium concentration which can be detected by the formation of a 
complex with such fluorescent dye. 
 
 
Figure 66. Structure of estreified Oregon Green (Oregon Green acetoxymethylester = Orgen 
Green AM). 
 
Activation of P2X and P2Y receptors subtypes results in an increase in [Ca
2+
]i either caused 
by an influx of Ca
2+
 through ligand gated ion channels (P2X1-7) or by a release of Ca
2+
 from 
intracellular stores initiated by Gq-protein-coupled receptors (P2Y1,2,4,6,11). Thus, the 
measurement of intracellular Ca
2+ 
levels is used for studying the functional properties of 
different purinergic receptor subtypes. 
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3.5.1. Investigation of nicotinamide adenine dinucleotide (NAD) as a ligand of the P2Y1 
receptor by measurement of intracellular calcium release 
Extracellular nicotinamide adenine dinucleotide (NAD, 93) (Figure 67) is known to increase 
the intracellular calcium concentration [Ca
2+
]i in different cell types and by various 
mechanisms. It was shown that NAD triggers a transient rise in [Ca
2+
]i in human monocytes 
activated with lipopolysaccharide (LPS), which is caused by a release of Ca
2+
 from IP3-
responsive intracellular stores and an influx of extracellular Ca
2+
. P2 receptors play a role in 
the NAD-induced calcium response in activated monocytes. Recently it has been shown that 
high amounts of NAD (93) are set free during inflammation.
215
 The dinucleotide NAD
 
(93) 
shares structural characteristics with adenosine triphosphate (ATP). Similar to ATP, it 
contains an adenine based purine moiety. The action of ATP is far better understood than that 
of NAD
 
and it is already known to function as an extracellular messenger. Like NAD
 
(the 
intracellular concentration is about 1 mM), ATP is present in high concentrations (5–10 mM) 
in mammalian cells. 
Whereas ATP has been shown to function through the specific activation of P2 receptors, 
there is hardly any information about surface receptors triggering intracellular events induced 
by intact NAD. Only recently it was shown, that NAD is an agonist of the human P2Y11 
receptor in human granulocytes mediating an increase in [Ca
2+
]i responsible for the functional 
activation of these cells.
216
 Thus, NAD not only bears structural similarities with ATP but also 
shares its potential to modulate intracellular Ca
2+
 concentrations. 
 
Figure 67. Chemical structure of NAD (93). 
It was shown that NAD (93) acts as an agonist at the human P2Y11 receptor, which is coupled 
to Gq- and Gs-proteins. By using human granulocytes and 1321N1 astrocytoma cells stably 
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expressing the human P2Y11 receptor, an increase in intracellular Ca
2+
 and cAMP levels in 
response to extracellular NAD was found.
216
 
 
Figure 68. Fluorescence intensity: measured at 520 nm for 30 seconds at 0.4 second intervals 
for human P2Y1 receptors stably expressed in 1321N1 astrocytoma cells and stimulated with 
dilutions of ADP. 
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Figure 69. Concentration-dependent increase in intracellular calcium release by ADP and 
NAD (93) in 1321N1 astrocytoma cells stably transfected with the human P2Y1 receptor. The 
EC50 value of ADP was 113 ± 26 nM (n = 4). The EC50 value of NAD
 
(93) was 743 ± 274 nM 
(n = 3). NAD (93) showed an efficacy of 77 ± 10 % compared to the physiological agonist 
ADP (set at 100 % efficacy).  
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To determine whether P2Y1 receptors are also activated by NAD (93), we measured the effect 
of the dinucleotide on [Ca
2+
]i in human 1321N1 astrocytoma cell lines stably expressing either 
the P2Y1 receptor subtype. 
Non-transfected control cells did not show any calcium response after the addition of NAD 
(93) (100 µM, data not shown).
217
 1321N1 cells expressing the human P2Y1 receptor showed 
a concentration-dependent calcium mobilization (Figure 69) with an EC50 value of 743 ± 274 
nM (n=3) (Figure 69). In comparison the physiological P2Y1 receptor agonist ADP was about 
7-fold more potent exhibiting an EC50 value of 113 ± 26 nM (n=4). Compared to ADP, NAD
 
(93) was somewhat less efficacious (77±10 % of the maximal effect of ADP).  
Previous studies performed on 1321N1 astrocytoma cells transfected with the P2Y11 receptor 
had demonstrated that NAD activated the P2Y11 receptor.
216 
Here the effect of NAD
+
 was 
examined at human P2Y1 receptor transfected in 1321N1 astrocytoma cells. Extracellular 
NAD
+
 showed an increase in [Ca
2+
]i at the 1321N1 astrocytoma cells stably transfected with 
the P2Y1 receptor, whereas the native 1321N1 cells, which lack the expression of any known 
P2 receptor subtype showed no response. P2Y1 and P2Y11 receptors were found to be 
expressed on human monocytes and they were shown to be responsible for the NAD-induced 
calcium signal in activated monocytes. Thus extracellular NAD had similar effects as ATP on 
calcium levels in lipopolysaccharide (LPS) activated human monocytes by inducing transient 
rises in [Ca
2+
]i mediated in part by Ca
2+
 influx and in part by the release of Ca
2+
 from IP3-
sensitive intracellular Ca
2+
 stores.
217 
These cytoplasmic calcium signals have an important role 
in regulating biological activities of monocytes/macrophages.
218
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3.6. Molecular biology 
 
3.6.1. Cloning of the human P2X2 and P2X3 receptor DNAs into the vectors pQCXIP-
pQCXIN 
 
The P2X3 receptors are rapidly desensitizing receptors
21,36, 39-43 
and
 
therefore it is difficult to 
functionally characterize them. The P2X3 exists as a homomer or a heterodimer with P2X2 
receptors to form P2X2/3. Both P2X3 and P2X2/3 channels have similar pharmacological 
response but differ in their desensitization kinetics, the P2X2/3 receptor being slowly 
desensitizing.
39,41
 The retoviral transfection is fast and efficient to produce stable cell lines. 
Thus, we aimed to clone the P2X2 and P2X3 receptor DNA into the same retrovial vector 
using different selection antibiotics in order to select the cells which specifically express both 
receptor subtypes (P2X2 and P2X3) after the transfection. 
 
3.6.1.1. Polymerase chain reaction (PCR) 
 
Human P2X2 and P2X3 were obtained using suitable primers from the P2X2-plXSN or P2X3-
pLXSN, respectively. The PCR amplification was carried out with the denaturation procedure 
of the template, the annealing of primers, and the elongation of the primers with DNA-
polymerase.  
The resulting PCR products are shown in figure 70. The human P2X2 product (1,443-pbs) and 
the human P2X3 receptor (1,221-bps) were obtained, by gel extraction of the DNA.  
 
 
Figure 70. PCR products: hP2X2 DNA pieces (1443 bps), and hP2X3 receptor DNA (1221 
bps). 
 
3.6.1.2. Restriction of the PCR product  
 
The PCR products were restricted using NotI and EcoRI restriction enzymes in order to 
prepare them for ligation. In addition, the vectors (pQCXIP or pQCXIN) were restricted with 
the same enzymes. The results of the restrictions are shown in figure 72. The restriction of the 
PCR products of the P2X2 DNA piece with NotI and EcoRI showed 1,423 bps length while 
that of the restriction of the P2X3 DNA piece had a length of 1,201 bps. The restriction of the 
1353 
1078 
872 
hP2X2 hP2X3 
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pQCXIP and the pQCXIN vectors showed lengths of 7,120 bps and 7,339 bps, respectively 
(Figure 71). 
 
3.6.1.3. Extraction of DNA from an agarose gel 
After the DNA samples were run on an agarose gel, the gel was placed on a UV 
transilluminator to make the ethidium bromide-stained DNA visible. The desired bands were 
identified, cut out and transferred to Eppendorf tubes. The extraction of the DNA was 
performed as described in the QIAquik
® 
Gel Extraction Kit protocol. 
 
3.6.1.4. Ligation of DNA fragments 
Ligation of double-stranded DNA fragments (after restrictive digest) was performed with T4-
DNA-Ligase. DNA fragments were added in a molar ratio of vector to insert 1:3.  
 
Figure 71. Restriction products of hP2X2, hP2X3, pQCXIP and  pQCXIN 
 
 
Ligation resulted in P2X2 cloned into pQCXIP (8,543 pbs) and P2X3 was cloned into 
pQCXIN (8,540 pbs) (Figure 72). 
 
 
 
hP2X2 
hP2X3 
pQCXIP 
pQCXIN 
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Figure 72. Cloning of the human P2X2 and P2X3 receptor DNAs into the vectors pQCXIP, or 
pQCXIN respectively. 
 
3.6.1.5. Transforming chemically competent cells 
 
The ligation products were transformed into the chemically competent Top 10 (Escherichia 
coli) cells. Then, single bacterial colonies from each transformation were incubated in 
individual sterile culture LB medium. After that, the DNAs were isolated: up to 40 µg of 
plasmid DNA was obtained from 4 ml of liquid culture. Resulting DNAs were analyzed by 
digestion with restriction enzymes to identify those carrying the desired DNA sequence. 
Restriction was done as described before using NotI and EcoRΙ as restriction enzymes (Figure 
73). DNA sequencing was done by GATC Biotech. 
 
  
 
Figure 73. Restriction of Miniprep of hP2X2 cloned in pQCXIP and hP2X3 cloned in 
pQCXIN using EcoRΙ and NotI to select the positive colonies (containing insert for desired 
receptors gene). 
 
Clone two of P2X2 DNA in pQCXIP and clone three of P2X3 DNA in pQCXIN showed the 
desired DNA sequences.  
In conclusion, we successfully cloned the human P2X2 and P2X3 receptor DNAs into the 
vectors pQCXIP-pQCXIN. Subsequently these DNAs were used to produce a stable 1321N1 
astrocytoma cell line expressing the human P2X2/3 receptor. 
  
hP2X2 in pQCXIP hP2X3 in pQCXIN 
1          2         3        4           5          6        1         2         3         4          5          6 
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3.6.2. Cloning of the human P2Y11 receptor DNA into the pLXSN vector 
 
The human P2Y11 receptor cloned into the pLXSN vector was obtained from the group of Dr. 
T. Kendall Harden (Medical School, University of North Carolina, Chapel Hill). This DNA 
was used in retroviral transfection several times in order to produce a stable cell line 
expressing human P2Y11 receptors. During the selection all the cells died without 
understanding the reason for it; therefore, we decided to clone the receptor again in our 
laboratory in order to find out the problem. 
 
3.6.2.1. PCR cloning primers 
 
 
The cloning of human P2Y11 receptor DNA into pLXSN was performed as described before. 
In brief, PCR was performed using the forward, the reverse primers and the template for 
hP2Y11 DNA (see the experimental part). Then, the PCR product and the pLXSN vector were 
prepared for ligation by restriction using EcoRI and XhoI followed by ligation using T4-
DNA-Ligase. After that, the ligation product was transformed into E. coli and the DNA was 
isolated from individual clones. Sequencing was performed by GATC Biotech (Konstanz, 
Germany).  
 
3.6.2.2. Results 
 
The sequence of clone two and three showed unexpected results which include two pieces from 
different DNAs, one is a guanine deaminase and the other one is the P2Y1 receptor as shown 
below:  
>for 
CCATCTCCTTTATCCAGCCCTCACTCCTTCTCTAGGCGCCGGAATTCTAAGTCGAGGAGGAGAGAATGTACCCCTA
CGACGTGCCCGACTACGCGTCCGATCGAGGTGCCAAGTCCTGCCCTGCCAACTTCTTGGCAGCTGCCGACGACAAA
CTCAGTGGGTTCCAGGGGGACTTCCTGTGGCCCATACTGGTGGTTGAGTTCCTGGTGGCCGTGGCCAGCAATGGCC
TGGCCCTGTACCGCTTCAGCATCCGGAAGCAGCGCCCATGGCACCCCGCCGTGGTCTTCTCTGTCCAGCTGGCAGT
CAGCGACCTGCTCTGCGCCCTGACGCTGCCCCCGCTGGCCGCCTACCTCTATCCCCCCAAGCACTGGCGCTATGGG
GAGGCCGCGTGCCGCCTGGAGCGCTTCCTCTTCACCTGCAACCTGCTGGGCAGCGTCATCTTCATCACCTGCATCA
GCCTCAACCGCTACCTGGGCATCGTGCACCCCTTCTTCGCCCGAAGCCACCTGCGACCCAAGCACGCCTGGGCCGT
GAGCGCTGCCGGCTGGGTCCTGGCCGCCCTGCTGGCCATGCCCACACTCAGCTTCTCCCACCTGAAGAGGCCGCAG
CAGGGGGCGGGCAACTGCAGCGTGGCCAGGCCCGAGGCCTGCATCAAGTGTCTGGGGACAGCAGACCACGGGCTGG
CGGCCTACAGAGCGTATAGCCTGGTGCTGGCGGGGTTGGGCTGCGGCCTGCCGCTGCTGCTCACGCTGGCAGCCTA
CGGCGCCCTCGGGCGGGCCGTGCTACGCAGCCCAGGCATGACTGTGGCCGAGAAGCTGCGTGTGGCAGCGTTGGTG
GCCAGTGGTGTGGCCCTCTACGCCAGCTCCTATGTGCCCTACCACATCATGCGGGTGCTCAACGTGGATGCTCGGC
GGCGCTGGAGCACCCGCTGCCCGAGCTTTGCAGACATAGCCCAGGCCACAGCAGCCCTGGAGCTGGGGCCCTACGT
GGGCTACCAGGTGATGCGGGGCCTCATGCCCCTGGCCTTCTGTGTCCACCCTCTACTCTACATGGCCGCAGTGCCC
AGCCTGGGCTGCTGCTGCCGAAACTGCCCCGGCTACAGGGACAGCTGGAACCCAAAAGACGCCAAAAACACTGGCC
AAACCTCTGCCCCTCAATGCCAAAGCCGCCCCTAAACCGTCAAAACCCCAGTCTCGTAGACGTTGACCAATGACTT
CGAGAAACCCGGCTTGGGAAATGTTGTCTACTTAAGGGGTTGGAAAAGTCCCCAAGG 
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Leishmania donovani guanine deaminase (GDA) gene, complete cdsLength=1392 
 
Score = 54.7 bits (29), Expect = 3e-05, Identities = 29/29 (100%), Gaps = 0/29 (0%) 
Strand=Plus/Plus 
 
Query  19  ATGTACCCCTACGACGTGCCCGACTACGC  47 
           ||||||||||||||||||||||||||||| 
Sbjct  1   ATGTACCCCTACGACGTGCCCGACTACGC  29 
 
Homo sapiens cDNA, FLJ94559, highly similar to Homo sapiens purinergic receptor P2Y, G-
protein coupled, 1 (P2RY1), mRNALength=1397 
 
Score = 36.2 bits (18), Expect = 0.68 
Identities = 18/18 (100%), Gaps = 0/18 (0%) 
Strand=Plus/Plus 
 
 Query  1    TAAGTCGAGGAGGAGAGA  18 
             |||||||||||||||||| 
 Sbjct  258  TAAGTCGAGGAGGAGAGA  275 
 
 
Similar problems occurred to other colleagues due to a general DNA contamination problem 
in the labaratory, which has been solved by now. In order to overcome this problem a new 
primer was designed to attach the missing DNA sequence in the hP2Y11 sequence and then 
the cloning procedure was repeated. 
 
The first PCR was performed using the following primers: 
 
f-hP2Y11-ATG: 5'-atggcagccaacgtctcgggtgccaagtcctgccctg-3' (64°C) 
r-hP2Y11-XhoI: 5'- cttactactcgagtcattggctcagctcacggg (62°C) 
 
The PCR steps were done as mentioned before using 62°C as annealing temperature.  
 
 
Figure 74. The first PCR product (1139 pbs): hP2Y11 receptor.       
 
The PCR product (1139 pbs) from the first PCR (Figure 74) was used as a template for the 
second PCR. The second PCR for the hP2Y11 was carried out using the primers f-hP2Y11-
EcoRI and r-hP2Y11-XhoI and the results (1152 pbs) are shown in figure 75.  
  
3. Results and discussion  127 
 
Figure 75. The second PCR product (1152 pbs): hP2Y11 receptor. 
 
 
3.6.2.3. Restriction of the second PCR product 
 
The PCR-product of the hP2Y11 DNA (1152 pbs) and the pLXSN vector were prepared for 
ligation by digestion with the restriction enzymes EcoRΙ and NotI. The restriction of the 
pLXSN vector showed a length of 5,863 bps and the hP2Y11 DNA showed a length of 1132 
bps (Figure 76). 
 
 
Figure 76. Restriction products of the human P2Y11 and  pLXSN 
 
 
 
Figure 77. Cloning of the human P2Y11 receptor into the pLXSN vector. The insert contained 
the sequence of the human P2Y11 receptor and was ligated into the pLXSN vector. 
 
pLXSN 
 
hP2Y11 
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The ligation product of the human P2Y11 receptor cloned into the pLXSN vector (Figure 77), 
with a DNA length of 6,995 bps, was transformed into E. coli and the DNA was isolated from 
individual clones using the PureLink™ HiPure Plasmid DNA Miniprep Kit as described in the 
manufacturer’s protocol. 
 
Resulting DNAs were analyzed by digestion with restriction enzymes to identify those 
carrying the desired DNA sequence. Restriction was done as mentioned above using EcoRI 
and XhoI as restriction enzymes (Figure 78). DNA sequencing was done by GATC Biotech. 
 
 
 
Figure 78. Restriction of Miniprep DNA of the hP2Y11 receptor cloned into the pLXSN 
vector using EcoRΙ and XhoI to select the positive colonies (containing the insert for the 
desired receptor gene). 
Clone five was carrying the desired DNA sequence of the hP2Y11 which could be used to 
produce a stable cell line, expressing the hP2Y11 receptor. 
In conclusion, the human P2Y11 DNA was successfully cloned into the pLXSN vector using 
PCR technique. After recombination in E. coli DNA was purified and the plasmids were 
digested using restriction enzymes. The sequence analysis showed the desired DNA sequence 
of the human P2Y11 which was subsequently used to produce a stable 1321N1 astrocytoma 
expressing human P2Y11 receptor.  
 
 
 
 
 
 
hP2Y11in pLXSN 
 1     2    3     4     5 
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3.7. Retroviral transfection of 1321N1-astrocytoma cells for the stable expression of hP2X2 
and hP2X2/3 receptors  
The human P2X2 and P2X3 DNAs were inserted into the retroviral vector pQCXIP and 
pQCXIN, respectively, as described above. The DNA was transfected into 1321N1 
astrocytoma cells using a retroviral system
192
 with minor modification. GP+envAM12 
packaging cells were first transiently cotransfected with a retroviral vector and a viral 
expression vector (pVSV-G) to generate two retroviruses. The retroviral vector containing the 
hP2X2 as insert was initially used to create a stable astrocytoma cell line, expressing P2X2, 
which was then infected with a P2X3 containing virus carrying a neomycin resistance gene for 
selection. In a second approach, astrocytoma cells were co-infected with the two retroviruses 
carrying the P2X2 and P2X3 DNAs, respectively, and simultaneously selected with G418 (800 
µg/ml) and puromycin (6 µg/ml) to produce the desired stable cell line, expressing both 
receptors.  
 
3.8. Functional characterization of selected P2X receptors  
 
3.8.1. Functional characterization of the P2X2 receptor  
 
The human P2X2 receptor cloned in pLXSN or pQCXIP vectors and stably transfected in 
astrocytoma cells was functionally characterized on the basis of agonist-mediated increase in 
[Ca
2+
]i caused by an influx of Ca
2+
 through ligand-gated ion channels. The same was 
performed for double transfected astrocytoma cells expressing the human P2X2/3 receptors. 
The fluorescent Ca
2+ chelating dye Fura-2 AM was used as an indicator of the relative levels 
of intracellular Ca
2+
 in a 96-well format using a Novostar
®
 fluorimeter. Agonists and 
antagonists were used in order to characterize the P2X receptors.  
P2X2 receptor activation leads to large and non-desensitizing transmembrane current and Ca
2+
 
influx. The human P2X2 receptor expressed in 1321N1 astrocytoma cells was maximally 
activated by ATP. ATP showed an EC50 value of 3.09 ± 0.96 µM at the human P2X2 receptor 
cloned in pLXSN vector and stably expressed into the 1321N1 cells (Figure 79A and 80). 
These results are similar to those obtained with human P2X2 receptors cloned into pQCXIP 
and transfected in 1321N1 astrocytoma cells, where ATP showed an EC50 value of 2.45 ± 
0.97 µM (Figure 79B and 81). This means that both cell lines are suitable for characterization 
of human P2X2 receptor ligands. 
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Figure 79. (A) Functional characterization of human P2X2 receptors cloned in pQCXIP. (B) 
Functional characterization of human P2X2 receptors cloned in pLXSN. Human P2X2 receptor 
function was measured using Fura-2AM Ca
2+
 influx assay. The cell line shown was treated 
with increasing concentrations of ATP. EC50s: 2.45 ± 0.97 (A) and 3.09 ± 0.96 µM (B). Data 
are shown as the mean percentage of the maximum signal mediated by ATP (n=3). 
 
 
Figure 80. Concentration-dependent effects of ATP on 1321N1 astrocytoma cells expressing 
the hP2X2 receptor cloned in pLXSN. Cells were loaded with the fluorescent, calcium 
sensitive dye Fura-AM. Fluorescence intensity was measured at 380 nm for 30 seconds at 0.4 
second intervals. 
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Figure 81. Concentration-dependent effects of ATP on 1321N1 astrocytoma cells expressing 
the hP2X2  receptor cloned in pQCXIP.  
 
3.8.1.1 Functional characterization of P2X2 receptor antagonists 
 
1321N1 astrocytoma cells, expressing the human P2X2 receptor were pre-incubated with 
suramin or reactive blue-2 for 15-20 min before activation with agonist (4 µM ATP). 
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Figure 82. Functional characterization of P2X2 receptor antagonists, measured by a Fura-AM 
Ca
2+
 influx assay. The cells were treated with increasing concentrations of antagonist and 4 
µM of ATP. Data are shown as the mean percentages of the maximum signal mediated by 
ATP (4 µM) in the absence of antagonist (n=3). (A) Reactive blue-2 showed an IC50 value of 
12.6 ± 1.81 µM and (B) sumarin an IC50 value of 19.4 ± 3.7 µM, respectively. 
 
Reactive blue-2 and sumarin showed antagonistic properties with a quite similar potency at 
human P2X2 receptors (Figure 82A and B) with IC50 values of 12.6 ± 1.81 µM and 19.4 ± 3.7 
µM, respectively. 
 
  
3. Results and discussion  132 
3.8.2. Functional characterization of human P2X2/3 receptors  
 
The activation of P2X3 receptors produces a rapidly desensitizing transmembrane and Ca
2+
 
current influx which rapidly returns to base line in the continued presence of agonist.
 21,36, 39-43  
Consistent with pervious reports
39,41 
 the heteromeric receptor consisting of P2X2 and P2X3 
subunits (P2X2/3) shared the pharmacological properties of P2X3 with respect to activation by 
nucleotides. Studies using whole cell recording techniques have shown that endogenous P2X 
receptors expressed in sensory neurons exhibit functional properties and pharmacological 
profiles unlike either the P2X2 or the P2X3 receptor subtype.
41,219
  The receptors were 
sensitive to activation by α,ß-methylene ATP but did not desensitize in continued presence of 
agonist. 
 
The human P2X2/3 receptor expressed in 1321N1 human astrocytoma cells using serial 
transfection, showed an increase in intracellular calcium with an EC50 value of 0.566 ± 0.006 
µM after stimulation with ATP (Figure 83 and 84A). α,ß-Methylene-ATP which is a selective 
agonist at P2X3 and P2X2/3 receptors activation versus P2X2 receptor activation  mediated a 
submaximal response when compared to ATP (Figure 84B and 85). The α,ß-methylene ATP 
showed an EC50 value of 3.71 ± 1.52 µM (n = 4).  
 
 
 
Figure 83. Concentration-dependent effects of ATP on 1321N1 astrocytoma cells expressing 
the human P2X2/3 receptor (serial transfection). Cells were loaded with the fluorescent, 
calcium-sensitive dye Fura-AM. Fluorescence intensity was measured at 380 nm for 30 
seconds at 0.4 second intervals. 
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The 1321N1-hP2X2/3 cell line which expressed both the human P2X2 and P2X3 receptor 
subtypes, exhibit α,β-meATP sensitivity and slow desensitization kinetics. α,β-MeATP  
mediated a sub-maximal response (84%) when compared to ATP in these cells. Since α,β-
meATP selectively activates human P2X3 and human P2X2/3 receptors, the greater response to 
ATP relative to α,β-meATP is assumed to the additional presence of homomeric ATP-
sensitive human P2X2 receptors in 1321hX2/3 cells (Figure 85 ). These results were consistent 
with the reported ones for rat P2X2/3 stably expressed in 1321N1 astrocytoma cells, where 
α,β-meATP showed sub-maximal effects compared with ATP (71%) with an EC50 value of 
3.39 µM.
21 
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Figure 84.  Functional characterization of human P2X2/3  receptor, measured by Fura-AM 
Ca
2+
 influx assay. The cell line shown was treated with (A) increasing concentrations of ATP 
or (B) increasing concentrations of α,β-meATP. An EC50 values of 0.566 ± 0.006 µM and 
3.71 ± 1.52 µM were determined for ATP and α,β-meATP, respectively. 
 
 
 
Figure 85. Concentration-dependent effects of α,ß-meATP on 1321N1 astrocytoma cells 
expressing the human P2X2/3 receptor (serial transfection) compared with the maximal effect 
of ATP. 
  
3. Results and discussion  134 
3.8.3. Functional characterization of the human P2X4 receptor 
 
The human P2X4 receptors cloned into the pLXSN vector and stably transfected in 1321N1 
astrocytoma cells using a retroviral transfection system was also functionally characterized on 
the basis of agonist-mediated increases in [Ca
2+
]i caused by an influx of Ca
2+
 through the 
ligand-gated ion channels.  
 
Figure 86. Concentration-dependent effects of ATP on 1321N1 astrocytoma cells expressing 
the human P2X4  receptor. Cells were loaded with a lipophilic ester derivative of the 
fluorescent, calcium-sensitive dye Fura (Fura-AM). Fluorescence intensity: measured at 380 
nm for 30 seconds at 0.4 second intervals. 
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Figure 87.  Functional characterization of human P2X4 receptors. Concentration-response 
curve for the agonist ATP.  Data represent the mean percentage of the signal mediated by 
ATP ± SEM (n=3, maximal effect of ATP = 100 %). An EC50 value of 1.07 ± 0.46 µM was 
determined for ATP. 
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The activation of the human P2X4 receptor expressed in 1321 N1 astrocytoma cells leads to an 
increase in [Ca
2+
]i by calcium influx. ATP showed an EC50 value of 1.07 ± 0.46 µM (Figure 
86 and 87). Reactive blue 2 and sumarin were inactive as antagonists in concentrations up to 
100 µM at the human P2X4 receptor expressed in 1321N1 astrocytoma cells (Figure 88 and 
89).   
 
 
Figure 88. Increase in fluorescence caused by an increase of intracellular Ca
2+
 due to 
stimulation of the human P2X4  receptor recombinantly  expressed  in 1321N1 astrocytoma, 
by ATP (4 µM). Reactive blue-2 in a concentration of 100 µM did not block the effect of ATP 
4 µM. 
 
 
 
Figure 89. Increase in fluorescence caused by an increase of intracellular Ca
2+
 due to 
stimulation of the human P2X4  receptor  recombinantly  expressed  in 1321N1 astrocytoma. 
Suramin in a concentration of 100 µM did not block the effect of ATP 4 µM. 
In conclusion, the human P2X2, P2X2/3 and P2X4 receptors recombinantly expressed in 
1321N1 astrocytoma cells were functionally characterized on the basis of agonist-mediated 
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increases in [Ca
2+
]i caused by an influx of Ca
2+
 through the ligand-gated ion channels. The 
function was determined by measuring a Fura-AM Ca
2+
 influx assay. The produced stable cell 
lines may be used for screening of different chemical compounds in order to search for 
selective ligands, agonists and antagonists, for these receptor subtypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4. Summary  137 
 
4. Summary 
 
The thesis deals with the development of different cell-based assay techniques in order to 
characterize the receptors under investigation at the protein level, mapping of the distribution 
of the receptors of interest in different cells and tissues, studying receptor-ligand interactions 
and investigating signaling pathways inside the cells subsequent to activation or blocking of 
these receptors. Such information is important for assessing the receptors' potential as drug 
targets.  
 
The following assays have been employed:   
 Radioligand binding assays including saturation, competition and kinetic experiments in 
order to characterize the receptors at the protein level and for characterizing novel 
ligands.   
 Functional assays have been established via measurement of cAMP accumulation, 
measurement of intracellular Ca
2+
 levels and quantification of ERK signalling.  
The assays were performed in native cells using intact cell lines or membrane preparations 
from the receptors under investigation, or at receptors that we have successfully expressed in 
different cell lines using molecular biology techniques.  
 
The most important results are summarized below. 
 
4.1. Adenine receptors (P0 receptors) 
 
We have successfully characterized the human adenine receptors in intact HEK293 cells using 
different assays including saturation, competition and kinetic experiments, and subsequently 
compared the obtained results with those obtained with membrane preparations of HEK293 
cells.  
 
 The saturation experiments in intact HEK293 cells showed that [3H]adenine exhibited two 
binding sites with a KD1 value of 92.4 ± 4.7 nM and a Bmax1 value of 1.882 ± 0.075 
pmol/mg of protein, and a second one with a KD2 value of 4.15 ± 0.5 M and a Bmax2 value 
of 0.381 ± 0.095 pmol/mg of protein. The receptor density was quite high with a Bmax in 
picomolar range for the high affinity site. The obtained result was in a agreement with that 
obtained from a membrane preparation with the exception that in whole HEK293 cells 
[
3
H]adenine labelled two binding sites, one with high affinity and a second one with low 
affinity. 
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 We have performed, for the first time, kinetic studies at HEK293 cell. The results showed 
that [
3
H]adenine bound to intact HEK293 cells rapidly, and the steady state appeared to be 
reached after 15 min and sustained for at least 200 min (Kobs ). The binding was slowly 
reversed with only 30% of dissociation being evident after 60 min. A kinetic KD value 
could not be determined and the law of mass action did not apply to the system. 
 For better understanding of the binding properties of adenine to adenine receptors in intact 
HEK293 cells, the binding site of adenine receptors in HEK293 cells was further 
characterized using competition assays. Adenine showed an affinity of 3.44 µM in whole 
cell binding assays which means a 73-fold lower affinity than in competition assays using 
adenine and a membrane preparation of HEK293 cells. This may be explained by a fast 
degradation or uptake of the physiological agonist adenine by the cells. 
 
The coupling of adenine receptors in HEK293 cells to adenylate cyclase, either Gi or Gs, and 
the possible coupling to other pathways namely the ERK-pathway were examined and the 
obtained results were as follows: 
 Functional studies at human adenine receptors in HEK293 cells using cAMP 
accumulation assays showed that two distinct subtypes of adenine receptors might exist in 
HEK293 cells, one was found to inhibit adenylate cyclase via Gi protein and the second 
one to stimulate it via Gs protein. The other suggested explanation could be that the 
adenine receptors in HEK293 cells might couple to inhibition as well as to activation of 
adenylate cyclase. To further test this assumption, the effect of PTX on adenine receptor 
in HEK293 was studied. Cells were pre-treated with PTX over night before the cAMP 
assay was performed. By inactivating the Gi- coupling of the adenine receptor we only see 
the stimulatory effect of adenine with an EC50 value of 372 nM. 
 
Furthermore, the ERK-pathway was studied at the human adenine receptors in HEK293 cells. 
We succeeded to establish a luciferase reporter gene assay using SRE-LUC as a reporter gene 
for human adenine receptors in HEK293 cells. Adenine induced the SRE-LUC reporter gene 
expression in a dose-dependent manner, reflected by the elevated levels of SRE-LUC 
expression and phosphorylated ERK with an EC50 value of 21.5 ± 2.1 nM.  
 
We have screened more than 80 compounds based on modifications of the physiological 
agonist adenine. Adenine derivatives bearing substituents at the 2-, N
6
-, 8- or 9-position, a 
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series of deazapurines and some adenine-related structures were investigated in [
3
H]adenine 
binding studies at adenine receptors in rat brain cortical membrane preparations (rAde1R) and 
membrane preparations of HEK293 (human) cells to test species differences. The obtained 
results and the structure activity relationships were as following: 
  
o The 2-substituted adenine derivatives tested showed no measurable affinity for the AdeR 
or possessed micromolar affinity. The rank order of potency was similar at human adenine 
receptors in membrane preparations of HEK293 cells and at the adenine receptor 
expressed in rat brain cortex.  
o At position 8, basic substituents e.g. 8-aminoadenine (7) led to higher AdeR affinities than 
bulky, lipophilic residues. The introduction of 8-alkyl- and 8-arylsulfanyl residues 
diminished the AdeR affinity. Compound 7 exhibited a Ki value of 0.0341 µM at the 
human binding site and thus it was more potent than adenine itself (Ki = 0.0471 µM).  
o 9-Phenethyladenine (23) exhibited low affinity, whereas the 9-substituted adenine 
derivatives bearing polar substituents (28, 29 and 30) showed affinity in the low 
micromolar range indicating that the introduction of polar functions at position 9 
positively affected the AdeR affinity.  
o At position N6 small polar substituents led to higher AdeR affinities than alkyl residues 
indicating that N
6
-acylation is more favorable in terms of increased AdeR affinity than N
6
-
alkylation.  
o At position N6 a basic terminal amino group further enhanced the potency. The most 
potent adenine receptor ligand in this series was N
6
-(3-aminopropionyl)adenine (61) 
exhibiting an even higher affinity for rat adenine receptors (Ki value of 21.5 nM) than the 
natural ligand adenine itself (Ki value of 29.2 nM). In addition, compound 61 showed 
similar affinity for human adenine receptors with a Ki value of 52.6 nM compared with the 
endogenous ligand adenine (Ki = 44.6 nM).  
Based on the results of binding studies of more than 80 adenine derivatives at membrane 
preparations of both rat and HEK293 cells, we concluded that HEK293 cells and rat brain 
cortex express binding sites for adenine with similar but not identical structure-activity 
relationships. Differences in binding affinities may be due to species differences and/or could 
be explained by the existence of different adenine receptor subtypes. The latter explanation is 
more likely since no highly homologous gene (> 80% sequence identity) could be identified in 
the human genome database.  
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In order to investigate whether the potent AdeR ligands identified in this study were agonists 
or antagonists we have established and performed functional studies for selected compounds. 
Thus, 1321N1 astrocytoma cells were stably transfected with the sequence for the rAde1R 
using a retroviral expression system. Selected adenine derivatives were tested for their effects 
to inhibit isoproterenol-induced cAMP accumulation. Investigated compounds showed 
agonistic effects at rAde1R expressed in astrocytoma cells.  
 
For Further characterization, a luciferase luminescence reporter gene assay was also 
established for the most potent adenine receptor ligands identified in radioligand binding 
studies. Compounds 61, 63, 65, 67, 55 and 50 represent adenine receptor agonists. The 
agonistic properties of compound 61 were further confirmed by its concentration-dependent 
inhibition of isoproterenol-stimulated cAMP-dependent luciferase assay. Adenine (1) and 61 
both inhibited the maximal cAMP produced with IC50 value of 3.18 ± 1.51 nM and 28.4 ± 4.3 
nM, respectively. N
6
-(3-methyl-amino-propionyl)adenine (62) exhibited no significant effect 
on isoproterenol-induced cAMP dependent luciferase assay. To further investigate the 
antagonistic properties of 62, we monitored the inhibitory effect of the natural agonist adenine 
on the cAMP formation in the absence and in the presence of 62. In the presence of 62 the 
dose-response curve of adenine was shifted to the right. The calculated Kb value was 0.165 
µM. This result revealed compound 62 represents the first adenine receptor antagonist 
described so far.  
 
We also investigated ERK phosphorylation by a gene reporter assay measuring SRE-
dependent luciferase activity in astrocytoma cells stably transfected with rAde1R. This 
experiment revealed that rat adenine receptors are involved in the regulation of kinase 
pathways. In contrast to the physiological agonist adenine, compound 61 is more potent and 
efficacious in activation the ERK pathway than in inhibition of adenylate cyclase. 
 
As a next step we studied the affinity of 12 of the most potent adenine derivatives at 
adenosine A1 and A2A receptors subtypes in order to assess the compounds` selectivity for 
adenine receptors. None of screened compounds showed measurable affinity for adenosine 
receptors at a concentration of 100 µM. 
 
We also functionally characterized the cloned mouse adenine 2 receptor (mAde2R) using 
cAMP accumulation assays. Adenine inhibited isoproterenol-induced cAMP accumulation in 
a concentration-dependent manner with an IC50 of 8 nM and a maximal of inhibition about 
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40 %. 2-Fluoroadenine caused an inhibition of cAMP production with an IC50 of 15 nM and a 
maximal inhibition of about 60 %. 
 Saturation experiments at membrane preparations of Sf21 cells expressing the mAde2R 
with [
3
H]adenine revealed a single-high affinity binding site with a KD value of  113 ± 17 
nM, and a Bmax value of 1.98 ± 0.39 pmol/mg protein. Competition binding experiment 
using membrane preparations of infected Sf21 cells and selected adenine derivatives 
showed the following rank order of potency: adenine (1) > N
6
-(4-aminobutyryl)adenine 
(67) > 2-fluoroadenine (83) > N
6
-(3-aminopropionyl)adenine (61) > 7-methyladenine (85) 
> N
6
-acetyladenine (49) > 1-methyladenine (83) >> N
6
-benzyladenine (34) > N
6
-
dimethyladenine (38).  
 
 Chinese hamster ovary cells (CHO K1) cells showed inhibition of forskolin stimulated 
adenylate cyclase activity in a concentration dependent manner with an IC50 value for 
adenine of 4.04 ± 2.7 nM. Saturation binding studies performed with membrane 
preparations of the CHO-K1 cells exhibited a single binding site with a KD value of 121 
nM and a Bmax value of 1.536 pmol/mg of protein. Thus, the hamster also appears to 
express at least one adenine receptor coupled to inhibition of adenylate cyclase and high 
expression level was found in CHO K1 cells. 
 Homologous competition experiments were performed for characterization of the 
endogenous rat adenine receptors in PC12 cells. Adenine showed relatively low affinity at 
native adenine receptors in membrane preparations of PC12 cells with an IC50 value of 
489 ± 206 nM. The apparent KD value calculated from homologous competition 
experiments was 479 ±106 nM and a high receptor density with a Bmax value of 21.3 ± 5.6 
pmol/mg was detected in membrane preparations of PC12 cells. 
 The functional properties of the rAdeR in PC12 cells were investigated by measuring the 
activity of adenylate cyclase in a cAMP-dependent luciferase assay. Adenine inhibited 
forskolin-stimulated cAMP levels with an IC50 value of 12.8 ± 2.1 µM. The explanation 
for this high IC50 value could be that PC12 cells express an adenine receptor subtype 
which is different from the rAde1R. It might also be possible that the adenine receptor in 
PC12 cells forms heteromers with other receptors or interacts with other proteins which 
modulate receptor activation. 
 In order to investigate whether PC12 cells express mRNA for the rAde1R, mRNA was 
extracted from PC12 cells. From the functional studies and preliminary mRNA 
localization studies for endogenous rat adenine receptors in PC12 cells. We can conclude 
that PC12 cells very likely express the rAde1R. Further studies must be performed in 
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order to determine the exact sequence of endogenous rat adenine receptors in PC12 cells 
and to compare it with the rAde1R sequence.  
 
4.2. Adenosine receptors (P1 receptors) 
 
Beside the new adenine receptors, the well-established families of adenosine receptors has 
been studied. 
 Characterization of CHO cells stably expressing the human A2B receptor was performed 
using the non-selective agonist NECA (86) and the selective agonist BAY-60–6583 (90) 
in cAMP accumulation assay. The compounds were found to exhibit agonistic properties 
with EC50 values of 0.035 ± 0.014 µM and 0.016 ± 0.004 µM, respectively.  
 cAMP accumulation assays at CHO cells stably expressing the human adenosine A2A 
receptor were performed and the agonistic properties of a newly synthesized selective 
adenosine A2A receptor agonist PBS-0777 in comparison with the non-selective adenosine 
receptor agonist NECA was evaluated. They showed EC50 values of 17.6 ± 14 nM and 117 
± 10 nM, respectively. PSB-0777 acts as a full agonist at human adenosine A2A receptors 
expressed in CHO K1 cells.  
 cAMP accumulation assays at CHO cells stably expressing the human adenosine A2A 
receptor were used for investigation of the new adenosine A2A receptor antagonist AA-01. 
AA-01 appears to be a competitive antagonist at human adenosine A2A receptors with KB 
value of 4.14 nM.  
 Luciferase cAMP assays were performed for Mongolia extract using CHO K1 cells stably 
transfected with human adenosine A1 receptors and transiently transfected with pCRE-luc. 
The Magnolia extract M completely inhibited forskolin-stimulated cAMP accumulation in 
CHO cells expressing the adenosine A1 receptor. The extract seemed to disturb the assay 
system by an unknown mechanism.  
 The functional properties of the magnolia extract M were investigated in GTP-shift 
experiments using a rat cortical membrane preparation containing adenosine A1 receptors. 
The GTP-shift and cAMP experiments with the Magnolia extract M indicate that it may 
be either a week partial agonist or an antagonist. 
 
4.3. P2 receptors 
Several studies were performed to investigate P2 receptors. 
Characterization of the high-affinity, subtype-selective P2Y12 antagonist radioligand 
[
3
H]PBS-0413 was performed:  
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 We expressed the human P2Y12 receptor in 1321N1 astrocytoma using a retroviral 
expression system. The produced cells were functionally characterized in cAMP 
accumulation assay using ADP and 2-MeSADP as agonists.  
 The saturation radioligand binding studies showed two classes of binding sites one 
exhibiting high affinity with a KD value of 13.1 ± 1.1 nM and a total number of binding 
sites (Bmax) of 61,925 ± 10,153 receptors per cell. The second binding site had a low 
affinity with a KD value of 0.229 ± 0.041 M and a Bmax value of 30,737 ± 8,228 receptors 
per cell. 
 The IC50 values obtained from competition assays at the human P2Y12 receptor expressed 
in 1321N1 astrocytoma cells were similar to IC50 values obtained in functional cAMP 
assays and comparable with the rank order of potency in competition assays at P2Y12 
receptors natively expressed in human platelets.  
 The selectivity of [3H]PSB-0413 as a radioligand for P2Y12 receptors was determined vs 
human P2Y13 receptors, human P2Y1 receptors and at non-transfected astrocytoma cells. 
The results showed that the astrocytoma cells expressing the human P2Y12 receptors 
showed the highest binding affinity for [
3
H]PSB-0413. Human P2Y13 receptors, human 
P2Y1 receptors and non-transfected cells showed very low specific binding.  
  
The effect of NAD
+
 on [Ca
2+
]i in human 1321N1 astrocytoma cell lines stably expressing 
P2Y1 receptors was measured and the results showed a concentration-dependent calcium 
mobilization with an EC50 value of 743 ± 274 nM. Compared to ADP, NAD
 
was somewhat 
less efficacious (77 ± 10 % of the maximal effect of ADP).  
 
The human P2X2 receptor cloned in the pLXSN or the pQCXIP vector and expressed in 
1321N1 astrocytoma cells. It was activated by ATP and found to exhibit similar EC50 values, 
3.09 ± 0.96 µM and 2.45 ± 0.97 µM, respectively indicating that both cell lines can be used 
for characterization of human P2X2 receptors. 
 
The human P2X2/3 receptor expressed in 1321N1 human astrocytoma cells using serial 
transfection, showed an increase in intracellular calcium with an EC50 value of 0.566 ± 0.006 
µM after stimulation with ATP. α,ß-Methylene ATP showed an EC50 value of 3.71 ± 1.52 µM.  
 
Human P2X4 receptors cloned into the pLXSN vector and stably transfected in 1321N1 
astrocytoma cells using a retroviral transfection system was also functionally characterized 
and ATP showed EC50 value of 1.07 ± 0.46 µM.  
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We have been successful in recombinantly expressing the human P2X2, P2X2/3 and P2X4 
receptors in 1321N1 astrocytoma cells and we functionally characterized the transfected 
receptors on the basis of agonist-mediated increase in [Ca
2+
]i caused by an influx of Ca
2+
 
through the ligand-gated ion channels. The produced stable cell lines will be used for 
screening of different agonist or antagonists. 
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5. Experimental section 
    
5.1. Instruments 
 
Analytical balance Sartorius CP225D 
Autoclave Varioklav
®
 Dampfsterilisator, H+P 
Bacteria shaker Innova 4200 Incubator Shaker, New Brunswick Scientific 
Centrifuge Allegra™ 21 R, Beckman Coulter 
Avanti™ J-201, Beckman 
BIOFUGE pico, Heraeus 
Rotofix 32, Hettich 
Filter Whatman GF 51, Schleicher & Schuell Microscince, 
Germany 
Whatman GF/B Glass fibre cuts, 10428183, Germany. 
Machery & Aager GF-2, 071102, Germany 
Hamilton syringe Syringes 705 (10 μl, 50 µl), Roth 
Harvester Brandell M24, 48, Gaithersburg, MD, U.S.A. 
Heater Thermomixer comfort, Eppendorf 
Heidolph MR 3001 
Homogenizer RW 16 basic, IKA Labortechnik, Germany 
Incubators Jouan IG 650, Heraeus HERAcell
®
 240 
Laminar airflow workbenches NUNC
®
 Safe flow 1.2 
NUNC
®
 BIOFLOW 
LSC-counter Tricarb
®
 2900 TR, Canberra Packard/Perkin Elmer 
Magnetic stirrer and hot plate 
 
RCT Basic, IKA Labortechnik 
Microscope Axiovert 25, Zeiss 
Hund Wetzlar (Seiler) 
 
Microplates 655095, white 96-well plate, clear bottom, Greiner Bio-
One 
655096, black 96-well plate, clear bottom, Greiner Bio-
One 
EW-01929-60  white 96-well plate, Nunc
TM
 Nunclon
TM
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21313241, imaging plate 96 FC, Zell Kontakt 
Multipette Eppendorf Multipette Plus 
Microwave Microwave 800, Severin 
Pipettes 
 
Eppendorf research (0,5-10 µl, 10-100 µl, 20-200 µl, 100-
1000 µl, 1000-5000 µl) 
pH Meter WTW pH Electrode SenTix 41 
WTW pH 197 
Photometer Beckman DU 
®
, 530 Life Science 
Plates 6, 24 Loch Sarstedt 
Photo documentation system Geldoc, BioRad 
Safe-lock tubes Eppendorf 
Water bath GFL
®
 1083 
Memmert WNB 14 
Shaker  Mini rocker MR-1 
Software 
 
Chromas 1.45, Conor McCarthy 
ChemDraw Ultra 9.0 
ClustalW2, European Bioinformatics Institute 
DNAtrans 2.0, Dr. A. Schiedel / J. Bosmann 
Isis™/Draw 2.5, MDL Information Systems 
Prism
®
 4.0, GraphPad 
Sterile filters Filtropur 0.22 μm, Sarstedt, 831826001 
Voltage equipment 
(electrophoresis) 
Power Pac
®
 3000, BioRad 
 
Thermocycler Biometra
®
 TPersonal 
Thermomixer HeizThermoMixer MHR 23 
Eppendorf thermomixer confert 
Ultrasonic bath Bandelin SONOREX RK 52H 
Vortexer IKA Labortechnik MS1, Minishaker 2x
3
, UniEquip 
Ultraturrax T25 basic, IKA Labortechnik, Germany. 
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5.2. Materials 
 
  5.2.1. Chemical substances 
 
 
ADP Applichem, 16178-48-6 
ADPβS  Sigma, A8016  
Adenine  Sigma, A8626 
ATP Roth,  987-65-5 
Agarose  Roth, 2267.2  
Ampicillin sodium salt  AppliChem, A0839  
BSA / albumin fraction V  AppliChem, A1391  
Bromphenol blue  AppliChem, 3640  
Calcium chloride dihydrate  Fluka, 21097  
[
3
H] cAMP  Biotrak assay system Amersham Bioscience, TRK 432  
Caffeine University of Bonn 
CADO  Fluka, 22997 
Copper sulphate pentahydrate  AppliChem, A1034  
CPA RBI, A-17 
Di-sodium carbonate  AppliChem, A 1881  
Di-sodium hydrogen phosphate  AppliChem, A 1646  
DMSO  AppliChem, A3608  
DMSO for cell culture  AppliChem, A3672  
DPCPX  Sigma, C-101  
EDTA  Roth, 8040.3  
Ethanol p.a.  ZVE Universität Bonn, 123974  
Ethidium bromide, 1%  AppliChem, A1152  
Folin's reagent Sigma, F-9252  
Forskolin Applichem, 66575-29-9 
Fura-2 AM Molecular probes, F1221 
Glacial acetic acid Merck, 1.00063.1011 
GTP dilithium salt Applichem, 95648-84-3 
D-(+)-Glucose  Sigma, G-7021  
Glycerine  AppliChem, A1123,1000  
HEPES  Sigma, H-3375  
Hydrochloric acid, 37 %  AppliChem, A 0659  
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IBMX Fluka, 58620 
Isoprenaline hydrochloride Fluka, 59650 
Isopropanol  
 
ZVE Universität Bonn, 123903  
Luciferase assay kit Bright-Glo
TM
 luciferase assay buffer, luciferase assay 
substrat, Promega, 608-274-4330 
LB-Agar  Invitrogen, 22700-041  
LB-powder medium  AppliChem, A0954,901  
Lipofectamine  Invitrogen, 11668019  
Magnesium chloride  Sigma, M-8266  
Magnesium sulphate Sigma, M-2643  
2-Mercaptoethanol AppliChem, A4338 
2-MeS-ADP trisodium salt Tocris, 1624 
α,β-Methylen-ATP  
 
Sigma, M6517 
Monopotassium phosphate Sigma, P-9791  
Mycophenolic acid Tocris, 1505  
NAD  Applichem, 53-84-9 
NECA  Sigma, E-2387  
Oregon Green
®
 488 BAPTA-1, 
AM 
Molecular probes, O6807 
Paraformaldehyde  AppliChem, 3813,025  
Pluronic F-127 Sigma, P2443 
PMSF AppliChem, A0999 
Polybrene  Aldrich, 10,768-9  
Poly(ethyleneimine) in 50% 
(W/V) water 
 
Sigma Aldrich, P 3143-1L 
Potassium chloride Fluka, 60128  
Reactive blue 2 Alexis biochemicals, 550-293-G005 
Ro20-1724  Hoffmann La Roche 
Scintillation cocktail Ready safe scintillation cocktail, Beckmann,141349 
Luma safe scintillation cocktail, Perkin Elmer, 3087 
Sodium acetate  AppliChem, 4555,025  
Sodium butyrate  Fluka, 19364  
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Sodium chloride  Sigma, P-9541  
Sodium hydrogen carbonate  Sigma, S-5761  
Sodium hydroxide  Fluka, 71689  
Suramin  Sigma, S2671 
Di-sodium tetrate dihydrate AppliChem, A 2662  
TRIS  Roth, AE15.3  
Triton X-100  Sigma, X-100  
Xanthine  AppliChem, 6665,001  
Yeast extract  AppliChem, A3732,01  
 
5.2.2. Compounds for cell culture  
 
Dulbecco's Modified Eagle Medium (DMEM)           Gibco, 41966-029 
 
Dulbecco's Modified Eagle Medium:  
Nutrient Mixture F-12 (DMEM-F12) 
Gibco, 31330 
Cell culture flasks, sterile Sarstedt 
Counting chamber Neubauer improved Marienfeld 
Cryovials, sterile Sarstedt, 72380 
Falcon tubes                                                                        Sarstedt, 62547254 
Fetal calf serum (FCS) Sigma, F-0804  
G418                                                                                Calbiochem, 345810 
L-Glutamine Cambrex Bioscience 
Horse serum (HS) Sigma, H1138  
Pipette for single use only Sarstedt, 62547254 
Pen-Strep Gibco, 15140 
Phenol red 0.5%, liquid, sterile-filtered Sigma-Aldrich, P0290 
RPMI 1640 Gibco, 31870-025 
Trypsin Lonza, 17-160 
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5.3. Cell lines 
 
 1321N1 human astrocytoma cells from human brain. 
 CHO cells from Chinese hamster ovary. 
 NG108-15 cells are hybrid cells of mouse neuroblastoma and rat glioma. 
 PC12 cells are obtained from a rat adrenal pheochromocytoma.  
 HEK-293 human embryonic kidney cells. 
 Melanoma 1539 cells were provided by A. Horstmeyer (Pharmaceutical Institute, 
University of Bonn). 
 GP+envAM12 cells obtained from mouse embryo fibroblasts. 
 Human adenosine A2A expressed in CHO cells obtained from AK Prof. Dr. Karl-Norbert 
Klotz, Pharmazeutisches Institut, Würzburg. 
 Adenosine A2B receptors expressed in FlpIn-CHO-cells obtained AK Prof. Dr. Christa E. 
Müller. 
 mAde2R expressed in 1321N1 human astrocytoma cells obtained from AK Prof. Dr. Ivar 
von Kügelgen. 
 
  Cell culture media 
  Media for Different CHO cell lines. 
 
 CHO-K1 FlpIn-CHO Transfected CHO 
cells* 
DMEM/ F12 + + + 
10% FCS + + + 
100 U/ml penicillin G + + + 
100 µg/ml streptomycin + + + 
1 % GlutaMAX + + + 
200 µg/ml G 418 _ _ + 
100 µg/ml zeocin _ + _ 
*Receptors expressed in CHO cells cloned in vectors which contain neomycin as a resistance gene. 
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Media for different 1321N1 human astrocytoma cell lines 
 
 1321N1 
astrocytoma 
Transfected 
1321N1 
astrocytoma* 
Double 
transfected 
1321N1 
astrocytoma
#
 
DMEM + + + 
10% FCS      + + + 
100 U/ml penicillin G + + + 
100 µg/ml streptomycin + + + 
1 % GlutaMAX + + + 
800-400 µg/ml G 418 _ + + 
8 µg/ml prumycin _ _ + 
*Receptors expressed in 1321N1 human astrocytoma cells cloned in vectors which contain neomycin as a 
resistance gene #Receptor expressed in 1321N1 human astrocytoma cells cloned in vectors which contains 
neomycin and second receptor cloned in vector which contain puromycin as a resistance gene. 
 
Media for various cells 
 
 PC12 HEK293 Melanoma NG108-15 
RPMI 1640 + _ _ _ 
DMEM _ + + + 
10% FCS      + + + + 
100 U/ml penicillin G + + + + 
100 µg/ml streptomycin + + + + 
1 % GlutaMAX + + + + 
5% HS + _ _ _ 
2% HAT* _ _ _ + 
* Containing 5 mM  hypoxanthine, 20 μM and aminopterin and 0.8 mM thymidine 
 
5.4. Tissues  
 
 Frozen Sprague-Dawley rat brains were purchased from Pel-Freez Biologicals (Rogers, 
AR, U.S.A.). 
 Calf adrenals were obtained from a local slaughterhouse (Cologne, Germany). 
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5.5. Radioligands 
 
 [3H]Adenine (S.A.: 28 Ci/mmol, S.A.: 26 Ci/mmol, S.A.: 27 Ci/mmol) obtained from 
Amersham Bioscience, 
 [3H]DPCPX (S.A.: 129 Ci/mmol) obtained from Amersham Life Science, 
 [3H]MSX-2 (S.A.: 84 Ci/mmol) obtained from Amersham Life Science, UK Amersham 
Biosciences, UK, 
 [3H]PSB-0413 (S.A.: 85 Ci/mmol) labelled by Amersham Int.l, UK, the precursor PSB-
0412 was synthesized in our group by  Dr. Ali El-Tayeb Ak Prof. Müller,
213
 
 [3H]cAMP (S. A.: 23 Ci/mmol) obtained from Amersham Bioscience, 
 [3H]cAMP (S. A.: 13 Ci/mmol) obtained from Hartmann Analytic, 
 [3H]CCPA (S.A.: 42.6 Ci/mmol) obtained from Perkin Elmer Life Sciences. 
 
5.6. Buffer and solutions 
 50 mM Tris/HCl buffer, pH 7.4 
Tris (6.05 g) was dissolved in 1000 ml; pH was adjusted to 7.4 using concentrated HCl        
(37 %). For adenine assay the washing or incubation buffer was autoclaved before use. 
 
 Incubation buffer for [3H]PSB-0413 binding assay 
Tris (6.05 g, 50 mM), of NaCl (5.84 g, 100 mM) and of MgCl2 (0.476 g, 4.99 mM) were 
dissolved in 1000 ml of water. The pH was adjusted with HCl to 7.4. 
 
 Sucrose (0.32 M) solution 
 Sucrose (109.5 g) was dissolved in 1000 ml of water. 
 
 Krebs-Hepes buffer (KHP), pH 7.4 (buffer for calcium assay) 
NaCl (16.8 g, 118.6 mM), KCl (0.875 g, 4.7 mM), KH2PO4 (0.4 g, 1.2 mM), NaHCO3 (0.875 
g, 4.2 mM), D-glucose (5.25 g, 11.7 mM), HEPES (5.95 g, 10 mM), CaCl2 (0.14 g, 1.3 mM) 
and of MgSO4 (0.07 g, 1.2 mM) were dissolved in 1000 ml of water and a kept at 4 °C, then 
the pH value was adjusted to 7.4. 
 
 Hanks buffer salt solution (HBSS), pH 7.3 (buffer for cAMP assay) 
Hepes (4.77 g, 20 mM), NaCl (7.59 g, 130 mM), glucose (0.99 mg,  5.5 mM), MgSO4 (0.99 g, 
0.83 mM), MgCl2.6 H2O (0.1 g, 0.5 mM), CaCl2.2H2O (0.205 g, 1.4 mM), NaHCO3 (0.35 g, 
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4.17 mM), KCl (0.399 g, 5.36 mM), KH2PO4 (0.054 g, 0.4 mM) and Na2HPO4 (0.043 g, 0.3 
mM) were dissolved in autoclaved water and the pH was adjusted to 7.3 using 1 N NaOH. 
 
 Lysis buffer pH 7.3 (buffer for cAMP assay) 
 
Na2EDTA (1.49 g, 4 mM) were dissolved in 1000 ml of water and the pH was adjusted to 7.3 
using HCl (37 %). Then 100 µl of triton X-100 (0.01%) was added. 
 
 
 Phosphate buffered saline (PBS), pH 7.3 (washing buffer for cells) 
 
NaCl (8 g, 137 mM), KCl (0.2 g, 2.7 mM), Na2HPO4 (0.609 g, 4.3 mM) and KH2PO4 (0.2 g, 
1.47 mM) were dissolved in 1000 ml of water. HCl (37 %) was used to adjust the pH to 7.3. 
 
 
 Buffer for cAMP binding protein from bovine adrenals 
 
Tris (12.1 g, 100 mM) were dissolved in 1000 ml of water and the pH was adjusted to 7.4 
using HCl (37 %). Then NaCl (14.6 g, 250 mM), Na2EDTA (3.7 g, 10 mM), 0.1% 2-
mercaptoethanol, and of sucrose (85 g, 0.25 M) were added. 
 
 Buffer for membrane preparation of PC12 cells, melanoma cells, HEK293 cells, 
1321N1 human astrocytoma cells and rAde1 or human P2Y12 receptor expressed in 
1321N1 human astrocytoma cells 
 
Tris (0.605 g, 5 mM) were dissolved in 1000 ml of water and then the pH was adjusted to the 
pH 7.4 using HCl (37 %). Finally, of Na2EDTA (0.744 g, 2 mM) was added.  
 
 Buffer for membrane preparation of Sf21 cells expressing mAde2R 
TRIS (6.05 g, 50 mM) with of PMSF (0.137 g, 1 mM) were dissolved in 1000 ml of water. 
The pH was adjustd using 37% HCl to 7.4. 
 
 Tris-acetate-EDTA buffer (TAE), pH 8 (buffer for agarose gel electrophoresis) 
TRIS (4.84 g, 40 mM) was dissolved in 1000 ml of water. The pH was adjusted to 8 using 
glacial acetic acid, then Na2EDTA (0.744 g, 2 mM) was added. 
 
 Hypoxanthine or Xanthine 
About 80% of the required volume of water was added to suspend hypoxanthine (10 mg/ml) 
or xanthine (10 mg/ml). To the suspension sterile few drops of 1 N aq. NaOH solution the rest 
of the water was added. Then the solution was sterile-filtered and kept at -20°C till further use. 
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 Mycophenolic acid 
Mycophenolic acid (10 mg/ml) was suspended in water and dissolved by addition of some 
drops of 1 N aq. NaOH solution. Then the solution was sterile filtered and frozen at -20 °C 
protected from light  
 
 Hygromycin B 
Hygromycin B (50 mg/ml) was dissolved in water, sterile-filtered and kept at-20°C. 
 
 HXM Medium 
DMEM (500 ml) medium containing 10% FCS, 100 U/ml penicillin G, 100 µg/ml 
streptomycin, 1% Ultraglutamin, hypoxanthine (0.75 ml, 10 mg / ml), xanthine (12.5 ml, 10 
mg / ml), mycophenolic acid (1.25 ml, 10 mg/ml) and hygromycin B (2 ml, 50 mg/ml). 
 
 SOC-Medium (medium for molecular biology) 
Tryptone (20.0 g), extract of yeast (5.0 g), NaCl (0.5 g, 8.5 mM), KCl (18.9 g, 0.25 M), 
MgCl2 (2 M) and glucose (1 M) all were dissolved in water (1000 ml). The pH was adjusted 
with 1 N NaOH aq. to 7.0. Then the medium was autoclaved. 
 
 LB-Medium (medium for molecular biology) 
LB-powder medium (25 g) was dissolved in 900 ml water, and the pH was adjusted with 1 N 
aq. NaOH at 7.5. After the volume was completed to 1000 ml, the medium was autoclaved. 
 
 
 Oregon Green stock solution 
The fluorescent dye Oregon Green 488 BAPTA-1/AM (Mr = 1258.07 g/mol; 50 µg was 
dissolved in 39.7 μl DMSO in order to get a 1 mM concentration. The stock solutions were 
aliquoted into Eppendorf vials and kept in 20°C until used at calcium assays. 
 
 Fura-2 stock solution 
Calcium-sensitive dye Fura-2/AM (Mr =1001.86 g/mol; 50 µg) were dissolved in 49.9 μl 
DMSO to get a stock solution of 1 mM. Then it was aliquoted into Eppendorf vials and kept 
at -20 ° C. 
 
 Pluronic® -F-127 stock solution 
Pluronic F-127 (200 mg) was dissolved in 800 µl of DMSO to give a 20% (w/v) stock 
solution. This requires heating at ~30° for about 20 minutes. The solution is stored at room 
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temperature. The Pluronic F-127 comes out of solution if it is refrigerated or frozen. If the 
solution does crystallize, it can be reheated until it goes back into solution. 
 
5.7. Preparation of stable cell lines 
 
5.7.1. Molecular biology 
  
 
5.7.1.1. Gel electrophoresis 
 
 
For preparing agarose gels, 1% agarose solution was made in 100 ml Tris acetate EDTA 
(TAE). A solution of up to 4% can be used if small DNA molecules are analyzed, and for 
large molecules, a solution as low as 0.8% is preferable. The solution was boiled to dissolve 
the agarose in a microwave oven and was cooled down to about 60 °C at room temperature. 
Ethidium bromide (5 µl, 0.01%) was added for 50 ml gel solution. The solution was poured 
into the gel rack. A comb was inserted at one side of the gel, about 5-10 mm from the end of 
the gel. After the gel has cooled down and become solid, the comb was removed and the gel 
was placed into a tank with TAE buffer. The gel was completely covered with TAE. DNA 
samples, stained with loading dye were pipetted into the slits. The lid of the electrophoresis 
chamber was closed and a current was applied (100 V for about 30 minutes). The DNA was 
detected by UV using a gel-Doc system.  
 
5.7.1.2. Extraction of DNA from an agarose gel 
After the DNA samples were run on an agarose gel, the gel was placed on a UV 
transilluminator to make the ethidium bromide-stained DNA visible. The desired bands were 
identified, cut out and transferred into Eppendorf tubes. The extraction of DNA was 
preformed as described in the QIAquik
® 
Gel Extraction Kit protocol.  
 
5.7.1.3. Agar plates 
LB-agar (32 g) was added to 800 ml of deionized water. The agar was melted in the 
microwave oven and the volume was adjusted to 1L with deionized water. The solution was 
sterilized by autoclaving. The solution was cooled down to about 50 °C at room temperature. 
Ampicillin was added to the sterilized solution in a final concentration of 100 µg/ml. About 
15-20 ml of agar solution was poured into 10 cm Petri dishes. The plates were kept in a plastic 
back in 4 °C. 
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5.7.1.4. Vectors 
 
PQCXIN PQCXIP PLXSN 
 
 
 
5'-acgccatccacgctgttttgacct-3' 
5'-aagcggcttcggccagtaacgtta-3' 
5'-acgccatccacgctgttttgacct-3' 
5'-aagcggcttcggccagtaacgtta-3' 
5’-cccttgaacctcctcgttcgacc–3’ 
5’-gagcctggggactttccacaccc–3’ 
 
5.7.1.5. PCR primer design 
 
PCR primers define the target region to be amplified and generally range in length from 15–
30 bases. Ideally primers have a GC-content of 40–60%. Avoid three G or C residues in a row 
near the 3′-end of the primer to minimize nonspecific primer annealing. Also, avoid primers 
with intra- or intermolecular complementary sequences to minimize the production of primer-
dimers. Intermolecular regions of the secondary structure can interfere with primer annealing 
to the template and should be avoided. Ideally, the melting temperature (Tm), the temperature 
at which 50% of the primer molecules are annealed to the complementary sequence, of the 
two will be within 5°C, so the primers anneal efficiently at the same temperature. Primers can 
be designed to include sequences that can be useful for downstream applications. 
 
5.7.2. Cloning of the human P2X2 and P2X3 receptor DNAs into pQCXIP or pQCXIN 
vectors, respectively  
 
4.7.2.1. PCR primer design 
 
o The sequence of the cloning primers used for P2X2: 
f-hP2X2-NotI: 5'-cgagacggcggccgcatggccgccgcccagcc (62°C) 
r-hP2X2-EcoRI: 5'-cttactgaattctcagagttgagccaaacctttg (64°C ) 
o The sequence of the cloning primers used for P2X3: 
f-hP2X3-NotI: 5'-gtgacagcggccgcatgaactgcatatccgacttc (60°C)  
r-hP2X3-EcoRI: 5'-cttactagaattcctagtggcctatggagaagg (62°C) 
 
5.7.2.2. The polymerase chain reaction (PCR) 
The PCR amplification was carried out with the following denaturation procedure of template, 
annealing of primers, and elongation of primers with DNA polymerase.  
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This was preformed under the following conditions: 94°C initial denaturation for 4 min, 
followed by 1 min denaturation at 94°C and 1 min at 60°C annealing, 2 min elongation at 
72 °C for 35 cycles. A final elongation was preformed for 10 min at 72°C and then maintained 
indefinitely at 4°C. KOD Hot Start Polymerase was used as a thermostable DNA-polymerase. 
 
10x Buffer                                   2.5 µl 2.5 µl 
25 mM MgSO4                            1.5 µl 1.5 µl 
2 mM dNTPs                              2.5 µl 2.5 µl 
Forward primer                           1 µl 1 µl 
Reverse primer                            1 µl 1 µl 
DNA template 
KOD Hot Start Polymerase                                  
1 µl 
1 µl
0.5 µl 
1 µl 
H2O   14.5µl 15 µl 
 
All samples were prepared in a 25 µl reaction volume. The total primer concentration was 0.2 
pmol/µl. 
 
5.7.2.3. Restriction 
 
o Restriction of the PCR product 
 
The PCR-products and vectors were prepared for ligation by digestion with the restriction 
enzymes EcoRΙ and NotI as follow: 
 
BSA (10x) 5 µl 
Buffer 4 (10x) 3.5 µl 
EcoRI 2.5 µl 
NotI 2.5 µl 
H2O 5 µl 
P2X2 or P2X3 DNA 30 µl 
 
All samples were prepared in a 50 µl total volume.  
 
 
o Restriction of the vectors 
 
BSA (10x) 1 µl 
Buffer 3 (10x) 1 µl 
EcoRI 0.5 µl 
NotI 0.5 µl 
H2O 6 µl 
pQCXIP or pQCXIN vector 30 µl 
 
The samples were incubated for one hour at 37 °C. 
 
5.7.2.4. Extraction of DNA from an agarose gel 
After the DNA samples were run on an agarose gel, the gel was placed on a UV 
transilluminator to make the ethidium bromide-stained DNA visible. The desired bands were 
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identified, cut out and transfered to Eppendorf tubes. The extraction of the DNA was 
performed as described in the QIAquik
® 
Gel Extraction Kit protocol.  
 
5.7.2.5. Ligation of DNA fragments 
Ligation of double-stranded DNA fragments (after restrictive digest) was performed with T4-
DNA-Ligase. This enzyme forms ATP-dependent phosphodiester bond catalysis between 3’-
hydroxyl and 5’-phosphate ends. DNA fragments were added in a molar ratio of vector to 
insert of 1:3. The ligation reaction was incubated at 25°C for two hours.  
 
pQCXIP or pQCXIN vector 12.5 µl 
hP2X2 or hP2X3 25 µl 
T4-Ligase buffer (10x) 6 µl 
ATP (10 mM) 6 µl 
T4-DNA-Ligase 3.5 µl 
H2O 7 µl 
 
5.7.2.6. Transforming chemically competent cells 
 
The chemically competent Top 10 or DH5α™ (Escherichia coli) cells were thawed on ice. 
The ligation product of each ligation reaction was directly added to the competent cells (100 
µl) and was gently mixed. The vial was incubated on ice for 30 minutes followed by a heat-
shock for about 1-2 minutes at 37°C in the water bath. Afterwards the vial was transferred to 
ice for 2 minutes and 300 µl of SOC medium was added. The bacteria were incubated at 37°C 
for 1 hour while shaking at ~300 rpm. Each transformation sample was spread on separate, 
labelled LB agar plates containing 100 µg/ml ampicillin. The plates were inverted and 
incubated at 37°C overnight. On the next day, single bacterial colonies from each 
transformation were incubated in individual sterile culture tubes containing 5 mL of LB with 
100 ug/mL ampicillin. The incubation was performed at 37 ºC overnight with constant 
shaking. 
 
5.7.2.7. DNA preparation 
 Miniprep method  
DNA minipreparation is a method for the isolation of up to 40 µg plasmid DNA from 4 mL 
liquid culture. The PureLink™ HiPure Plasmid DNA Miniprep Kit was used as described in 
the manufacturer’s protocol. Resulting DNAs were analysed by digestion with restriction 
enzymes to identify those carrying the desired DNA sequence. Restriction was done as 
mentioned above using EcoRΙ and NotI as restriction enzymes. 
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 Midiprep method  
Midiprep isolation of DNA is used for producing up to 500 µg of plasmid DNA from 100 mL 
of liquid culture: 5 mL of a pre-culture were added to 95 mL of LB-amp and were grown 
overnight at 37
o
C with shaking. The DNA was isolated from the liquid culture using 
PureLink™ HiPure Plasmid DNA Midiprep Kit according to the manufacturer's protocol. The 
concentration of each DNA sample was determined, and DNA was stored at -20
o
C. 
 
5.7.2.8. Determination of DNA stock concentration 
DNA stock (2 µl) was mixed with 998 µl of water. The concentration was determined using a 
photometer.  Water was used as zero value and the absorption was determined at 260 nM. 
 
5.7.2.9. DNA sequencing 
DNA sequencing was done by GATC Biotech. 
 
5.7.2.10. Creating a glycerol stock 
An overnight culture (800 µl) containing the bacteria with the desired plasmid with the insert 
was mixed with 200 µl of sterile glycerol, and gently resuspended. Once the solution was 
homogenous, the glycerol stock was stored at -80
o
C. This stock can be used for the next 
several years to inoculate a fresh liquid culture in order to amplify more DNA. Simply a small 
portion of the frozen glycerol stock is removed (thawing the tube is not required) from the 
tube by scraping the surface with a pipette tip, and deposited in a sterile culture tube 
containing LB-amp. The culture should be incubated overnight at 37
o
C with agitation before 
proceeding to step 1. 
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5.7.3. Cloning of the human P2Y11 receptor DNA into the pLXSN vector  
 
5.7.3.1. PCR cloning primers 
 
f-hP2Y11-EcoRI: 5'-gtgacagaatcgatggcagccaacgtctcgg (62°C)  
r-hP2Y11-XhoI: 5'- cttactactcgagtcattggctcagctcacggg (62°C) 
 
The cloning of human P2Y11 receptor DNA into pLXSN was preformed as mentioned above. 
In brief, PCR was performed using the forward, the reverse primers and the template for 
hP2Y11 DNA as follows:  
 
Initial denaturation    94°C       4 min 
Denaturation              94°C        1 min 
Annealing                  62°C        1 min          25 cycles 
Elongation                 72°C        1 min 
A final elongation   72°C       10 min 
Cooling                       4°C 
 
The PCR product and the pLXSN vector were prepared for ligation by restriction using EcoRI 
and XhoI followed by ligation using T4-DNA-Ligase. The ligation product was transformed 
into Top 10 E. coli and the DNA was isolated from individual clones. Sequencing was 
performed by GATC Biotech (Konstanz, Germany).  
 
A problem appeared in which a DNA sequence in the hP2Y11 sequence was missing. In order 
to overcome this problem a new primer was designed to attach the missing DNA sequence 
and then the cloning procedure was repeated. 
 
The first PCR was performed using the following primers: 
 
f-hP2Y11-ATG: 5'-atggcagccaacgtctcgggtgccaagtcctgccctg-3'(64°C) 
r-hP2Y11-XhoI: 5'- cttactactcgagtcattggctcagctcacggg (62°C) 
 
The PCR steps were done as mentioned before using 62°C as annelling temperature. The PCR 
product from the first PCR was used as a template for the second PCR. The second PCR for 
hP2Y11 was carried out using the primers f-hP2Y11-EcoRI and r-hP2Y11-XhoI at 62°C for 30 
cycles.  
 
5.7.3.2. Restriction 
 
 Restriction of the second PCR product 
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The PCR products and vectors were prepared for ligation by digestion with the restriction 
enzymes EcoRΙ and NotI as follows: 
BSA (10x) 5 µl 
10x buffer 4 3.5 µl 
EcoRI 2.5 µl 
XhoI 2.5 µl 
H2O 5 µl 
Second PCR product 30 µl 
 
 Restriction of the vectors 
 
BSA (10x) 1 µl 
10x buffer 4 1 µl 
EcoRI 0.5 µl 
XhoI 0.5 µl 
H2O 6 µl 
pLXSN vector 1 µl 
 
The sample was prepared in a total volume of 10 µl. The incubation was performed as 
mentioned before at 37 °C for one hour, followed by ligation using T4-DNA-Ligase which 
was performed over night at 16 °C. 
 
The ligation prodct was transformed into E. coli and the DNA was isolated from individual 
clones using the PureLink™ HiPure Plasmid DNA Miniprep Kit as described in the 
manufacturer’s protocol. Resulting DNAs were analysed by digestion with restriction 
enzymes to identify those carrying the desired DNA sequence. Restriction was done as 
mentioned above using EcoRI and XhoI as restriction enzymes.  
 
5.7.4. Stable transfection  
 
The packing cell line (GP+envAM12260) was split one day before transfection (1.5x10
6
 in 25 
cm
2
 flask) in normal culturing medium (HXM-medium) without xanthine, hypoxanthine and 
mycophenolic acid. Cells were transfected by using lipofectamine 2000. Briefly, 10 µg of 
DNA (6.25 µg of plasmid and 3.75 µg of VSV-G protein DNA) was incubated in a final 
volume of 625 µl of DMEM (without FCS or antibiotics); then, 25 µl of lipofectamine 2000 
was incubated in 600 µl DMEM (without FCS or antibiotics) for 5 minutes. The lipofectamine 
in the medium was mixed with the DNA-medium mixture and incubated for 20 minutes. The 
DNA-lipid mixture was added to the GP+envAM12260 cells (80% confluent; 25 cm
2
flask) 
and incubated for 12-15 hour. Then the medium was changed with 3 ml medium (DMEM, 
10% FCS, 100 U/ml penicillin G, 100 µg/ml streptomycin and 1% ultraglutamine) and 30 µl 
of sodium butyrate was added. The cells were cultured at 32°C for 2 days. Finally, 3 ml of 
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virus supernatant were collected and filtered though 45 µm filters. The sterile virus 
supernatant with 6 µl of polybrene solution was infected into 1321N1 human astrocytoma 
cells (80% confluent 25 cm
2 
flask) for 2 hour, and then the medium was exchanged for new 
one. 48 hours after transfection, cells were subcultured in growth medium containing 800 mg 
ml
-1
 G 418 (human P2X2 HAtag, human P2X3 HAtag, human P2X2-3, human P2Y12 and 
human P2Y13, P2Y14 and rAde1). Cells expressing P2X2, P2X3 and P2Y12 and P2Y13 receptors 
were maintained at 37°C in DMEM with 4 mM L-glutamine, 10% fetal bovine serum, 100 
U/ml penicillin G, 100 µg/ml streptomycin and 400 µg ml
-1 
G 418. 
 
 Retroviral transfection of 1321N1 human astrocytoma cells for the stable expression 
of hP2X2 and P2X2/3 receptors  
 
The human P2X2 and P2X3 DNAs were inserted into the retroviral vector pQCXIP and 
pQCXIN, respectively, as mentioned above.  
 
Single infection Co-infection
Single-transfected cell line Double-transfected cell line
Packaging
system
Packaging
system
 
 
Figure 90. Packaging cells are first transiently cotransfected with a retroviral vector and a 
viral expression vector containing pVSV-G for pseudotyping to generate retroviruses. Those 
viruses are initially used to generate a stable cell line, expressing one receptor only. This cell 
line can then be used for the infection with viruses containing a second gene of interest. This 
produces a cell line that expresses two receptors or proteins of interest in the presence of 
doxycycline (left). Target cells may also be coinfected with the two retroviruses carrying two 
genes of interest and selected simultaneously with G418 and puromycin to produce the 
desired cell line, expressing two different proteins (right).  
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The DNA was transfected in 1321N1 human astrocytomacells using a retroviral system as 
described
192
 with some modifications. GP+envAM12 packaging cells were first transiently 
cotransfected with a retroviral vector and a viral expression vector (pVSV-G) to generate two 
retroviruses 
The retroviral vector containing the hP2X2 insert was initially used to create a stable 1321N1 
human astrocytoma cell line, expressing P2X2, which was then infected with a P2X3 
containing virus carrying a neomycin resistance gene for selection. In a second approach, 
1321N1 human astrocytoma cells were co-infected with the two retroviruses carrying the 
P2X2 and P2X3 DNAs, respectively, and selected simultaneously with G418 (800 µg/ml) and 
puromycin (6 µg/ml) to produce the desired stable cell line, expressing both receptors (Figure 
90). 
 
5.8. Cell culture 
 
5.8.1. Thawing of cells 
 
The backups of the cell lines were thawed as quickly as possible and transferred to a cell 
culture bottle under laminar air flow. Then the cells were cultured in the incubator at 95% 
humidity, 5% CO2 and 37 °C. After about 5 hours in the incubator, the medium is exchanged 
with fresh one. The medium is exchanged in order to remove the dead cells which are toxic. 
 
5.8.2. Cells splitting  
After the cell line is approximately 80-90% confluent, the cells are washed with about 10 ml 
of medium PBS buffer. This washing step is in order to remove the remaining FCS or HS-
serum which negatively influences the enzymatic action of trypsin / EDTA. For the separation 
of the adherent by growing cells, depending on the enzymatic activity of trypsin, 
approximately 3-4 ml of trypsin / EDTA are added to the cells. The sterile bottle was 
incubated for 5 min in the incubator to increase the enzymatic activity of trypsin. Afterward, 
the still adherent cells were detached by gentle tapping of the cell culture bottle. Sufficient 
volume of medium was rapidly added to the cell suspension. The volume of medium added is 
depending on the ratio of splitting. In turn the ratio of the splitting will affect the speed of 
growth of cells obtained from different cell lines. The resulting cell suspension is pipetted 
several times, allowing the cells to be isolated and increase the homogeneity of the suspension.  
 
5.8.3. Freezing of cells producing backups 
To create backups cell medium is removed from the culture flask. After the cells have been 
detached from the flask using trypsin / EDTA solution the contents was transferred into a 50 
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ml Falcon tube. The cell suspension was centrifuged at 200 g, 4 °C for 5 min. The pellet was 
resuspended in a 10% solution of sterile DMSO, 40 % medium and 50 % FCS. The solution is 
aliquoted into cryovials (2 ml). The cryovails remained for 2 days at -20 °C, then 6 days at 
80 °C and at the end they were transferred into the liquid nitrogen tank. 
 
5.8.4. Cell membrane preparation 
For the adherent by growing cell lines, the cells are grown in dishes until 80-90% confluent. 
The medium are removed and the cells are washed with sterile PBS buffer. After removing 
the PBS buffer the dishes were frozen at -80 ° C until further preparation.  
The cells were thawed and resuspended in 5 mM Tris and 2 mM EDTA, pH
 
7.4 (Tris/EDTA 
buffer). The cells were homogenized by using a glass-teflon homogenizer. The resulting 
suspension is
 
centrifuged at 1000 g for 10 min to remove unbroken cells and
 
nuclei. The 
supernatant is homogenized with an Ultraturrax and subsequently centrifuged at 48,400 g
 
for 
60 min. The resulting pellets are resuspended in 50 mM Tris-HCl buffer,
 
pH
 
7.4. Protein 
concentration
 
was determined, and the membranes were stored at –80°C until required.  
For the membrane preparation of a non-adherent by growing cell line, the cell culture was also 
grown in tissue culture dishes. The contents of the cell culture plates were transferred into a 
falcon tube, and it was followed by a first centrifugation at 200 g and 4 ° C for 5 min. The 
supernatant was discarded and the cell pellet was resuspended in 5 mM Tris-HCl buffer pH 
7.4 with 2 mM EDTA. All cell suspensions are combined and centrifuged under the same 
conditions, and subsequently stored on ice. After finishing the first centrifugation step, the 
preparation is continued as mentioned above. 
 
5.8.5. Membrane preparations from Sf21 cells expressing the mAde2 receptor  
After infection of cells with recombinant baculoviruses, cells were homogenized with 20 
strokes in a tight by fitting Dounce homogenizer in 50 mM Tris-HCl buffer, pH 7.4, 
containing 1 mM PMSF. The cell suspension was centrifuged for 10 min at 200 g, 4°C. The 
supernatant was then centrifuged at 48,000 g, 60 min, 4°C and the resulting pellet was 
resuspended in 50 mM Tris-HCl buffer, pH 7.4. The protein concentration was determined. 
Membranes were kept frozen at -80°C until use. 
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5.9. Membrane preparation of organs tissue 
5.9.1. Rat cortex 
Frozen brains were removed from the -80 °C freezer and immediately placed in ice-cold 
saline before dissection of the cortex. Tissues were homogenized in sucrose using a glass-
teflon homogenizer, the homogenate was centrifuged at 1000 × g for 10 min, and the resulting 
supernatant was centrifuged at 37,000 × g for 1 hour. The synaptosomal - mitochondrial P2 
pellet was homogenised with Ultraturrax for 10 s, then centrifuged at 37,000 × g for 60 min. 
The membrane pellet was resuspended in 50 mM Tris-HCl buffer (pH 7.4), and stored at 
−80°C. The protein concentration of the suspension was determined. 
 
5.9.2. Rat striatum 
After the cerebral cortex of rat brain had been scraped off, the left and right striatum was 
dissected and placed in ice cold 50 mM Tris-HCl buffer pH 7.4. The tissue was homogenized 
with an Ultraturrax (stage 3-4, about 2-3 s). The resulting suspension is centrifuged at 48,400 
g for 15 min. The supernatant is discarded, the pellet was resuspended in 50 mM Tris-HCl 
buffer pH 7.4, homogenized and again centrifuged under the above conditions. After this 
second washing step, the supernatant was discarded and the pellet was resuspended in 50 mM 
Tris-HCl buffer pH 7.4. After homogenization, the preserved tissue suspension was aliquoted 
in 1 ml Eppendorf tubes. The tubes were frozen in -80 °C after protein determination. 
 
5.9.3. Preparation of cAMP binding protein 
The bovine adrenals from four animals were dissected free of subcapsular fat and medullar 
tissue. They were then homogenized in 10 volumes of buffer consisting of 100 mM Tris/HCl, 
pH 7.4, 250 mM NaCl, 10 mM EDTA, 0.1% 2-mercaptoethanol, and 0.25 M sucrose with an 
Ultra-Turrax. The homogenate was filtered through cheesecloth and then cleared by 
centrifugation (30,000 g, 4°C for 60 min). The supernatant with the soluble proteins was used 
without further processing, as binding protein. The protein was frozen in l-ml aliquots at -
20 °C. Under these circumstances, the activity of the protein was retained for at least 2 years. 
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5.10. Protein determination 
5.10.1. Bradford protein determination 
The Bradford protein assay is a dye-binding assay based on the observation that the 
absorbance maximum for an acidic solution of Coomassie Brillant Blue G 250 shifts from λ= 
465 nm to λ= 595 nm when binding with protein occurs. To determine the concentration of 
the protein following the Bradford procedure, a master solution was prepared, made of 100 
mg Coomassie brilliant Blue G diluted in 50 ml ethanol (v/v), with 100 ml phosphoric acid 
and diluted with water to 1000 ml when the dye has completely dissolved. The Bradford 
reagent should be of a light brown in color. Bovine serum albumin was used as a standard 
protein. The Coomassie protein assay was calibrated within a protein concentration range 
from 10 to 250 µg (λ = 595 nm). The samples are diluted with water so that their 
concentrations amount to approximately 10-100 µg proteins. A volume of 0.1 ml of these 
dilutions was mixed with 2.0 ml Bradford reagent. The sample-dye mixtures were assayed 
within 1 hour of mixing, due to the progressive reduction of the optical density. The basic 
amino acids, arginine, lysine and histidine play a role in the formation of dye-protein 
complexes color. Small proteins less than 3 kDa and amino acids generally do not produce 
color changes. 
 
5.10.2. Lowry protein determination 
             This procedure is one of the most used for quantification of soluble proteins. Protein 
concentrations are determined and reported with reference to standards of a common protein 
bovine serum albumin (1 mg/ml). A series of dilutions of the protein standard is prepared in 
appropriately labelled test tubes (Table 25).  
Reagents 
 
A Na2CO3 2 % 10 g 
 NaOH 0.1 N  500 ml 
B Cu2SO4 . 5H2O 0.5 % 0.25 g   
 Na- Tartrat 1 % 0.5 g                 
 Deionised water  50 ml                
 
C Frishly prepared by mixing: 50 parts of reagent A with 1 part of reagent 
D  Folin & Ciocalteaus phenol reagent working solution: 
Add 90 ml of deionised water to 18 ml Folin Reagent (F-9252) and store in dark at room 
temperature. 
 
In this method, protein is pretreated with copper (II) in a modified biuret reagent (alkaline 
copper solution stabilized with sodium potassium tartrate; C). Addition of Folin & Ciocalteus 
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phenol reagent (D), which contains sodium molybdate and sodium tungstate in phosphoric 
acid, generates a change of reagent colour from yellow to blue colour. That is due to the 
reduction of Folin & Ciocalteus phenol reagent by the copper – protein complex that gives an 
increasing in absorbance between 550–750 nm. Normally, absorbance at the peak (750 nm) or 
shoulder (660 nm) is used to quantitate protein concentrations between 1–100 µg/ml while 
absorbance at 550 nm is used to quantitate higher protein concentrations. 
 
A volume of 1 ml of Lowry reagent is added to 0.2 ml of protein sample (appropriately 
diluted) and incubated exactly 20 minutes at room temperature. The last step is to add the 
Folin-Ciocalteau reagent and incubate it for 30 minutes at room temperature. The 
concentration of each unknown protein sample is determined based on the standard curve. 
 
Table 25. Dilutions of the bovine serum albumin (BSA) 
 
Protein standard solution (µl) Deionised water (µl) Protein conc. (µg/ml) 
10 
20 
40 
60 
80 
190 
180 
160 
140 
120 
50 
100 
200 
300 
400 
 
 
5.11. Radioligand binding studies 
5.11.1. Saturation buinding studies 
5.11.1.1. Saturation experiments using intact cells 
5.11.1.1.1. Saturation experiments for human adenine receptors using intact cells  
HEK293 cells were grown to confluence, washed and resuspended in HBSS buffer solution. 
Cells (3 x10
5
)
 
were incubated with increasing amounts (0.5 - 200 nM) of [
3
H]adenine as 
radioligand in a total volume of 200 µl for 60 min at room temperature. Nonspecific binding 
was determined with 100 µM adenine. Incubation was terminated using vacuum filtration 
through Whatman GF/B glass fibre filters, using a Brandel 24 or 48-channel cell harvester. 
The vials were rinsed three times with 3 ml of Tris-HCl buffer (50 mM, pH 7.4) and 
consequently both bound and free radioligand were separated. The filters were punched out 
and transferred to 4 ml scintillation vials. 2.5 ml Ultima Gold
®
 scintillation cocktail was 
added and samples were counted after 6 hours for 1 min each, using a liquid scintillation 
counter (LSC). 
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Scheme for pipetting  
 
50 µl  Tris 90 % / DMSO 10 % total binding; containing adenine (100 µM) for 
nonspecific binding 
50 µl [
3
H]adenine (final concentration 0.5 - 200 nM) in HBSS buffer; pH 7.3 
100 µl Cell suspension  in HBSS buffer; pH 7.3 
200 µl Total volume 
 
5.11.1.1.2. Saturation experiment of [
3
H]PSB-0413 at intact 1321N1 human astrocytoma 
cells expressing human P2Y12 receptor 
 
1321N1 human astrocytoma cells expressing the human P2Y12 receptor were harvested with 
0.05 % trypsin / 0.02 % EDTA and rinsed with culture medium. The cell suspension was 
centrifuged at 200 x g and resuspended (5 x 10
5
 cells/ml) in DMEM medium, supplemented 
with 100 U/ml penicillin G, 100 µg/ml streptomycin, 1 % GlutaMAX and 400 µg/ml G418. 
Increasing concentrations of [
3
H]PSB-0413 (0.05-30 nM) were incubated with cell suspension. 
The nonspecific binding measured in the presence of ADP (10 mM). Samples were incubated 
for 60 min at 37 ºC in 500 µl total volume. The incubation was stopped by vacuum filtration 
through Whatman GF/B glass fiber filters, using a Brandel 24- or 48-channel cell harvester. 
The vials were rinsed three times with 1 ml aliquots of PBS buffer.  
 
Scheme for pipetting  
 
50 µl  HBSS buffer; pH 7.3, ADP 10 mM  
50 µl [
3
H]PSB-0413 (0.05-30 nM) in HBSS buffer; pH 7.3 
400 µl Cell suspension  in DMEM medium 
500 µl Total volume 
 
5.11.1.2. Saturation experiments using membrane preparations 
5.11.1.2.1. Membrane preparation of mAde2 receptor expressed in Sf21 cells or CHO 
cells 
 
For the saturation assay increasing amounts (0.75-150 nM) of [
3
H]adenine in 50 mM Tris-HCl, 
pH 7.4 in a total volume of 200 µl were used. Nonspecific binding was determined with 100 
µM adenine. The binding was terminated as mentioned before. In brief, vacuum filtration 
through Whatman GF/B glass fibre filters was used to separate binding radioligand from free 
radioligand, using a Brandel 24- or 48-channel cell harvester. The vials were rinsed three 
times with 3 ml of ice-cold Tris-HCl buffer (50 mM, pH 7.4). 
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Schematic for pipetting  
 
50 µl  Tris 90 % / DMSO 10 %, adenine (100 µM)  
50 µl [
3
H]adenine (final concentration 0. nM) in 50 mM Tris-HCl buffer pH 7.4 
100 µl Protein membrane preparation (100 µg/vial) in 50 mM Tris-HCl buffer, pH 7.4 
200 µl Total volume 
 
5.11.2. Competition experiments 
5.11.2.1. Competition experiments at intact cells 
5.11.2.1.1. Competition experiment using whole cells of HEK 293 
HEK293 cells were grown to 85% confluence, washed and collected in HBSS buffer 
(containing 20 mM HEPES, pH 7.3). The incubation was started by addition of [
3
H]adenine 
(15 nM) to the cell (3 x10
5
) suspension. About 6-9 dilutions of adenine were made in HBSS 
buffer. The incuabtion was preformed at room temprature for 60 minutes in a total volume of 
200 µl. Nonspecific binding was determined with 100 µM adenine. The binding was 
terminated as described before. 
 
Scheme for pipetting:  
 
50 µl  HBSS buffer; pH 7.4, adenine (100 µM) or tested compound 
50 µl [
3
H]adenine (final concentration 15 nM) in HBSS buffer, pH 7.4 
100 µl Cell suspension in HBSS buffer, pH 7.4 
200 µl Total volume 
 
5.11.2.1.2. Competition experiment with [
3
H]PSB-0413  cell at whole human P2Y12  
1321N1 human astrocytoma cells expressing the human P2Y12  receptor, were harvested with 
0.05 % trypsin / 0.02 % EDTA and rinsed with culture medium. The cell suspension was 
centrifuged at 200 x g and resuspended (5 x 10
5
 cells/ml) in DMEM medium, supplemented 
with 100 U/ml penicillin G, 100 µg/ml streptomycin, 1 % GlutaMAX and 400 µg/ml G 418.  
The nonspecific binding measured in the presence of ADP (10 mM). Samples were incubated 
for 60 min at 37 ºC in a total volume of 500 µl. The incubation was stopped using vacuum 
filtration through Whatman GF/B glass fiber filters using a Brandel 24- or 48-channel cell 
harvester. The vials were rinsed three times with 1 ml aliquots of PBS buffer.  
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Scheme for pipetting  
 
50 µl  HBSS buffer, pH 7.3, ADP 10 mM or test compound 
50 µl [
3
H]PSB-0413 (5 nM) in HBSS buffer, pH 7.3 
400 µl Cell suspension in DMEM medium 
500 µl Total volume 
 
5.11.2.2. Competition experiments using membrane preparations 
5.11.2.2.1. [
3
H]Adenine competition experiments using membrane preparations 
The competition assays were carried out using [
3
H]adenine in a concentration of 10 nM and 
were done in triplicates. For the non-specific binding, adenine (100 µM) was dissolved in 
Tris-HCl / DMSO mixture buffer (9:1). 6-9 Dilutions of test compounds previously dissolved 
in DMSO were prepared using Tris-HCl / DMSO mixture buffer. The mixture was added to 
the incubation tubes. After the addition of [
3
H]adenine and protein (rat cortical membranes, 
HEK293 membranes, PC12 cell membranes, melanoma cell membranes, the membrane 
preparations of recombinant mAde2R expressed in Sf21 insect cells, or NG108-15 membrane 
preparations), the samples were incubated for 60 min at room temperature. The incubation 
was stopped using vacuum filtration through Whatman GF/B glass fibre filters, using a 
Brandel 24 or 48-channel cell harvester. The vials were rinsed three times with 3 ml of Tris-
HCl buffer (50 mM, pH 7.4) and consequently both bound and free radioligand were 
separated. The filters were punched out and transferred to 4 ml scintillation vials. 2.5 ml 
Ultima Gold
®
 scintillation cocktail was added and samples were counted after 6 hours for 1 
min each, using a liquid scintillation counter (LSC). 
 
Scheme for pipetting  
 
50 µl  Tris 90 % / DMSO 10%, adenine (100 µM) or tested compound 
50 µl [
3
H]adenine (final concentration 10 nM) in 50 mM Tris-HCl buffer pH 7.4 
100 µl Protein membrane preparation (100 µg/vial) in 50 mM Tris-HCl buffer, pH 7.4 
200 µl Total volume 
 
 
5.11.2.2.2. [
3
H]PSB-0413 competition experiments at membranes of human P2Y12 receptors 
expressed in 1321N1 astrocytoma cells 
 
The competition assays were carried out using [
3
H]PSB-0413 in a concentration of 5 nM. The 
non-specific binding was determined using 10 mM ADP. 6-9 dilutions of test compound were 
prepared using assay buffer. The assays were performed in triplicate in a final volume of 500 
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µl in test tubes containing 50 mM Tris-HCl, pH 7.4. Samples were incubated for 60 min at 
room temperature. The incubation was stopped using vacuum filtration through Whatman 
GF/B glass fiber filters, using a Brandel 24 or 48-channel cell harvester. The vials were rinsed 
three times with 1 ml aliquots of Tris-HCl buffer 50 mM pH 7.4. 
 
Scheme for pipetting  
 
50 µl  50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2; pH 7.4, ADP 10 mM or test 
compound 
50 µl [
3
H]PSB-0413 (5 nM) in 50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 
7.4 
100 µl Membrane preparation of cells (100-150 µg/ml) 
300 µl 50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4  
500 µl Total volume 
 
5.11.2.2.3. Adenosine A2A receptor competition assays  
The competition assays were carried out using [³H]MSX-2 (3-(3-hydroxypropyl)-8-(m-
methoxystyryl)-7-methyl-1-propargylxanthine, antagonist)
193
 in a concentration of 1 nM and 
were done in triplicates. Non-specific binding was determined using NECA (50 µM). After 
the addition of [³H]MSX-2 and test compound, the incubation was started by the addition of 
protein (rat striatum with 2 IU ADA/ml) for 30 min at RT in Tris-HCl, 50 mM, pH 7.4. The 
incubation was performed in a total volume of 400 µl. The binding was terminated as 
described before using vacuum filtration with a minor modification: the GF/B filter was 
preincubated in 0.3 % PEI solution for 30 min to minimize non-specific binding to the filter 
prior to harvesting.  
 
Scheme for pipetting 
  
 
10 µl  DMSO, total binding, NECA (50 µM) or test compound diluted in DMSO 
100 µl [
3
H]MSX-2 (1 nM) in 50 mM Tris-HCl buffer pH 7.4; KD = 8 nM
193
 
100 µl Protein membrane preparation in 50 mM Tris-HCl buffer, pH 7.4 
190 µl 50 mM Tris-HCl buffer, pH 7.4 
400 µl Total volume 
 
5.11.2.2.4. Adenosine A1 receptor competition experiments  
The competition assays was performed using [³H]CCPA (2-Chlor-N
6
-cyclopentyladenosine 
42.6 Ci/mmol)
194
 in a concentration of 1 nM and were done in triplicates. CADO (2-
chloroadenosin, agonist) 10 µM was used for non-specific binding. The incubation started 
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with addition of protein (rat cortex with 2 IU ADA/ml) and lasted for 90 min at room 
temperature in Tris-HCl buffer, 50 mM, pH 7.4, in a total volume of 400 µl. The incubation 
was terminated as described before.  
 
Scheme for pipetting  
 
 
10 µl  DMSO, total binding, NECA (50 µM) or test compound diluted in DMSO 
100 µl [³H]CCPA (1 nM in 50 mM Tris-HCl buffer pH 7.4); KD = 0.2 nM
194
 
100 µl Protein membrane preparation in 50 mM Tris-HCl buffer, pH 7.4 
190 µl 50 mM Tris-HCl buffer, pH 7.4 
400 µl Total volume 
 
5.11.3. Kinetic experiments  
5.11.3.1. Association kinetics for human adenine receptors in HEK293 cells 
The association was initiated by the addition of HEK293 whole cells in HBSS, pH 7.3, with 
[
3
H]adenine (15 nM) in a total volume of 200 µl and at different time interval from 2 to 240 
minute. Nonspecific binding was determined by addition of 100 µM adenine. The incubation 
process was performed at room temperature for 1 hour. The experiments were carried out in 
triplicate. The incubation was terminated by rapid vacuum filtration through Whatman GF/B 
glass fibre filters. The vials were rinsed three times with 3 ml ice-cold tris buffer (50 mM), to 
allow the separation of the bound from the free radioligand. The filters were punched out, 
transferred into 4 ml scintillations vials and 2.5 ml Ultima Gold Cocktail was added. The 
incubation of samples with scintillation fluid was allowed to take place for sufficient time (6 
hours). The radioactivity was measured, 1 minute per sample, using a liquid scintillation 
counter (LSC).  
 
5.11.3.2. Dissociation experiments for human adenine receptors in HEK293 cells 
Binding was initiated by addition of re-suspended HEK293 whole cells to incubation tubes 
with HBSS buffer, pH 7.3, and 15 nM [
3
H]adenine, for 1 hour. The dissociation was initiated 
by addition of adenine (100 µM) and specific binding was then measured at different time 
interval (2–120 minutes). The incubation process was performed at room temperature. The 
experiments were carried out in triplicates. The incubation was terminated as described above.  
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5.12. Functional studies 
5.12.1. cAMP assays  
General procedure 
Receptor function was assessed by analyzing the activity of cellular adenylate cyclase. For 
this purpose, cells stably expressing the recombinant receptor were cultured on 24-well plates 
(150,000-200,000 cell/well). After removal of the culture medium, cells were washed with 
HBSS (containing 20 mM HEPES, pH 7.3) buffer and then incubated with the same buffer for 
2 h at 37 °C. Additives were added to the cells at 36.5 °C. After incubation with additives the 
reaction was stopped by removal of the reaction buffer followed by the addition of a hot lysis 
solution (500 µl; 90 °C; Na2EDTA 4 mM; Triton X 100, 0.1 ‰). 
 
Cyclic AMP levels were quantified by incubation of an aliquot with cAMP binding protein 
and [
3
H]cAMP. The assay is based on competition between unlabelled cAMP and a fixed 
amount of [
3
H]cAMP for binding to a protein which has high affinity for cAMP. The amount 
of labelled protein-cAMP complex formed is inversely related to the amount of unlabelled 
cAMP present in the assay sample (Figure 91). Measurement of the protein–bound 
radioactivity enables the amount of unlabelled cAMP in the sample to be calculated. 
Separation of the labelled protein from unlabeled one is achieved by one of the following 
methods: 
 Adsorption of the free nucleotide on coated charcoal, in which 50 µl of charcoal was 
added to each tube. The samples were incubated on ice for 5 min at 4 ºC, then 
centrifuged at the same temperature at 14000 rpm for 5 min. An aliquot of the 
supernatant was transferred to scintillation vials, mixed with scintillation cocktail and 
incubated for two hours. Then each sample was measured for 10 min using a liquid 
scintillation counter.  
 Filtration through GF/B filters using a Brandel 24- or 48-channel cell harvester. The 
filters were punched out and transferred to 4 ml scintillation vials. 2.5 ml Ultima 
Gold
®
 scintillation cocktail was added and samples were counted after 6 hours for 1 
min. 
[3H]cAMP
  cAMP
+ Binding protein
Free Bound
 [3H]cAMP-binding protein
 cAMP-binding protein
 
Figure 91.  cAMP determination. 
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Cyclic AMP protocol (separation by adsorption) 
Tube Lysis buffer Standard Unknown [
3
H]cAMP 
(3 nM) 
Binding 
protein 
Zero dose 25 µl _ _ 30 µl 40 µl 
Charcoal blank 65 µl _ _ 30 µl 40 µl 
Standard _ 25 µl _ 30 µl 40 µl 
unknown _ _ 25 µl 30 µl 40 µl 
 
Cyclic AMP protocol (separation by filtration) 
Tube Lysis 
buffer 
Standard Unknown [
3
H]cAMP 
(3 nM) 
Binding 
protein 
(50 µg/ml) 
Zero dose 50 µl _ _ 30 µl 40 µl 
Standard _ 50 µl _ 30 µl 40 µl 
unknown _ _ 50 µl 30 µl 40 µl 
 
 
Analysis of Data 
 
 Average of the cpm for samples in 
the absence of unlabeled cAMP 
was calculated (C0). 
 C0/Cx was also determined for 
each concentration of cAMP and 
unknowns in the assay. 
 3. C0/Cx was plotted against 
pmoles of standard cAMP; a 
straight line should be obtained 
with an intercept of 1. 
 
 
 
Calibration curve
0 10 20 30 40
0
1
2
3
cAMP, pmol
C
0
/C
 
 
 
5.12.1.1. cAMP assay  for Gi  protein-coupled  receptors (Gi signaling pathway)  
 
5.12.1.1.1. rAde1 receptor or mAde2 receptor expressed in 1321N1 human astrocytoma 
cells 
 
Cellular cAMP production was stimulated by the addition of 3 nM isoproterenol at 37 °C. 
Solvent (control), adenine or adenine derivatives were added together with isoproterenol. 
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5.12.1.1.2. Adenine receptor natively expressed in CHO K1 or CHO flp-in cells 
 
Cells were stimulated for cAMP production by the addition of 5 µM forskolin at 37 °C. 
Solvent (control) and adenine was added. 
 
5.12.1.1.3. Human P2Y12 receptor or human P2Y13 receptor expressed in 1321N1 human 
astrocytoma cells 
 
The cells were preincubated with phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine 
(IBMX), 100 µM, and caffeine (250 µM), a mixed adenosine receptor antagonist, to block the 
effects of adenosine generated by degradation of nucleotides for 10 min at 37 °C.
R
 
Nucleotides were then added to a final volume of 500 µL, 30 s before forskolin (4 µM). 
  
5.12.1.2. cAMP assays  for  Gs  protein-coupled receptors (Gs signaling pathway)  
5.12.1.2.1. Human adenosine A2A receptors or human adenosine A2B receptors expressed 
in CHO cells 
 
The cells were incubated with HBSS buffer containing adenosine deaminase (1 IU/ml) for 
120 min at 37 °C. Then the cells were then preincubated with the phosphodiesterase inhibitor 
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidone (Ro 20-1724), 40 µM, for 10 min. Drugs 
were added in 0.1 ml HBSS buffer and incubations were continued for 10 minutes at 37 °C.  
For experiments with antagonists, cells were incubated with different concentrations of 
adenosine A2A antagonists for 10 min before addition of the agonist NECA (1 nM - 100000 
nM). Then the cells were incubated for 10 more minutes. Alternatively both, agonist and 
antagonist were added at the same time. 
5.12.1.2.2. cAMP assays for adenine receptors in HEK293 cells 
The function of adenine receptor in HEK293 cells was assessed by analyzing the activity of 
cellular adenylate cyclase activity. A 24-well plate was coated with poly-L-lysine, 0.001 % 
solution was applied. Coating of the 24-well plate was carried out for 30-60 min at room 
temperature. The 24-well plate was then washed with PBS twice and with culture medium for 
once. After that, cells were cultured on the 24-well plates for one day in the culture medium at 
37 °C, 5% CO2. The assay was continued with the modified procedure as described before.  
Furthermore another experiment was performed with these cells in which the effect of PTX on 
adenine receptors in HEK293 was studied. Cells were pre-treated with PTX 100 ng/ml over 
night before the cAMP assay was performed. 
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5.13. Reporter gene assay  
General remarks 
 
Reporter constructs incorporating the coding sequence of luciferase (Luc) are convenient tools 
with which to perform high-throughput screens of multiple cellular function.
134
 These reporter 
genes are introduced into mammalian cell lines by transfection so that the level of Luc activity 
may be determined in whole-cell lysates or living cells in which Luc-catalyzed oxidation of 
luciferin generates photons detected by a photomultiplier tube or an imaging photon detector. 
When the expression of Luc is placed under the control of a minimal promoter incorporating a 
cyclic adenosine monophosphate (cAMP) response element (CRE), cAMP-elevating agents 
act via protein kinase A (PKA) and the CRE-binding protein transcription factor (cAMP 
response element binding protein, CREB) to activate the  gene expression of Luc. This 
technology is particularly applicable to the screening of cell lines expressing recombinant G 
protein–coupled receptors (GPCRs) positively linked to cAMP production. For example, 
small molecules with GPCR agonist activity or orphan GPCRs with constitutive activity can 
be identified on the basis of their ability to stimulate Luc expression via the cAMP 
pathway.
139
 
 
Cell culture and DNA transfection 
rAde1 receptor stably expressed in 1321N1 human astrocytoma cells, human adenosine A1 
receptors expressed in CHO cells or PC12 cells were cultured in 75 cm
2
 flasks (3.2 x 10
5
) for 
24 h without antibiotics so that they were 90-95% confluent before transfection. The cAMP 
responsive reporter plasmid (pCER-luc), 5 µg, was transfected into the cells using 
Lipofectamine 2000 as a transfection reagent. 
 
5.13.1. Luciferase assay as an alternative measurment for cyclic adenosine 
monophosphate (cAMP) 
 
5.13.1.1. rAde1R expressed in 1321N1 human astrocytoma cells 
 
Reporter cells were seeded at a density of 200,000 – 150,000 cells/well in a 24-well plate 18-
20 h prior to assay. After removal of the culture medium, cells were washed twice with 
Hanks’ balanced salt solution. Adenine and selected adenine derivatives were diluted in 
Hanks’ balanced salt solution containing 3 nM isoproterenol and then incubated with reporter 
cells in the same buffer for 3 h at 37 °C. The reaction was stopped by removal of the reaction 
buffer and the luciferase expression was determined using the Bright-Glo
TM
 Luciferase assay 
system (Promega) as described in the kit protocol. Plates were shaken for 2 min to ensure 
complete lysis of cells. Then the total volume from each well was transferred to a white 96-
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well plate (Greiner bio-one). Luminescence was determined using a NOVOstar microplate 
reader (BMG labtech); each well was counted for 2 s at 20 °C. 
 
5.13.1.2. Endogenous rat adenine receptors in PC12 cells 
 
After 48 hours of transienent transfection, culture medium was removed from reporter cells by 
centrifugation at 200 x g for 5 min. Cells were washed twice with Hanks’ balanced salt 
solution (containing 20 mM HEPES, pH 7.3) and resuspended in the same buffer. The cells 
were plated in a white opaque 96-well plate. Adenine was diluted in Hanks’ balanced salt 
solution and then added to a final volume of 100 µl, 30 s before forskolin (4 µM). The 
reporter cells with additives were incubated at 37 °C for 3 hrs. The reaction was stopped 
according to the Bright-Glo
TM
 Luciferase assay system (Promega) and the luminescence 
measurement was continued using a NOVOstar microplate reader (BMG labtech). 
 
5.13.1.3. Human adenosine A1 receptor expressed in CHO cells 
Reporter cells were stimulated for cAMP production using 4 µM forskolin and the reaction 
was continued as described above. 
 
5.13.2. Reporter gene assay for ERK signaling pathway 
 
 Cell culture and DNA transfection 
1321N1 cells stably expressing rAde1R were cultured in DMEM supplemented with 10% 
(v/v) FCS, L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 U/ml) and 800 
µg/ml G418, at 37 °C under a humidified atmosphere containing 5% CO2. Cells were cultured 
in 75 cm
2
 flasks (3.2 x 10
5
) for 24 h without antibiotics so that they were 90-95% confluent 
before transfection. The ERK responsive reporter plasmid (SRE-luc) was transfected into 
1321N1 cells expressing rat adenine receptors using Lipofectamine 2000 as a transfection 
reagent. 
 
 Luciferase assay 
Reporter cells were seeded at a density of 200,000 – 150,000 cells/well in a 24-well plate 18-
20 hr prior to the assay. After the cells were attached and started growing the medium was 
exchanged for medium without FCS. After removal of the culture medium, cells were washed 
twice with Hanks’ balanced salt solution with out HEPES, pH 7.3. Adenine was diluted in the 
same buffer and then added to the cells, which were incubated for 6 h at 37 °C. The reaction 
was stopped by removal of the reaction buffer, and the luciferase expression was determined 
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using Bright-Glo
TM
 Luciferase assay system (Promega) as described in the kit protocol. Plates 
were shaken for 2 min to ensure complete lysis of cells. Then the total volume from each well 
was transferred to a white 96-well plate (Greiner bio-one). Luminescence was determined 
using a NOVOstar microplate reader (BMG labtech); each well was counted for 2 s at 20 °C.  
 
5.13.3. GTP-shift experiment  
 
The competition assays were carried out using adenosine A1 receptor selective antagonist 
radioligand [
3
H]DPCPX in a concentration of 0.4 nM and were performed in triplicate. The 
assays were performed with or without 100 µM GTP. For the non-specific binding, DPCPX 
(10 µM) was used. 6-9 dilutions of test compound or plant extract previously dissolved in 
DMSO were prepared. The samples were added to incubation tubes. After the addition of 
[
3
H]DPCPX and protein (preincubated with 2 U/ml ADA ) the samples were incubated for 90 
min at room temperature. The incubation was stopped using vacuum filtration and Tris-HCl 
buffer (50 mM, pH 7.4) as a washing buffer.  
 
 
Scheme for pipetting 
  
 
25 µl DMSO, total binding, 10 µM DPCPX (10 µM) or test compound diluted in 
DMSO 
50 µl 100 µM GTP in 50 mM Tris-Puffer, pH 7.4 
100 µl [³H] DPCPX (0.4 nM in 50 mM Tris-HCl buffer pH 7.4); KD = 0.28 nM 
100 µl Protein membrane preparation (70 µg/ml) in 50 mM Tris-HCl buffer, pH 7.4 
725 µl 50 mM Tris-HCl buffer, pH 7.4 
1000 µl Total volume 
 
5.13.4. Calcium assay  
5.13.4.1. Measurement of intracellular calcium mobilisation (Gq signaling pathway) 
Measurements were performed using a Novostar®
 
microplate reader. Calcium assays were 
performed according to published procedures.
192 
1321N1 human astrocytomacells expressing 
the human P2Y were harvested with 0.05 % trypsin / 0.02 % EDTA and rinsed with culture 
medium. The cells were kept under 5 % CO2 at 37°C for 45 min and then centrifuged at 200 x 
g and 4°C for 5 min. After that the cells were incubated for 1 h at 25°C in Krebs-Ringer-
HEPES buffer, pH 7.4 containing 3 μM Oregon Green BAPTA-1/AM and 1 % Pluronic® 
F127.  
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Setting off the Novostar
® 
 
Measurement parameters Oregon Green BAPTA-1 Fura-2 
Excitation wavelength 485, bandwidth 25 nM 320, bandwidth 25 nM 
Emission wavelength 520, bandwidth 25 nM 520, bandwidth 25 nM 
Number of flashes per well interval 10 (20) 10 (20) 
Gain Variable Variable 
Measurement start time 1 (2) 0 s (11.6 s) 0 s (11.6 s) 
End time of kinetic windows 4 s (35.6 s) 4 s (35.6 s) 
Interval time 0.4 0.4 
No. of interval 60 60 
Injection start time 11.6 11.6 
Pump speed 65 µl/s 65 µl/s 
 
The cells were rinsed 3 times with KRH buffer, diluted and plated into 96-well plates with 
clear bottoms at a density of approximately 16,000 cells/well and left for 20 min. 
Fluorescence intensity was measured at 520 nm for 30 s at 0.4 s intervals. Buffer or test 
compounds were injected sequentially into separate wells using the automatic pipetting device. 
At least three independent experiments were performed in quadruplicates. 
 
5.13.4.2. Calcium assay at P2X receptors (Ligand – gated ion channel receptor) 
The human P2X2 receptor cloned in pQCXIP and pLXSN and stably transfected in 1321N1 
human astrocytoma cells were functionally characterized on the basis of agonist-mediated an 
increase in [Ca
2+
]i caused by an influx of Ca
2+
 through ligand gated ion channels.The same 
was performed for double-transfected 1321N1 human astrocytoma containing the human 
P2X2/3 receptors.  
 
The fluorescent Ca
2+
 chelating dye Fura-2 AM was used as an indicator of the relative levels 
of intracellular Ca
2+
 in a 96-well format using a Novostar
®
. The cells (60,000) were grown to 
confluence in 96-well black-walled tissue culture plates and loaded with 2.4 µM Fura-2 AM 
and Pluronic
®
 F127 in KRH buffer, pH 7.4 for 2 hr at 23 ºC. Prior to the assay, each plate was 
washed three times with 100 µl KRH buffer, to remove extracellular dye. Dilutions of ATP 
were prepared in KRH buffer. 35 µl of tested compound was added into a second 96-well-
microtiter plate-with V-base. The middle injector takes 20 µl from the reagent plate wells and 
injects it into the wells of the measurement plate. For testing antagonists, the receptor-
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expressing cell lines were pre-incubated with antagonists for 15-20 min prior to activation 
with agonists (4 µM ATP). Finally, the fluorescence in each well was measured at 0.4 second 
intervals.  
 
5.14. mRNA localization studies for endogenous rat adenine receptors in PC12 cells 
 
In order to check whether PC12 cells express mRNA for rAde1R, mRNA was extracted from 
PC12 cells using Trizol
®
 reagent (Invitrogen), In brief, a 1 ml of Trizol
®
 was mixed with 0.2 
ml chloroform and PC12 cells pallet before centrifugation. Two different samples of PC12 
cells were used at the same time. The aqueous phase was collected for mRNA extraction. 
mRNA was detected after treatment with Omniscript reverse transcriptase (Qiagen), according 
to the manufacturers’ instructions, and polymerase chain reaction (PCR) assay with  primers 
was performed (table 20; primer set 1). β-actin was used as a positive control for mRNA 
detection by another set of primers (table 20; primer set 2). Aliquots of 3 μl cDNA were used 
for each PCR reaction, which was carried out using Taq DNA polymerase supplied in 
BioMix™ (Bioline) amplification kit, the plamid of rAde1R used as a control in PCR reaction. 
The PCR parameters were as follows: an initial denaturation at 94 °C for 10 minutes, followed 
by 25 cycles of 94 °C for 75 seconds, 60 °C for 90 seconds, and 72 °C for 90 seconds, with a 
final extension step of 72°C for 10 minutes. PCR products were separated by electrophoresis 
using a 1.5 % agarose gel and visualised by GelRed
TM
 staining.  
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A-317491 5-([(3-Phenoxybenzyl)[(1S)-1,2,3,4-tetrahydro-1-
naphthalenyl]amino]carbonyl)-1,2,4-benzenetricarboxylic acid 
AC Adenylate cyclase  
ADA Adenosine deaminase  
ADP Adenosine diphosphate 
AdeRs Adenine receptors  
 AdoRs Adenosine receptors  
ALPHA screen Amplified luminescent proximity homogeneous assay 
 AP-1 Activator protein 1 
Ap3A Diadenosine triphosphate 
A3P5PS Adenosine-3'-phosphate-5' -phosphosulfate 
ARC109318 2,3-Dihydroxy-4-(7-(2-phenylcyclopropylamino)-5-(propylthio)-3H-
[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentanecarboxamide 
ARC69931MX N
6
-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)- 
β,γ-dichloromethylene ATP 
ARC67085MX 2-Propylthio-D-β,γ-dichloromethylene-ATP 
ATL146e 4-{3-[6-Amino-9-(5-ethylcarbamoyl-3,4-dihydroxytetrahydro-furan-
2-yl)-9H-purin-2-yl]-prop-2-ynyl} cyclohexanecarboxylic acid 
methyl ester
 
ATP Adenosine triphosphate 
AZD Astra-zene-ca drugs 
AZD6140 3-{7-[2-(3,4-Difluoro-phenyl)-cyclopropylamino]-5-propylsulfanyl 
[1–3]triazolo[4,5-d]pyrimidin-3-yl}-5-(2-hydroxymethoxy)-
cyclopentane-1,2-diol 
BAY 60-6583 2-[6-Amino-3,5-dicyano-4-[4 (cyclopropylmethoxy)phenyl]pyridin-2-
ylsulfanyl]acetamide 
Bmax A measure of the density of the receptor in certain tissue 
BSA Bovine serum albumin 
CADO 2-Chloroadenosine  
cAMP Cyclic adenosine-3´,5´-monophosphate 
[Ca
2+
]i Intracellular calcium concentration 
[Ca
2+
]c Cytosolic calcium concentration 
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CCPA   2-Chloro-N
6
-cyclopentyladenosine 
cDNA Complementary DNA  
GF/B Glass fiber filter -type B 
CGS 21680 2(4-((2-Carboxymethyl)phenyl)ethylamino)-5'-N-
ethylcarboxamidoadenosine 
Ci Curie (1 Ci = 37 GBq) 
Cl-IB-MECA 2-Chloro-N
6
-(3-iodobenzyl)adenosine-5'-N methylcarboxamide 
CPA N
6
-Cyclopentyladenosine 
cpm Counts per minute  
CRE cAMP response element  
CREB Response-element binding protein  
CS-747 2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-
tetrahydrothieno[3,2-c]pyridine hydrochloride 
CVT-510 N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside 
CVT-3146 2-{4-[(Methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine 
DAG Diacylglycerol 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid  
DPCPX 8-Cyclopentyl-1,3-dipropylxanthine 
DRG Dorsal root ganglion  
EC50 The molar concentration of an agonist, which produces 50% of the 
maximum possible response for that agonist (50 % Effective 
concentration) 
E. coli Escherichia coli 
EDTA Ethylene diamine tetra acetic acid 
ELISA Enzyme-linked immunosorbent assay  
E-NTPD Ecto-nucleoside triphosphate diphosphohydrolase 
ERK Extracellular-signal-regulated kinases  
FCS Fetal calf serum 
FP Fluorescence polarization  
G418 Geneticin  
GDP Guanosine diphosphate  
GFP Green fluorescent protein  
GPCRG Protein-coupled receptors 
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GR79236 N-[(1S, trans)-2-hydroxycyclopentyl]adenosine 
GTP Guanosine triphosphate  
h Human 
HBSS Hanks buffer salt solution  
HENECA 2-Hexynl-5'-N-ethylcarboxamidoadenosine 
HEPES 4-(2-Hydroxyethyl)-1-piperazine ethanesulfonic acid  
HS Horse serum  
HTRF Homogeneous time-resolved fluorescence 
 
HTS High throughput screening assay 
IBMX Isobutylmethylxanthine 
IC50 The molar concentration of an antagonist, which produces 50 % of the 
maximum possible inhibitory response for that antagonist (50 % 
Inhibitory concentration) 
IP5I Diinosine pentaphosphate 
IP3 Inositol 1,4,5-trisphosphate 
IU International units  
KA Association binding constant  
k+1 Rate constant for association 
k-1 Rate constant of dissociation 
Kb The dissociation constant for the binding of the antagonist 
KD Dissociation binding constant (is the affinity of the radioactive ligand 
for the receptor) 
kDa Kilo Dalton 
Ki Inhibition constant 
KD Dissociation binding constant  
KHP Krebs-Hepes buffer  
KO Knockout 
kob The observed rate constant  
KW-6002 (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-1H-purine-
2,6(3H,7H)-dione 
L-268605 (3-(4-Methoxyphenyl)-5-amino-7-oxothiazolo[3,2]pyrimidine 
L Ligand 
LG-medium Lysogeny broth-medium 
LPS Lipopolysaccharide  
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LR Ligand-receptor complex 
LSC Liquid Scintillation Counter 
M Magnolia  
m Mouse 
MAPK Mitogen-activated protein kinases 
min Minutes 
MRE 2029-F20 N-[1,3] benzodioxol -5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetra 
hydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide 
mRNA Messenger ribonucleic acid  
MRS Molecular recognition section 
MRS2365 (1´S,2´R,3´S,4´R,5´S)-4-[(6-amino-2-methylthio-9Hpurin- 
9-yl)-1-diphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3- 
diol
 
MRS3997 2-(3´´-(6´´-Bromoindolyl)ethyloxy)adenosine 
MRS2179 2'-Deoxy-N
6
-methyladenosine 3',5'-bisphosphate 
MRS2279  2-Chloro-N
6
-methyl-(N) methanocarba-2'-deoxyadenosine-3',5'-
bisphosphate 
MRS1220 9-Chloro-2-(2-furyl) [1,2,4]triazolo[1,5-c]quinazolin-5- 
phenylacetamide 
MRS1523 5-Propyl 2-ethyl-4-propyl-3-(ethylsulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate 
MRS1191 3-Ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(±)-
dihydropyridine-3,5-dicarboxylate 
MRS1706 N-(4-Acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1 ,3-dipropyl-
1H-purin-8-yl)phenoxy]acetamide 
MRS1754 N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1, 3-dipropyl-
1H-purin-8-yl)phenoxy]-acetamide 
MSX-2 3-(3-Hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargyl-
xanthine 
MSX-3 3-(3-Hydroxypropyl)-8-(m-methoxystyryl)-7-methyl-1- 
propargylxanthine-phosphate-disodium salt  
 
MSX-4 
L-valine-3-{8-[(E)-2-[3-methoxyphenyl)ethenyl]-7-methyl-1-
propargylxanthine-3-yl}propyl ester hydrochloride  
NAD Nicotinamide adenine dinucleotide  
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NECA 5′-N-ethylcarboxamidoadenosine  
NF279 8,8'-(Carbonylbis(imino-4,1 -phenylenecarbonylimino-4,1-
phenylenecarbonylimino))bis(1,3, 5-naphthalenetrisulfonic acid) 
NF449 4,4',4'',4'''-[Carbonylbis(imino-5,1,3-benzenetriyl-bis 
(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid, octasodium salt 
NFAT-RE Nuclear factor of activated T cells  
NS Non-specific binding  
Orgen Green AM Oregon Green acetoxymethylester 
P2 Second pellet 
PBS Phosphate buffered saline  
pEC50 -log EC50 
PEI polyethyleneimine 
PIA N
6
- Phenylisopropyl adenosine  
PI3Kγ Phosphoinositol 3-kinaseγ  
PIP2 Phosphatidylinositol-4,5-bisphosphate 
pKB -log KB 
PKC Protein kinase C 
PLC  Phospholipase C 
PDE Phosphodiesterase  
PMSF Phenylmethanesulfonylfluoride 
PPADS Pyridoxal-phosphate-6-azophenyl-2´,4´-disulfonate 
PPi Pyrophosphate 
PSB Pharmaceutical Sciences Bonn 
PSB-0413 2-Propylthioadenosine-5´-adenylic acid (1,1-dichloro-1- 
phosphonomethyl-1-phosphonyl) anhydride 
PSB-10 8-Ethyl-1,4,7,8-tetrahydro-4-methyl-2-(2,3,5-trichlorop henyl)-5H-
imidazo[2,1-i]purin-5-one monohydrochloride 
PSB-11 3H-8-ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H- 
imidazo[2.1-i]purin-5-one  
PSB-298 (8-{4-[2-(2-Hydroxyethylamino)-2-oxoethoxy]phenyl}-1-
propylxanthine 
PSB-603 8-[4-[4-(4-Chlorophenzyl)piperazide-1-sulfonyl)phenyl]] -1-
propylxanthine 
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PSB-36 1-Butyl-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-
3-(3-hydroxypropyl)-1H-purine-2,6-dione 
PSB-1115 1-Propyl-8-p-sulfophenylxanthine 
PTX Pertussis toxin 
R Receptor 
r Rat 
RO-3 5-[[4,5-Dimethoxy-2-(methylethyl)phenyl]methyl]-2,4-pyr 
imidinediamine 
Ro20-1724 4-(3-Butoxy-4-methoxyphenyl)methyl-2-imidazolidone 
RT Room temprature 
RT-PCR Reverse transcription polymerase chain reaction 
SCG Superior cervical ganglia  
SCH420814 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] 
SCH58261 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4] 
triazolo[1,5-c]pyrimidin-5-amine 
s Seconds 
S-ENBA S-N
6
-(2-endo-norbornyl)adenosine 
S.E.M Standard error of the mean 
SRE Serum response element  
TAE Tris-acetate-EDTA buffer  
TB Total binding  
TRIS 2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris(hydroxyl 
methyl)amino methane) 
TM  Transmembrane 
Tm Melting temperature  
TNP-ATP 2′,3′-O-(2,4,6- trinitrophenyl)adenosine 5′-triphosphate 
TR-FRET Time-resolved fluorescence resonance energy transfer  
Triton X-100 t-Octylphenoxypolyethoxyethanol 
UDP  Uridine diphosphate 
UTP  Uridine triphosphate 
UV Ultraviolet 
vs. Versus 
VSV-G Envelope glycoprotein from the vesicular stomatitis virus  
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VT160  N
6
-methoxy-2-(2-pyridinyl)-ethynyl-5´-N 
methylcarboxamidoadenosine 
 VUF5574 N-(2-Methoxyphenyl)-N′-[2-(3-pyridinyl)-4-quinazolinyl]-urea 
VUF8504 4-Methoxy-N-[2-(2-pyridinyl)quinazolin-4-yl]benzamide  
WRC-0571  8-(N-methylisopropyl)amino-N
6
-(5'-endohydroxy- endonorbornyl)-9-
methyladenine 
WT Wild type 
ZM241385 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-
ylamino]ethyl)phenol 
Z Ziziphus  
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